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 ABSTRACT 
Deliberate enzymatic production of superoxide (O2.-) was originally thought to be restricted 
to the membrane-associated multi-subunit NADPH Oxidase in phagocytic cells, which use 
superoxide as a precursor to secondary reactive oxygen species (ROS) to destroy engulfed 
pathogens as a part of innate immunity. Recent discovery in nonphagocytic tissues of an 
entire family of proteins (Nox) homologous to the catalytic subunit of the phagocytic 
NADPH Oxidase has led to the recognition of the role of ROS in normal cellular signaling, 
with an increasing awareness of the pathological consequences when this signaling becomes 
dysregulated. These Nox proteins normally produce low-level, intracellular superoxide, 
although many factors can stimulate their activity. Nox1 has emerged as a key oxidase in 
the vasculature with the discovery that factors which promote vascular disease additionally 
stimulate its activity. Knowledge of the three-dimensional structure of the holoenzyme or of 
the cytosolic domain, which catalyzes the first electron transfer step, could aid in the design 
of specific inhibitors as novel therapeutics. In this work, methods were developed to 
produce recombinant human Nox1 suitable for structure determination by X-ray 
crystallography. Investigations to promote the heterologous expression of recombinant full-
length human Nox1 in E. coli did not result in observable overexpression. In contrast, four 
constructs containing the cytosolic domain of human Nox1 were solubly expressed in low 
amounts. Expression and purification protocols were developed for these constructs. Of 
these, an N-terminally His-tagged truncated human Nox1 containing residues 290-564 was 
found to possess an intrinsic NADPH-dependent diaphorase activity of 0.95 mol reduced 
NBT/min/mol protein. This activity is similar in magnitude to that of a longer construct of 
the phagocytic homologue, and is higher than Nox1 activity measured in vivo. The purified 
truncated human Nox1 required high ionic strength conditions for stability, and incubation 
with phagocytic regulatory proteins slightly enhanced its intrinsic activity. This active 
truncated human Nox1 would be suitable for future structure determination studies. 
Protein backbone cyclization is a method to increase the inherent stability of a target 
protein, and may also be a useful tool to aid in the crystallization of proteins through 
stabilization of flexible loops. To evaluate the potential of this application, Rab7 GTPase 
(residues 7-185) was cyclized, characterized, crystallized in both GDP- and GTP-bound 
forms, and the corresponding structures were determined. Cyclization did not significantly 
alter the secondary structure of Rab7, but increased its thermal stability by 3.7°C. Cyclized 
Rab7 demonstrated similar GTPase activity and effector association–dissociation kinetics as 
an equivalent linear Rab7 construct. Cyclized Rab7•GDP crystallized readily and diffracted 
to significantly higher resolution than uncyclized Rab7•GDP. Crystal contacts involving 
residues from the linker used for cyclization stabilized the Switch I loop, which is 
disordered in Rab7•GDP structures, such that its structure could be determined. Cyclized 
Rab7•GppNHp was also crystallized, but these crystals were found to be 
pseudomerohedrally twinned with a high twinning fraction. In contrast to the stabilization 
seen in the cyclized Rab7•GDP structure, the final model of cyclized Rab7•GppNHp 
contained several regions of flexibility, including the Switch II loop, which is visible in 
other active Rab7 structures. These structures indicate that the N- and C- termini normally 
point in opposite directions. The linker used for cyclization may not be long enough to 
allow the protein to adopt this conformation, generating a strained conformation that affects 
other regions of the protein, like Switch II. In general, protein backbone cyclization can be a 
useful method to aid in the crystallization of proteins in which the N- and C-termini lie in 
close proximity to each other. 
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 ZUSAMMENFASSUNG 
Bisher wurde angenommen dass die gezielte enzymatische Produktion von Superoxid (O2.-) 
ausschließlich in der membran-assoziierten NADPH-Oxidase in Phagozyten stattfindet. 
Diese verwenden Superoxid als Vorstufe sekundärer reaktiver Sauerstoff-Spezies (ROS), 
um im Rahmen der angeborenen Immunantwort umhüllte Pathogene zu zerstören. Die in 
letzter Zeit in nicht-phagozytischem Gewebe entdeckte „Nox“ Protein-Familie, welche 
homolog ist zur katalytischen Untereinheit der phagozytischen NADPH-Oxidase, hat zu der 
Erkenntnis geführt dass ROS auch außerhalb von Phagozyten als Signalmoleküle eine 
wichtige Rolle spielen. Damit einher ging auch ein Verständnis für die pathologischen 
Konsequenzen einer Fehlregulation von ROS. Nox-Proteine produzieren normalerweise 
kleine Mengen intrazellulares Superoxid, obwohl viele verschiedene Faktoren diese 
Aktivität stimulieren können. Mit der Erkenntnis dass viele Herzkreislauferkrankungen 
verursachende Faktoren auch die Aktivität von Nox1 stimulieren können, wurde in Nox1 
eine der wichtigsten NADPH-Oxidasen des Gefäßsystems erkannt. Die Kenntnis der 
dreidimensionalen Struktur des ganzen Enzyms Nox1 oder seiner cytosolischen Domäne, 
welche den ersten Elektronübergang katalysiert, würde die Entwicklung spezifischer 
Inhibitoren als potentielle neuartige Medikamente unterstützen. 
Im Rahmen dieser Arbeit wurden zur Strukturaufklärung mit Hilfe der 
Röntgenstrukturanalyse ein Expressionsprotokoll und ein Reinigungsprotokoll für die 
rekombinante Proteinerzeugnung des menschlichen Nox1s (hNox1) entwickelt. 
Untersuchungen der Expression des Volllängenproteins hNox1 in E. coli zeigten keine 
nennenswerte Protein-Produktion. Im Gegensatz wurden vier Konstrukte der zytosolischen 
Domäne in niedrigen Mengen löslich exprimiert. Eines dieser Konstrukte, welches einen N-
terminalen Hexahistidin-Tag und die Aminosäurereste 290-564 einschließt, zeigte eine 
Aktivität von 0,95 mol reduziertes NBT/min/mol Protein. Diese Aktivität ist vergleichbar 
mit der Aktivität eines längeren verkürzten Konstrukts des phagozytischen Homologs, und 
größer als die für Nox1 in vivo gemessene Aktivität. Dieses gereinigte, verkürzte Konstrukt 
von hNox1 benötigte zur Stabilisierung Puffer mit einer hohen Ionenstärke. Die Inkubation 
mit phagozytischen zytosolischen Regulator-Proteinen führte zu einer leichten Erhöhung der 
intrinsischen Aktivität. Dieses aktive verkürzte Konstrukt könnte sich gut für zukünftige 
Röntgenstrukturanalysen eignen. 
Proteinzyklisierung ist eine Methode, die inhärente Stabilität eines Proteins zu erhöhen. 
Dadurch kann auch die Kristallisation eines Proteins ermöglicht werden, da z.B. flexible 
Bereiche des Proteins stabilisiert werden können. Um das Potential dieser Methode zu 
validieren, wurde die kleine GTPase Rab7 (Aminosäurereste 7-185) zyklisiert, 
charakterisiert, und in Komplex mit GDP und GTP kristallisiert. Die Zyklisierung verändert 
die Sekundärstruktur von Rab7 nicht bedeutsam, jedoch erhöht sich dadurch die thermische 
Stabilität des Proteins um 3,7°C. Zyklisiertes Rab7 hat eine mit linearem Rab7 
vergleichbare GTPase-Aktivität und Assoziations/Dissoziations-Kinetik für 
Effektormoleküle. Zyklisiertes Rab7 hat die Kristallisation und Diffraktion von Rab7•GDP 
erheblich verbessert. Neue Kristallkontakte, welche Aminosäurereste des zur Zyklisierung 
verwendeten Linker-Bereichs involvieren, stabilisieren den normalerweise ungeordneten 
Switch I Bereich so weit dass die Kristallstruktur dieses Bereichs aufgeklärt werden konnte. 
Zyklisiertes Rab7•GppNHp wurde auch kristallisiert, aber die erhaltenen Kristalle waren 
hochgradig pseudomerohedral verzwillingt. Im Gegensatz zum zyklisierten Rab7•GDP 
zeigt die Kristallstruktur von zyklisiertem Rab7•GppNHp viele flexible Bereiche, welche 
auch den normalerweise sichtbaren Switch II Bereich einschließen. In Strukturen von 
aktivem Rab7 zeigt der N- und C-Terminus in entgegengesetzte Richtungen. Der zur 
2 
 Zyklisierung verwendete Linker scheint jedoch zu kurz zu sein um eine vergleichbare 
energetisch günstige Konformation zu ermöglichen. Dadurch wird eine weniger günstige 
Konformation erzwungen, in der einige Bereiche des Proteins wie Switch II eine hohe 
Flexibilität aufweisen. Allgemein kann Proteinzyklisierung als eine sehr nützliche Methode 
zur Unterstützung der Kristallisation von Proteinen eingesetzt werden, in denen der N- und 
C-Terminus in enger räumlicher Nähe zueinander liegen. 
 
3 
  
  
 
 
Chapter 1. 
 
 
NADPH Oxidase 1 
 
 
 
  
Introduction  
 
1. INTRODUCTION 
 
Traditionally, reactive oxygen species have been regarded as harmful to the cell (Chance et 
al., 1979; Harman, 1981; Halliwell and Gutteridge, 1989; Davies, 1995), as evidenced by 
the numerous antioxidant mechanisms to detoxify these molecules (Yu, 1994). The classical 
exception to this was the NADPH Oxidase complex of phagocytic immune cells, which 
produces superoxide as a defense mechanism against invading bacteria (Babior et al., 2002). 
However, in recent years, an entire family of proteins homologous to the catalytic 
component of the phagocytic NADPH Oxidase has been discovered in nonphagocytic cells 
(Kikuchi et al., 2000; Geiszt et al., 2000; Yang et al., 2001; Shiose et al., 2001; Cheng et 
al., 2001; Banfi et al., 2001), and investigation of their biological roles has revealed the 
importance of reactive oxygen species as signaling molecules that affect a number of normal 
and pathophysiological processes. These NADPH Oxidases are found in diverse cell and 
tissue types, and modulate processes which include angiogenesis, cell growth, innate 
immunity, apoptosis, regulation of the extracellular matrix, and thyroid hormone 
biosynthesis (Lambeth, 2004). Recently, interest has increased in this family of proteins 
with the discovery of their participation in a wide variety of cardiovascular related diseases 
and most recently in neurodegenerative diseases and cancer, making them attractive novel 
therapeutic targets.  
 
1.1 REACTIVE OXYGEN SPECIES 
Although itself a radical, molecular triplet oxygen is not very reactive due to the fact that its 
two unpaired electrons reside in different molecular orbitals with parallel spins (Beckman 
and Ames, 1998). Since acceptance of two electrons would require them to both possess 
spins which are antiparallel to the spins of the unpaired electrons of oxygen (which is 
unlikely to be fulfilled by a typical pair of electrons in atomic or molecular orbitals), oxygen 
participates in one-electron transfers (Beckman and Ames, 1998). Reactive oxygen species 
(ROS) are oxygen-derived molecules, which, due to their high reactivity, readily participate 
in oxidation-reduction (redox) reactions. Biologically relevant reactive oxygen species can 
be divided into two types:  those which exist as radicals, which include superoxide (O2.-), 
hydroxyl radical (.OH), nitric oxide (NO.), and alkoxyl radical (R-O.); and those which do 
5 
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not, such as hydrogen peroxide (H2O2), peroxynitrite (ONOO-), singlet oxygen (1O2), 
hypochlorous acid (HOCl) and lipid peroxides (LOOH) (Guzik and Harrison, 2006). 
Many biologically relevant ROS can be derived from superoxide, the product of a one-
electron reduction of molecular oxygen. The cell possesses many enzymatic sources of 
superoxide. These include mitochondrial enzymes, cyclooxygenase, cytochrome P-450 
enzymes, xanthine oxidase, and NADPH Oxidases (Lassegue and Clempus, 2003; Guzik 
and Harrison, 2006). Superoxide has a half-life of a few seconds (Ray and Shah, 2005) and 
can function as both a reductant or an oxidant depending on the redox potential of the target 
molecule (Lambeth, 2004). Although a strong reductant, superoxide oxidizes a limited 
number of biological targets (Lambeth, 2004) such as [Fe-S] clusters in dehydratases like 
aconitase and fumerase, releasing Fe2+ (Kuo et al., 1987; Gardner and Fridovich, 1991; 
Gardner and Fridovich, 1992; Liochev and Fridovich, 1994; Gardner et al., 1994; Gardner et 
al., 1995). Much of superoxide’s harmful effects are due to the ability to further convert it 
into many other types of ROS that are far more damaging, such as hypochlorous acid 
(HOCl), hydroxyl radical (.OH), and peroxynitrite (ONOO-). When produced in low 
amounts in the picomolar range, detoxification by superoxide dismutase isoenzymes 
[copper-zinc-SOD (CuZnSOD), manganese-SOD (MnSOD), and extracellular SOD 
(ecSOD)] accelerates its otherwise spontaneous dismutation into hydrogen peroxide (Faraci 
and Didion, 2004), which, due to its ability to permeate cell membranes, can extend the 
range of its effects (Ray and Shah, 2005; Cai, 2005).  
Hydrogen peroxide is a stronger oxidant than superoxide, reacting with methionines or 
highly reactive cysteines in enzyme active sites of proteins like protein tyrosine 
phosphatases (Lee et al., 1998). Hydrogen peroxide can be neutralized to water by the 
action of catalase or glutathione peroxidase (Droge, 2002), or it can be further converted 
into a still more powerful ROS by the action of myeloperoxidase in neutrophils (a subtype 
of white blood cells) which generates HOCl as a potent antiseptic against engulfed bacteria 
(Hampton et al., 1998). In addition, hydrogen peroxide can react with Fe2+ via the Fenton 
reaction to form the hydroxyl radical (McCord and Day, Jr., 1978; Chance et al., 1979), the 
most reactive ROS which reacts with nearly diffusion-limited rates (reaction occurs 
immediately upon collision) (Beckman and Ames, 1998).  
Hydroxyl radicals react unselectively with any biological molecule within a short range of 
their formation (Halliwell and Gutteridge, 1986). They readily react with polyunsaturated 
6 
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fatty acid chains in the membrane to initiate peroxidation chain reactions. Such reactions 
produce various radicals that damage the membrane in many ways. This includes reduced 
membrane fluidity from cross-linked fatty acid chains, compromised membrane integrity as 
a result of fragmented fatty acid side chains, and inactivation of membrane-bound enzymes 
(Halliwell and Gutteridge, 1989). Additionally, hydroxyl radicals can react with DNA 
causing DNA base modifications and strand breaks (Mello Filho et al., 1984; Mello Filho 
and Meneghini, 1984), which is the main mechanism of damage caused by ionizing 
radiation (von Sonntag, 1987).  
Superoxide also readily reacts with nitric oxide (rate constant 6.7 x 109 M-1s-1) (Huie and 
Padmaja, 1993) to form peroxynitrite (ONOO-) (Beckman et al., 1990), a strong oxidant 
which nitrosylates proteins, oxidizes lipoproteins (Guzik and Harrison, 2006), reacts readily 
with thiols and initiates lipid peroxidation (Fridovich, 1995). It is worthy to note that 
superoxide reaction with NO. is 3 times faster than dismutation by SOD (2 x 109 M-1s-1) 
(Klug et al., 1972; Rotilio et al., 1972), resulting in significant production of ONOO- when 
NO. and O2.- are present at high nanomolar amounts (Darley-Usmar et al., 1995; Beckman 
and Koppenol, 1996; Ray and Shah, 2005; Cave et al., 2006).  
 
1.2 ROS AND VASCULAR DISEASE  
A growing body of evidence describes the role of low levels of ROS in normal cellular 
function. Dysregulation of their production can lead to pathological situations, which have 
recently been widely documented in many vascular diseases.  
 
1.2.1 Anatomy of the vascular wall    
Blood vessels are composed of three layers that enclose the lumen, the hollow area in which 
blood flows.  The innermost layer is known as the intima, and is topped by a single layer of 
endothelial cells (the endothelium), which contacts circulating blood. The intima is a thin 
layer comprised of extracellular connective tissue, such as proteoglycans and collagen, 
surrounded by an elastic membrane termed the internal elastica lamina. The second layer 
around the intima is a muscular layer known as the media, which consists of smooth muscle 
cells. The outer layer of the artery is known as the adventitia, which is made of fibroblasts 
and smooth muscle cells interspersed in connective tissues (Gray, 1918; Lusis, 2000).  
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Figure 1. Anatomy of the vascular wall, showing the three main layers of blood vessels and the cells 
that compose them. 
 
1.2.2 Normal endothelial function 
Contrary to the earlier idea that the endothelium serves only as an inert lining of blood 
vessels and the heart, it is now clear that this monolayer of cells has important roles in 
cardiovascular homoeostasis that affect vascular tone, hemostasis (the process that stops 
bleeding) and vascular cell growth (Kaiser and Sparks, Jr., 1987; Ray and Shah, 2005). It 
does this by sensing local environmental changes and blood borne signals to modulate the 
equilibrium between vasoconstriction and vasodilation, anti-thrombotic and procoagulant 
factors, and cell proliferation and apoptosis (Ray and Shah, 2005). In general, the 
endothelium has vasoprotective functions to maintain a vasodilated, anti-inflammatory and 
anti-coagulant environment within blood vessels.  
The vascular endothelium interfaces the bloodstream and the vessel wall, and mediates the 
effect of shear stress (tangential drag force of flowing blood over the endothelium; Fung and 
Liu, 1993) with the production of vasoactive substances such as NO. and prostacyclin (both 
vasodilators), and endothelin-1 (a vasoconstricting peptide) (Nerem et al., 1993; Guzik and 
Harrison, 2006). Endothelial NO. is a key mediator of vasodilation, and is produced by the 
enzyme endothelial nitric oxide synthase (eNOS) (Bredt and Snyder, 1990). NO. (previously 
known as endothelium-derived relaxing factor) diffuses from the endothelium to activate 
soluble guanylate cyclase in vascular smooth muscle cells, which increases cyclic GMP 
levels, leading to vasorelaxation (Rapoport et al., 1983; Moncada et al., 1991). Additionally, 
NO. helps to maintain many areas of normal endothelial function, including inhibition of 
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platelet aggregation (de Graaf et al., 1992), inhibition of monocyte adhesion to the 
endothelium (Kubes et al., 1991; Gauthier et al., 1995), as well as inhibition of vascular 
smooth muscle cell proliferation (Cornwell et al., 1994). Thus, NO. has many protective 
roles in the vasculature, which are critical for maintaining blood vessels in a healthy state. 
 
1.2.3 Roles of ROS in endothelial dysfunction:  impairing the cell’s protective 
mechanisms 
In light of its unique role as an interface between the blood and underlying tissues, 
disruption of the ability of the endothelium to modulate the equilibrium between opposing 
signaling mechanisms has wide-reaching effects. Endothelial dysfunction is observed in a 
number of vascular disease states, such as atherosclerosis, hypertension, heart failure and 
diabetes mellitus (Ray and Shah, 2005). Recently it has been recognized that impaired 
endothelial function is a strong indication of future cardiovascular complications and 
mortality (Halcox et al., 2002; Fichtlscherer et al., 2004). Endothelial dysfunction is 
characterized by impaired endothelium-dependent vasodilation, and an increase in factors 
that promote inflammation and thrombosis (Gimbrone, Jr. et al., 1995; Cave et al., 2006). It 
has become clear in recent years that elevated production of ROS are observed in many of 
the same pathological settings as endothelial dysfunction, such as hypercholesterolemia, 
hypertension and diabetes (Rajagopalan and Harrison, 1996; Harrison et al., 2003). ROS, 
and in particular superoxide, can interfere with normal endothelial function by interfering 
with the bioavailability of NO. (Guzik and Harrison, 2006). 
There are a number of ways that superoxide can affect endothelial NO. bioavailability, and 
thus contribute to endothelial dysfunction. As mentioned earlier, reaction of superoxide with 
NO. occurs faster than dismutation by SOD. Therefore, if superoxide and NO. are in the 
high nanomolar range, they will form ONOO-. This depletes the cell of NO. and removes the 
protective effects of NO. on the vasculature (Mugge et al., 1991). The resulting ONOO- can 
in turn oxidize tetrahydrobiopterin, an essential cofactor of nitric oxide synthase (NOS) 
(Vasquez-Vivar et al., 1998; Laursen et al., 2001). NOS, a multi-domain heme enzyme, 
produces NO. and citrulline by transferring electrons from its heme via tetrahydrobiopterin 
to its substrate L-arginine (Alderton et al., 2001). Loss of tetrahydrobiopterin causes the 
intermediate Fe2+-O-O to form superoxide instead of NO., a process known as NOS 
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uncoupling (Xia et al., 1998). ONOO- can also oxidize the zinc-thiolate center of 
endothelial NOS, which also leads to uncoupling to produce superoxide instead of NO. (Zou 
et al., 2002). This uncoupling of NOS leads to enhanced superoxide production at the 
expense of NO. production, which depletes the endothelium of NO., the major vasorelaxing 
factor in the endothelium, and leads to endothelial dysfunction. There exists, therefore, a 
delicate balance in the cell between different ROS species like nitric oxide and superoxide, 
which if disrupted can lead to pathological states such as atherosclerosis.  
 
1.2.4 Overview of atherosclerosis  
Atherosclerosis is a progressive disease of large and medium-sized arteries, including the 
coronary, carotid and aorta (Collins, 1993). The disease is characterized by a thickening of 
the normally thin intimal layer with lipid-ingested macrophages (termed foam cells) 
intertwined with fibrous elements. Established risk factors include hyperlipidemia, 
hypertension, smoking, and diabetes mellitus (Collins, 1993). Observations of disease 
progression from animal models indicate that following a diet high in fat and cholesterol, 
low-density lipoproteins (LDLs) accumulate in the intima, where they can be progressively 
oxidized. This is followed by adhesion of monocytes (circulating, phagocytic white blood 
cells) and T lymphocytes to the surface of endothelial cells, which subsequently cross the 
endothelial layer through intercellular endothelial tight junctions and enter the intima. Once 
in the intima, monocytes differentiate into macrophages, immune cells which normally act 
as scavengers that remove toxic substances from the cell. These macrophages engulf and 
sequester oxidized LDLs in an effort to protect endothelial and smooth muscle cells. 
However, macrophage ingestion of oxidized LDLs leads to the formation of foam cells, 
which subsequently mix with lymphocytes to form early atherosclerotic lesions known as 
the “fatty streak”, and develop into intermediate lesions with the migration and proliferation 
of smooth muscle cells (SMCs) from the media of the blood vessel. Alternating layers of 
macrophages and SMCs begin to form with the continued migration of new monocytes and 
subsequent propagation of macrophages. Foam cells eventually die, spilling their lipid 
contents (predominantly free and esterified cholesterol) and depositing cell debris in the 
core of the lesion. Smooth muscle cells secrete fibrous elements such as collagen and other 
extracellular matrix proteins that form a fibrous cap over this core and intermediate lesions 
progress to fibrous plaques, which increase in size and protrude into the lumen of the artery. 
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The lesion continues to grow with the entry of new monocytes and the formation of new 
foam cells at the lesion edge, which make the plaque vulnerable to rupture and thrombosis 
particularly if the fibrous cap is thin (Ross, 1993; Ross, 1999; Lusis, 2000; Madamanchi et 
al., 2005). This progressive occlusion of the arteries that typifies atherosclerosis can lead to 
an acute occlusion of the artery, which may result in clinical events such as a myocardial 
infarction (heart attack) or stroke.  
 
1.2.5 Roles of ROS in atherosclerosis:  The Oxidative Stress Hypothesis of 
Atherosclerosis   
Not only can elevated levels of ROS, such as superoxide, interfere with the cell’s 
vasoprotective mechanisms, they additionally promote events in the progression of 
atherosclerosis. Previously regarded as merely a disease of lipid accumulation, it is now 
recognized that atherosclerosis is a result of the body’s chronic inflammatory response to 
tissue injury in the vasculature, sparked by endothelial dysfunction (Ross, 1999; Lusis, 
2000). 
 
Oxidation of low-density lipoprotein 
Oxidized low-density lipoprotein (oxLDL) is key among the factors that can injure the 
endothelium, as well as promote adherence of monocytes and T lymphocytes to the 
endothelium and their subsequent migration into the intima (Ross, 1993). Oxidized LDL 
induces the expression of adhesion molecules of the selectin family, such as P-selectin 
(Vora et al., 1997), which are involved in the initial attachment of monocytes to the surface 
of the endothelium, and participate in monocyte rolling (Madamanchi et al., 2005). This 
rolling action brings integrins on the surface of the monocyte in contact with adhesion 
molecules such as endothelial intracellular adhesion molecule (ICAM-1) and vascular cell 
adhesion molecule (VCAM-1) on the endothelium to produce a firmer attachment (Behrendt 
and Ganz, 2002; Libby et al., 2002) (Figure 2). Oxidized LDL additionally induces the 
expression of monocyte chemoattractant protein-1 (MCP-1) (Cushing et al., 1990), the 
chemotactic factor that is responsible for monocyte migration into the intima, and also 
induces endothelial cells to release macrophage colony stimulating factor (M-CSF) 
(Rajavashisth et al., 1990), which is involved in monocyte differentiation into macrophages. 
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Additionally, oxidized LDL is a chemoattractant for T lymphocytes (McMurray et al., 
1993), and can activate them to secrete numerous cytokines which interact with 
macrophages and enhance the inflammatory response (Mahmoudi et al., 2007). Cytokines 
are small proteins involved in immune responses and cell-cell communication (Dyer and 
Fifer, 2003). Oxidized LDL is also cytotoxic to endothelial cells (Hessler et al., 1983), and 
can inhibit endothelial dependent vasodilation, contributing to endothelial dysfunction 
(Ohgushi et al., 1993). Thus, oxidized LDL affects multiple processes that can lead to the 
formation and progression of atherosclerosis. 
 
Figure 2. Role of adhesion molecules in leukocyte adhesion and transmigration across the 
endothelium. Members of the selectin family mediate the initial interaction of leukocytes with 
endothelial cells and rolling of leukocytes on the endothelial surface. Adhesion occurs if the integrins 
leukocyte function-associated antigen (LFA-1) and very late antigen (VLA-4) on leukocytes 
encounter endothelial intracellular adhesion molecule (ICAM-1) and vascular cell adhesion molecule 
(VCAM-1), respectively, during the rolling interval. Leukocytes transmigrate across the endothelium 
through the mutual interaction of platelet/endothelial cell adhesion molecule (PECAM-1) expressed at 
endothelial cell junctions and on leukocytes, as well as involving integrins. ESL-1, E-selectin ligand-
1; LSL, L-selectin ligand; PSGL-1, P-selectin glycoprotein ligand-1. Figure from Behrendt et al, 2002. 
 
ROS contribute to this initial injury of the endothelium through the initial oxidation of 
native low-density lipoprotein, a modification that causes it to be readily taken up by 
scavenger receptors on macrophages, and thus leads to foam cell formation (Shihabi et al., 
2002). Although there are numerous candidates proposed to oxidize LDL (and many agents 
used in vitro to produce oxidized LDL), in vivo there is evidence for the involvement of 
ONOO- and HOCl (both of which can be produced from superoxide) based on gas 
chromatography and mass spectrometry studies performed on LDL isolated from human 
atherosclerotic lesions (Heinecke, 1999; Mashima et al., 2001). α-tocopheroxyl radical has 
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also been implicated based on the accumulation of α-tocopherol-derived oxidation products 
such as 9-trans, cis and 13-cis, trans regio-isomers of hydroperoxides of cholesteryl esters 
in human lesions (Mashima et al., 2001). Modification of LDL by either ONOO- or HOCl, 
has been shown to produce forms that are recognized and readily taken up by the scavenger 
receptor on macrophages (Hazell and Stocker, 1993; Graham et al., 1993).  
 
ROS and endothelial activation:  induction of proinflammatory molecules 
Endothelial activation is an important initial step in the inflammatory response, and refers to 
the induction of 1) proteins involved in cell surface adhesion which mediate the attachment 
of monocytes from the circulating blood to the endothelium, and 2) chemotactic factors 
responsible for their subsequent migration into injured tissues. As mentioned above, it also 
plays a key role in the inflammatory response-to-injury caused by oxidized LDL in 
atherogenesis. ROS can contribute to endothelial activation through their ability to induce 
cell adhesion molecules. Prolonged exposure to ROS, such as hydrogen peroxide, have been 
found to induce P-selectin expression on the surface of endothelial cells (Patel et al., 1991), 
and administration of scavenging enzymes such as SOD and catalase demonstrated 
significant inhibition of monocyte adhesion to endothelial cells, thus implicating the 
involvement of superoxide and hydrogen peroxide in monocyte attachment to endothelial 
cells (Godin et al., 1993).  
The activation of cell adhesion molecules by hydrogen peroxide was found to affect a 
ubiquitous eukaryotic transcription factor known as NF-κB (nuclear factor κB). This 
discovery helped cast ROS in a new light as important signaling molecules, and not merely 
destructive by-products of aerobic metabolism (Reth, 2002). Many proteins involved in cell 
adhesion (VCAM-1, ICAM-1, E-selectin) and migration (MCP-1) are induced by 
inflammatory cytokines such as TNF-α (tumor necrosis factor-α), a process regulated at the 
transcriptional level by NF-κB (Marui et al., 1993; Chen and Medford, 1999; Baldwin, Jr., 
2001). NF-κB is involved in immune and stress responses, inflammation and apoptosis (Li 
and Karin, 1999). 
Interestingly, NO. prevents monocyte adhesion to endothelial cells on several levels that 
affect NF-κB mediated transcription. NO. donors have been shown to inhibit cytokine-
induced transcription of adhesion molecules VCAM-1 and ICAM-1 (Spiecker et al., 1997; 
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Spiecker et al., 1998), as well as the monocyte chemoattractant M-CSF (Hong et al., 1997). 
In the case of VCAM-1, it has been demonstrated in endothelial cells that NO. donors 
increase the transcription and nuclear translocation of IκBα (Spiecker et al., 1997), one of a 
family of proteins (IκBs) that inhibit NF-κB. IκBs can do this by either binding NF-κB in 
the cytosol and masking its nuclear localization signal (Collins and Cybulsky, 2001), which 
prevents its translocation to the nucleus and subsequent transcription of NF-κB target genes 
(Zabel and Baeuerle, 1990; Baeuerle and Baltimore, 1996), or by displacing NF-κB from its 
cognate DNA within the nucleus (Traenckner et al., 1994). Additionally, NO. can directly 
react with superoxide to prevent superoxide-mediated induction of proinflammatory 
molecules (Griendling et al., 2000). Once again, nitric oxide and superoxide mediate 
opposing signaling pathways in the vasculature.  
 
ROS and plaque stability:  induction of matrix metalloproteinases  
A main cause for the clinical complications of atherosclerosis arises from plaque instability 
and subsequent rupture, which can occlude the artery and result in a myocardial infarction 
or stroke (Lusis, 2000). The activity of extracellular matrix-degrading enzymes such as 
matrix metalloproteinases (MMPs) can promote plaque rupture, and active forms of these 
enzymes have been shown to co-localize in vulnerable shoulder regions of plaques from 
human atherosclerotic lesions (Galis et al., 1994). These shoulder regions are rich in foam 
cells (Lusis, 2000), and it has been shown that foam cells isolated from 
hypercholesterolemic animal models are abundant sources of MMP activity that can be 
inhibited in situ with the ROS scavenger, N-acetyl-L-cysteine (Galis et al., 1998). Like 
many proteases of the coagulation cascade, MMPs exist as proenzymes (Murphy et al., 
1994) in an autoinhibited form, which, upon proteolytic cleavage, releases the active 
enzyme.  MMPs contain a catalytic zinc which is coordinated by a conserved cysteine that 
maintains the propeptide in its autoinhibited state (Visse and Nagase, 2003). ROS can easily 
disrupt this interaction by reaction with the thiol group of cysteine leading to autoactivation 
(Suzuki et al., 1990). Interestingly, both H2O2 and ONOO- have been found to activate 
MMPs secreted by human vascular smooth muscle cells (Rajagopalan et al., 1996b). 
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1.2.6 Ineffectiveness of global antioxidant therapy to counter ROS effects in 
atherosclerosis 
In light of the growing body of evidence that implicate ROS in the pathophysiology of 
vascular disease, it was quite surprising and disappointing that administration of global 
antioxidants such as vitamin C, β-carotene, and vitamin E supplements failed to give 
conclusive beneficial results for patients with atherosclerosis (Landmesser and Harrison, 
2001; Shihabi et al., 2002). In some cases, antioxidant supplements exacerbated disease and 
increased mortality in vitamin E supplementation trials (Lonn et al., 2005; Miller, III et al., 
2005), increased the occurrence of lung cancer in β-carotene treatment (Lee et al., 1999), as 
well as negated the beneficial effects of statin-niacin therapy in lipid lowering studies 
(Cheung et al., 2001). Such results, while appearing to cast doubt on the oxidative stress 
hypothesis of atherosclerosis, may in fact highlight an incomplete understanding of the 
complicated nature of the role of oxidation as well as antioxidants in the disease.  
There are several important reasons why use of vitamin E would fail to prevent progression 
of atherosclerosis. A major factor to consider is that vitamin E does not effectively scavenge 
the ROS responsible for many of the events in the disease. Much of the motivation for 
global antioxidant therapy came from the observation that α-tocopherol, biologically and 
chemically the most active form of vitamin E (Burton and Ingold, 1986), is the most 
abundant lipid-soluble antioxidant in LDL (Thomas and Stocker, 2000). Additionally, in 
vitro oxidation experiments on LDL using non-physiologically high concentrations of 
transition metals as oxidants (predominantly Cu+1) (Esterbauer et al., 1989) or aqueous 
peroxyl radicals (Bowry and Stocker, 1993; Neuzil et al., 1997) demonstrated an initial lag 
phase in the rate of lipid peroxidation when α-tocopherol was present (Esterbauer et al., 
1989). Free transition metals, however, rarely occur in vivo, and as noted previously, 
analysis of LDL isolated from human atherosclerotic lesions identified HOCl and ONOO- as 
potential ROS sources of oxidation. It is interesting to note that α-tocopherol does not 
protect against apolipoprotein B-100 oxidation by myeloperoxidase in vitro, and HOCl-
induced lipid peroxidation occurs at a slower rate when α–tocopherol is depleted (Hazell 
and Stocker, 1997; Hazell et al., 1999). Apolipoprotein B-100 is the protein found in human 
LDL. As noted above, increased production of superoxide is associated with many vascular 
disease states. Vitamin E reacts with superoxide with a rate of 5 x 103 M-1s-1 (Gotoh and 
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Niki, 1992), 6 orders of magnitude slower than superoxide reaction with nitric oxide. 
Together, these findings indicate that vitamin E is unable to effectively protect against the 
physiologically relevant oxidants in atherosclerosis.  
Contrary to its proposed antioxidant nature, α–tocopherol can also help initiate and promote 
free radical chain reactions in lipid peroxidation, especially under mild oxidizing conditions 
(Bowry and Stocker, 1993; Neuzil et al., 1997). Interestingly, this process can be 
accelerated by enriching LDL with α–tocopherol, and is significantly suppressed in LDL 
lacking α–tocopherol (Thomas et al., 1996; Neuzil et al., 1997). LDL isolated from a 
patient with familial isolated vitamin E deficiency showed a high degree of resistance to 
oxidation, which could be reversed by dietary supplementation of vitamin E (Thomas et al., 
1996). In this study, supplementation with only vitamin E led to LDL that was more prone 
to oxidation, whereas co-administration of coenzyme Q (another antioxidant found to a 
much lesser extent in human LDL) and vitamin E yielded LDL that was more resistant to 
oxidation. These results lend more support for co-supplementation of vitamin E with other 
antioxidants such as vitamin C or coenzyme Q, as perhaps a more beneficial therapy than 
vitamin E alone. The pro-oxidant nature of α–tocopherol can be understood if one considers 
that by reacting with a radical, α–tocopherol itself becomes a radical, which is 
thermodynamically stable (Bisby and Parker, 1991), and can perpetuate the chain reaction 
instead of terminating it. Vitamin C on the other hand can be enzymatically converted back 
to ascorbic acid after reacting with a radical, which might explain the protective nature of 
this combination (Salonen et al., 2000).  
 
1.2.7 Success of angiotensin converting enzyme inhibitors and statins:  
effects on NADPH Oxidase 
In contrast to non-specific antioxidant treatment, two existing therapies that have shown 
significant clinical improvement in individuals with increased risk for cardiovascular 
disease have recently been shown to additionally inhibit NADPH Oxidase activity. These 
treatments reduce hypertension and hypercholesterolemia, respectively- two conditions that 
play a role in atherosclerosis and are strong risk factors for further cardiovascular 
complications. The first class of compounds, angiotensin converting enzyme inhibitors, 
inhibit the production of angiotensin II and block its effects on blood pressure. The second 
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family of compounds, statins, act to lower circulating levels of LDL by inhibiting 
cholesterol synthesis.  
 
The renin-angiotensin system 
The renin-angiotensin system is involved in regulation of fluid and electrolyte balance, as 
well as blood pressure, through the actions of angiotensin II on vascular smooth muscle, 
adrenal cortex, kidney, and brain (Reid, 1998). Angiotensin II is a peptide agonist, a 
substance that acts like a hormone, binding to its receptor, and mediating various signaling 
mechanisms to produce a desired action. It is produced after cleavage of angiotensin I by 
angiotensin converting enzyme (ACE), a dipeptidyl carboxypeptidase.  
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Angiotensin Converting
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Figure 3. Proteolytic processing of angiotensinogen to form angiotensin II. Amino acids are 
represented by one-letter codes. Figure made after Reid, 1998. 
 
Angiotensin II plays a role in blood pressure regulation and is a potent vasoconstrictor 
(Reid, 1998), whose levels are often elevated in individuals with hypertension (Ross, 1999). 
It affects not only the vasculature, but additionally acts on the hypothalamus in the brain to 
stimulate thirst, and the adrenal cortex to increase secretion of aldosterone, a hormone that 
increases sodium reabsorption and water retention (Dyer and Fifer, 2003; Xiao et al., 2003).  
Angiotensin II can additionally exert effects by inducing proinflammatory cytokines (Libby 
et al., 2002). ACE inhibitors prevent the formation of angiotensin II, thus reducing high 
blood pressure. They additionally improve endothelial dysfunction in patients with coronary 
artery disease, which may involve increased local NO. production and bioactivity through a 
bradykinin-mediated increase in expression and activity of endothelial NOS (Mahmoudi et 
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al., 2007). Bradykinin is another peptide agonist that is also a major substrate of ACE (Yang 
et al., 1970), but acts as a vasodilator in contrast to angiotensin II. In addition, unlike 
angiotensin II, bradykinin is inactivated by ACE through the cleavage of the last two C-
terminal residues (Xiao et al., 2003) and is subsequently degraded by the same enzyme 
(Dendorfer et al., 2001). 
 
Statins  
Statins are a class of compounds that competitively inhibit the rate-limiting step in 
cholesterol biosynthesis (Figure 4). Cholesterol is synthesized by nearly all cells in the 
human body, but a majority of it is produced by the liver (Ucar et al., 2000). Statins bind 
with nanomolar affinity to the liver enzyme 3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase, which catalyzes the generation of L-mevalonate from HMG-CoA 
(Greenwood et al., 2006). In addition to direct reduction of endogenous cholesterol 
production, this decrease in intracellular levels of cholesterol increases transcription and 
expression of the LDL receptor at the surface of liver cells, which increases LDL uptake 
from the bloodstream (Brown and Goldstein, 1986). Independent from its lipid lowering 
abilities, statins have a broad range of effects that counter many steps in the progression of 
atherosclerosis, which has lead to much enthusiasm for its widespread use. They have been 
found to upregulate endothelial NOS expression, increase fibrinolytic activity, inhibit 
smooth muscle cell proliferation and instead stimulate apoptosis, and inhibit expression of 
the monocyte chemoattractant MCP-1 (Palinski, 2001), in addition to having many anti-
inflammatory effects (Sparrow et al., 2001; Greenwood et al., 2006). Many of these effects 
can be attributed to the inhibition of isoprenoid intermediates in the cholesterol synthesis 
pathway, which are involved in prenylation, a post-translational lipid modification of 
proteins. Protein prenylation involves the transfer of lipid moieties such as farnesyl or 
geranylgeranyl groups to the C-terminus of a protein, and is required for the membrane 
localization of small GTPases which have critical regulatory roles affecting a wide variety 
of cell signaling cascades (Takemoto and Liao, 2001; Greenwood et al., 2006). 
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Figure 4. Synthesis of cholesterol and protein prenylation. Statin inhibition of HMG-CoA reductase 
not only inhibits cholesterol synthesis but also the biosynthesis of isoprenoids such as farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate, which are crucial to the post-translational 
modification of the small GTPases, Ras, Rac, Rho and Rab. Each has a specific C-terminal consensus 
sequence for the site of prenylation (C, cysteine; a, an aliphatic amino acid; X, any amino acid), and 
are targeted to specific membranes after prenylation. Cdc 42, cell-division cycle 42. Figure after 
Greenwood et al, 2006. 
 
Disadvantages of each therapy 
Due to their ability to affect multiple cellular processes, therapeutic use of ACE inhibitors or 
statins are associated with a few risks. As a consequence of ACE inhibition, inactivation and 
degradation of the pharmacological peptide bradykinin is prevented, resulting in maintained 
bradykinin levels. This is responsible for the side effect of dry cough, which makes ACE 
inhibitors less well tolerated by some patients (Sleight, 2002). As for statins, many of its 
pleiotropic effects are not fully understood, and recent reports have spotlighted some 
unfavorable actions of statins (Ucar et al., 2000; SoRelle, 2001; Staffa et al., 2002; Omar 
and Wilson, 2002), including skeletal muscle damage that can lead to the severe muscle 
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disorder rhabdomyolysis, where apoptosis of muscle cells can result in kidney failure and 
death. This is particularly true if statins are taken together with either another lipid-lowering 
drug derived from fibric acid or with inhibitors of cytochrome P450 3A4 (the enzyme which 
normally metabolizes them), taken in high doses (Graham et al., 2004), or taken over a long 
period of time (Ucar et al., 2000). Concerns are also growing that the concept of 
administering statins to individuals with no overt occlusive vascular disease as a preventive 
measure may also result in detrimental side effects rather than preventing disease 
(Abramson and Wright, 2007). Considering the broad scope of statin actions, it is clear that 
thorough and extensive investigations of its mechanisms of action outside of lipid lowering 
and interaction with other drugs are imperative to determine the optimal way to administer 
this widely prescribed drug.  
 
Mutual link with NADPH Oxidase point to a new therapeutic target 
It was, therefore, of great interest when it was discovered that both ACE inhibitors and 
statins could act to inhibit the actions of NADPH Oxidase. Initial studies in cultured 
vascular smooth muscle cells exhibited potent angiotensin II stimulation of NADPH 
Oxidase activity (Griendling et al., 1994), and this effect was confirmed in animal studies 
(Rajagopalan et al., 1996a; Pagano et al., 1997) and demonstrated in human blood vessels 
(Berry et al., 2000). As mentioned above, statins show many cholesterol-independent 
effects, which are mainly mediated through its concomitant inhibition of protein 
prenylation, affecting the small GTPases Ras, Rho, Rac, Rab, Ral and Rap. Rac is required 
for activation of NADPH Oxidase, and must be prenylated with a geranylgeranyl lipid 
moiety for proper membrane targeting. This modification is disrupted by the actions of 
statins, which have been found to reduce angiotensin II-induced superoxide production in 
vascular smooth muscle cells (Wassmann et al., 2002), as well as in cardiac myocytes 
(Takemoto et al., 2001) via mechanisms that specifically involve Rac. In the study using 
cardiac myocytes, the role of prenylation in angiotensin II-induced superoxide production 
was thoroughly demonstrated. Total intracellular oxidation was increased 2.7-fold upon 
addition of angiotensin II, which was completely inhibited when statin was co-administered. 
This inhibition could be reversed with the addition of L-mevalonate and 
geranylgeranylpyrophosphate, but not farnesylpyrophosphate, indicating the involvement of 
Rho GTPases (of which Rac is a member) and not Ras GTPases. Additionally, use of 
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dominant-negative and constitutively active forms of three different Rho GTPases: RhoA, 
Rac1, and Cdc42 clearly showed Rac1 as the GTPase responsible for angiotensin II-induced 
increase in and statin inhibition of superoxide production. 
 
1.3 NADPH OXIDASE:  A MAJOR SOURCE OF ROS IN VASCULAR DISEASE 
Over the last several years, a great deal of interest has grown in NADPH Oxidases, 
beginning with the discovery that these enzymes are expressed in virtually all tissues, and 
intensifying with the discovery that their activity can be regulated by a number of factors 
that are commonly associated with pathological settings (Harrison et al., 2003; Ray and 
Shah, 2005), particularly in cardiovascular diseases. Such factors include agonists like 
angiotensin II, thrombin, platelet-derived growth factor (PDGF), and TNF-α (Madamanchi 
et al., 2005). Many studies using animal models of different vascular diseases have found 
elevated superoxide production, including hypercholesterolemia (Ohara et al., 1993; 
Warnholtz et al., 1999), hypertension (Rajagopalan et al., 1996a; Fukui et al., 1997; 
Bauersachs et al., 1998), heart failure (Bauersachs et al., 1999), and diabetes (Kojda and 
Harrison, 1999). Superoxide production was shown to derive from NADPH Oxidase 
through the use of substrates (West et al., 2001) and/or inhibitors for various potential 
enzymatic sources of superoxide, including mitochondrial enzymes, xanthine oxidase, and 
uncoupled NOS (Warnholtz et al., 1999; Shi et al., 2001; West et al., 2001; Paravicini et al., 
2002; Hathaway et al., 2002). Each study indicated NADPH Oxidase as the source, with the 
exception of hyperlipidemic rabbits, where oxypurinol (an inhibitor of xanthine oxidase) 
additionally caused a partial reduction of superoxide production (Warnholtz et al., 1999). 
Studies of human blood vessels revealed that NADPH Oxidases are major sources of 
superoxide, with increased superoxide production correlating with impaired NO.-dependent 
vasodilation and increased atherosclerotic risk factors (Guzik et al., 2000). Investigations of 
human lesions have confirmed the role of NADPH Oxidase in vascular disease, with the 
finding that p22phox protein (a component of the NADPH Oxidase complex) and oxidase 
activity are present in atherosclerotic coronary arteries (Azumi et al., 1999). Subsequent 
studies demonstrated co-localization of oxidized LDL, oxidase protein and ROS generation 
in human atherosclerotic arteries (Azumi et al., 2002). Elevated NADPH Oxidase activity 
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was also found in human heart failure, compared to non-failing hearts (Heymes et al., 
2003). 
 
1.3.1 Nox proteins and tissue distribution 
The term Nox (NADPH Oxidase) refers to a family of enzymes that are homologous to the 
catalytic subunit, gp91phox, of the NADPH Oxidase complex, which deliberately produces 
superoxide from molecular oxygen and NADPH. This enzyme complex was originally 
thought to be restricted to phagocytic cells of the immune system until several homologues 
of gp91phox (also known as Nox2) were found in nonphagocytic cells by several groups 
independently (Kikuchi et al., 2000; Geiszt et al., 2000; Yang et al., 2001; Shiose et al., 
2001; Cheng et al., 2001; Banfi et al., 2001). To date, five human Nox proteins and two 
Duox proteins have been discovered, each with specific tissue distribution. All are 
membrane spanning proteins with a C-terminal cytosolic domain which shares distant 
homology to the ferredoxin-NADP+-reductase (FNR) family (Segal et al., 1992; Rotrosen et 
al., 1992; Sumimoto et al., 1992). Duox proteins contain an additional N-terminal calcium 
binding domain and an extracellular peroxidase domain, and thus are called Duox for dual 
oxidase (Cheng et al., 2001). In contrast to Nox enzymes, Duox enzymes produce hydrogen 
peroxide instead of superoxide (De Deken et al., 2002). They are found in the thyroid and 
are involved in thyroid hormone synthesis (Dupuy et al., 1999; De Deken et al., 2000). 
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Figure 5. Domain structure and tissue expression of Nox family members. Figure after Takeya et al, 
2003. 
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The first known Nox protein, gp91phox (Nox2), is found in phagocytic cells and is involved 
in host defense. It has subsequently been found to also be expressed in the endothelium 
(Jones et al., 1996; Bayraktutan et al., 1998; Gorlach et al., 2000; Bayraktutan et al., 2000), 
cardiac myocytes (Xiao et al., 2002), and lung (Cheng et al., 2001). Nox1 (58% sequence 
identity with gp91phox) was the first homologue of gp91phox discovered, with predominant 
expression in colon epithelial cells (Suh et al., 1999; Kikuchi et al., 2000), and additional 
expression in prostate, uterus, and cultured vascular smooth muscle cells (VSMC) (Suh et 
al., 1999). Nox3 (56% sequence identity with gp91phox) is found in fetal tissues and the adult 
inner ear (Banfi et al., 2004), and is required for the formation of specialized structures 
called otoconia, which are involved in the perception of balance and gravity (Paffenholz et 
al., 2004). Nox4 (39% sequence identity with gp91phox), also known as the kidney oxidase 
due to its high expression in epithelial cells of the renal tube (Geiszt et al., 2000; Shiose et 
al., 2001), is also found in vascular endothelial cells (Wingler et al., 2001; Ago et al., 2004; 
Kuroda et al., 2005), and has the broadest tissue distribution among homologues (Cheng et 
al., 2001) (Figure 5). Its precise function is still not known, but has been implicated in cell 
differentiation (Cucoranu et al., 2005), apoptosis (Mochizuki et al., 2006), growth 
(Menshikov et al., 2006; Sturrock et al., 2006) and endothelial cell proliferation (Petry et 
al., 2006). Nox5 is the most divergent of the five Nox proteins (26% sequence identity with 
gp91phox), bearing more similarity to the Duox proteins. It contains an additional 
calmodulin-like EF domain with four Ca2+ binding sites N-terminal to the regions 
homologous to gp91phox (Cave et al., 2006). Nox5 is present in lymphoid tissue, testis and 
spleen (Banfi et al., 2001), and its function is also unknown.  
In contrast to the high catalytic output and stimulus-dependent phagocytic NADPH oxidase, 
nonphagocytic Nox proteins constitutively produce low levels of superoxide without the 
need for stimulation, although various factors can increase oxidase activity (Cave et al., 
2006). Additionally, nonphagocytic Nox proteins produce intracellular superoxide, as is the 
case with Nox1 and Nox4, which localize in the caveolae and cytoskeleton of VSMCs, 
respectively (Hilenski et al., 2004). Nonphagocytic pools of gp91phox can produce 
superoxide intracellularly or extracellularly, depending on its location. It has been found 
preassembled in oxidase complexes in the perinuclear region of endothelial cells for 
intracellular ROS production (Li and Shah, 2002), as well as at or near the plasma 
membrane in endothelial and adventitial cells, which are capable of extracellular superoxide 
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production (Meier et al., 1993; Meyer et al., 1999; Wang H.D. et al., 1999; Barbacanne et 
al., 2000).  
 
1.3.2 The phagocytic NADPH Oxidase:  the classical NADPH Oxidase 
The first discovered and most well studied NADPH Oxidase is that of a class of immune 
system cells (phagocytes), which initiate the cell’s defense against foreign pathogens. In 
response to invading bacteria and microbes, certain phagocytic cells called neutrophils 
mobilize to sites of inflammation and engulf pathogens and/or parts of damaged tissues 
(DeLeo and Quinn, 1996). They dramatically increase their oxygen uptake, known as “the 
respiratory burst,” and elicit a tremendous burst in superoxide production to destroy the 
phagocytosed material as a primary action of innate immunity. The enzyme responsible for 
this is a carefully regulated, multi-component enzyme complex known as the phagocytic 
NADPH Oxidase. When active, it comprises six different proteins, two that are membrane-
bound, three cytosolic proteins, which translocate to the membrane upon stimulation, and 
the small GTPase Rac. The membrane heterodimer is composed of a Nox protein, gp91phox 
(or Nox2), and p22phox, another phagocytic oxidase protein component. For historical 
reasons they are collectively known as cytochrome b558, for b-type cytochrome with a 
maximal absorbance near 558 nm (Cross and Segal, 2004). All of the catalytic machinery 
resides in gp91phox, which contains putative sites for NADPH and FAD binding in its 
cytosolic C-terminal half, as well as four conserved histidines, which coordinate two hemes 
in the N-terminal transmembrane domain. p22phox serves to stabilize gp91phox and is essential 
for oxidase activity (Parkos et al., 1989; Maly et al., 1993; Cross and Segal, 2004). To 
generate superoxide, gp91phox and p22phox require interaction with four cytosolic proteins:  
three oxidase proteins called p47phox, p40phox and p67phox, and the small GTPase Rac (Figure 
6). The essential nature of this enzyme complex is highlighted by the occurrence of chronic 
granulomatous disease (CGD) caused by mutations in the genes for gp91phox, p22phox, 
p47phox, or p67phox. CGD is an inherited disorder characterized by severe and recurrent, often 
fatal, infections (Cross and Segal, 2004; Segal, 2005). Individuals develop granulomas 
where the pathogens have been phagocytosed, but are not destroyed due to an inactive 
NADPH Oxidase (Quinn and Gauss, 2004).  
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Figure 6. Overview of the activation of phagocytic NADPH Oxidase. In resting neutrophils, oxidase 
components are segregated between membrane-bound subunits and cytosolic regulatory proteins. 
Upon stimulation, these regulatory proteins translocate to the membrane to produce the active 
NADPH Oxidase, which transfers an electron from cytosolic NADPH to FAD, onto two hemes in the 
gp91phox subunit and finally to molecular oxygen, producing  superoxide. 
 
Molecular details of phagocytic NADPH Oxidase components 
As mentioned above, many details regarding the phagocytic NADPH Oxidase have been 
established. These serve as a basis to discuss the recently discovered homologues, with 
emphasis on Nox1 for the present work. The proteins that comprise the phagocytic NADPH 
Oxidase complex have historically been named according to their apparent molecular 
weight on SDS-PAGE, with the extension “phox” designating their participation in the 
phagocytic oxidase. 
gp91phox 
So termed for the heavy glycosylation that causes the protein to run at an apparent 
molecular weight of 91 kDa on SDS-PAGE, this 65 kDa membrane-associated glycoprotein 
is the catalytic center of the phagocytic oxidase. Since its initial discovery in 1961 (Hattori, 
1961) and rediscovery in 1978 (Segal et al., 1978; Segal and Jones, 1978), there has not 
been any three-dimensional structure of gp91phox available. Its cytosolic C-terminal domain 
shows weak sequence homology to the family of ferredoxin-NADP+ reductase (FNR) 
proteins, that allow the recognition of proposed binding sites for FAD and NADPH (Segal 
et al., 1992; Rotrosen et al., 1992). A model of the topology for the N-terminal domain 
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proposes six transmembrane helices, placing the N-terminus on the cytosolic side of the 
membrane. Four conserved histidines, residues 101, 115, 209 and 222 (Biberstine-Kinkade 
et al., 2001), coordinate two hemes with differential reduction potentials [Em7 = -265 mV 
and Em7 = -225 mV; (Cross et al., 1995)], which allow electron transfer from the cytosol, 
across the membrane, to the phagosome interior to destroy engulfed pathogens (Figure 7). 
Studies on the biosynthesis of cytochrome b558 have revealed the necessity of heme 
incorporation into gp91phox for heterodimer formation to occur (DeLeo et al., 2000). This is 
followed by asparagine (N)-linked glycosylation of gp91phox (Harper et al., 1985; Yu et al., 
1997) which is not required for catalytic activity (Kleinberg et al., 1989; Paclet et al., 2000), 
but instead may protect the protein from the degradative environment present in the 
phagocytic vacuole (Wallach and Segal, 1997).  
 
 
Figure 7. A, Destruction of foreign pathogens by phagocytic cells of the immune system. Phagocytes 
engulf microbes, forming phagosomes, which contain a membrane-bound NADPH oxidase that when 
activated produces superoxide from NADPH and molecular oxygen. This superoxide serves as a 
precursor to secondary ROS such as HOCl and .OH, which kill the microbes. B, Model of the 
structure of the complex between gp91phox and p22phox. Figures made after Sumimoto, 2005. 
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p22 phox 
The second member of the membrane-bound heterodimer is p22phox, a protein of 
approximately 21 kDa. Similar to gp91phox, little is known about its three-dimensional 
structure.  It also has a hydrophobic N-terminal region (residues 1-132) and a hydrophilic C-
terminus (residues 132-195). Hydropathy analysis predicts three or four hydrophobic 
regions (Parkos et al., 1988). The cytoplasmic C-terminus contains a proline-rich region 
(PRR) which interacts with the cytosolic protein p47phox (Sumimoto et al., 1994; Leto et al., 
1994). Although not required for the glycolysation of gp91phox, p22phox is required for the 
processing of the high mannose-content carbohydrate chains to N-acetylglucosamine and 
galactose to form the mature gp91phox (Maly et al., 1993; Porter et al., 1994). Each member 
of the heterodimer is mutually stabilized by the presence of the other as evidenced by the 
absence of both subunits in CGD patients with mutations in either gene (Parkos et al., 1988; 
Parkos et al., 1989; Verhoeven et al., 1989). p22phox mRNA shows broad and abundant 
tissue distribution (Parkos et al., 1988; Cheng et al., 2001), but protein expression is 
dependent on the presence of Nox proteins (Ambasta et al., 2004).  
 
p47 phox 
p47phox is a cytosolic, multi-domain adapter protein that serves as an “organizer” in the 
assembly of the NADPH Oxidase complex (Takeya and Sumimoto, 2006). A highly basic 
protein of 390 amino acids, (pI = 9.6), p47phox contains many motifs involved in protein-
protein interactions:  an N-terminal PX (for Phox homology) domain that binds 
phosphoinositides and is involved in membrane association; two consecutive SH3 (Src 
Homology 3) domains, which bind proline-rich sequences (Ren et al., 1993), like that which 
is found in the C-terminal tail of p22phox; an autoinhibitory region (AIR) that maintains 
p47phox in an autoinhibited state when the oxidase is not active; and a C-terminal proline-
rich region (PRR) which is involved in interaction with p67phox (Cross and Segal, 2004).  
 
 
Figure 8. Domain structure of p47phox. 
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The PX domain was originally discovered in two phagocytic oxidase proteins, p47phox and 
p40phox, and was subsequently found in other proteins involved in signal transduction and 
membrane association (Ponting, 1996). Membrane association is mediated through its 
ability to bind phosphoinositides. The PX domain of p47phox preferentially binds 
phosphatidylinositol-3,4-bisphosphate (PI(3,4)P2) (Kanai et al., 2001), and a recent x-ray 
crystal structure revealed two potential binding sites for phosphoinositides occupied by two 
bound sulfates (Karathanassis et al., 2002). The PX domain of p47phox also contains a 
proline-rich motif, which was found to interact with the C-terminal SH3 domain with an 
affinity of 50 µM based on NMR chemical shift perturbations (Hiroaki et al., 2001). This 
interaction may represent an intramolecular regulatory mechanism for membrane targeting, 
by preventing p47phox binding to phosphoinositides prior to oxidase activation (Figure 9).  
Following the PX domain are two SH3 domains which bind a polybasic region within the 
autoinhibitory domain (Ago et al., 1999; Huang and Kleinberg, 1999), maintaining 
autoinhibition. The tandem SH3 domains have also been crystallized along with the 
autoinhibitory region (Groemping et al., 2003). The structure revealed a “super SH3” 
domain comprised of both SH3 domains creating a groove with the autoinhibitory region 
bound in between. This autoinhibitory region contains a number of basic residues as well as 
several serines which undergo phosphorylation (El Benna et al., 1994) in response to stimuli 
that activate the resting NADPH Oxidase. This multiple phosphorylation disrupts the 
interactions with the SH3 domains, releasing p47phox from its autoinhibited form (Figure 9). 
It additionally allows two regions of the protein to bind to membrane targets:  binding of the 
PX domain to phosphoinositides (Karathanassis et al., 2002; Ago et al., 2003) and binding 
of the tandem SH3 domains to the proline-rich region of p22phox (Ago et al., 1999; Shiose 
and Sumimoto, 2000; Nobuhisa et al., 2006). The very C-terminus of  p47phox contains a 
proline-rich region that binds the C-terminal SH3 domain of p67phox independently of 
phosphorylation (Leto et al., 1994; Finan et al., 1994; Leusen et al., 1995) (Figure 10), and 
this interaction recruits p67phox to the membrane (Heyworth et al., 1991; Dusi et al., 1996). 
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Figure 9. Intramolecular autoinhibition of p47phox. Prior to oxidase activation, p47phox exists in an 
autoinhibited form, with the proline-rich region of its PX domain interacting with the C-terminal SH3 
domain, and the AIR binding between the SH3 domains (center schematic). The corresponding NMR 
solution structure (PDB Code 1GD5, Hiroaki, et al 2001) of the p47phox PX domain is shown as a 
ribbon representation with the proline-rich region highlighted in orange, as well as the crystal 
structure of the tandem SH3 domains (blue ribbon) of p47phox bound by the AIR (yellow). In response 
to stimuli, p47phox is heavily phosphorylated at 11 sites within the AIR which disrupts the 
intramolecular interactions and allows p47phox to bind membrane targets. Shown are the corresponding 
crystal structures of the p47phox PX domain (yellow ribbon) with the phosphoinositide binding sites 
indicated by two bound sulfate ions (red) (PDB Code 1O7K, Karathanassis et al, 2002), and the 
crystal structure of the tandem SH3 domains with a bound peptide of the p22phox C-terminus indicated 
by yellow stick representation, (which coincides with the site that binds the AIR). Both figures of the 
crystal structures of the tandem SH3 domains from Groemping and Rittinger, 2005 ((Groemping and 
Rittinger, 2005). 
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Figure 10. Interaction of the C-terminal 
proline-rich region of p47phox (beige ribbon) 
with the C-terminal SH3 domain of p67phox 
(green ribbon) as solved by NMR (Kami et 
al., 2002), with residues essential for the 
interaction shown as stick representations. 
 
 
p67 phox 
The second obligatory cytosolic oxidase component is p67phox (526 amino acids, pI= 6.21) 
(Cross and Segal, 2004). In contrast to p47phox, it plays a critical role in activation of 
NADPH oxidase activity, and is believed to participate in the electron transfer steps from 
NADPH to FAD (Cross and Curnutte, 1995). Like p47phox, it is also a protein composed of 
several motifs involved in protein-protein interactions. Its N-terminus contains 4 
tetratricopeptide repeats (TPR) which mediate Rac binding, followed by an activation 
domain (residues 199-210) that is needed for activation of oxidase activity. p67phox 
additionally contains two SH3 domains with a PB1 domain sandwiched in between.  
 
Figure 11. Domain structure of p67phox. 
 
The TPR motif is a repeating 34 amino acid motif (Sikorski et al., 1990) that 
characteristically forms an extended domain composed of pairs of antiparallel α-helices that 
adopt a right-handed superhelical twist creating an amphipathic groove (Melville et al., 
2000). The N-terminal region of p67phox comprising the TPR motifs have been shown to 
bind Rac (Diekmann et al., 1994; Ahmed et al., 1998; Koga et al., 1999), and as revealed in 
the crystal structure of the complex between the N-terminal region of p67phox (1-203) and 
Rac1, the binding interface is actually mediated by a β-hairpin insertion between TPR3 and 
30 
Introduction  
 
TPR4, and not the TPR groove (Lapouge et al., 2000). Instead, residues 168 to 186 fold 
back into the hydrophobic groove.  
 
Figure 12. Crystal structures of the p67phox TPR domain alone and in complex with Rac•GTP. Left, 
Ribbon representation of the p67phox TPR domain alone with the β-hairpin insertion colored in yellow-
green, and the additional C-terminal helix in orange. Right, Ribbon representation of the p67phox TPR-
Rac•GTP complex highlighting the Switch I and II regions in red, and the β-hairpin insertion colored 
green. Figures from Grizot et al, 2001 (left, PDB Code 1HH8) and Lapouge et al, 2000 (right, PDB 
Code 1E96). 
 
The TPR domain has also been crystallized alone (Grizot et al., 2001), utilizing a longer 
construct that includes the activation domain (although this region is not seen in the electron 
density), in contrast to the construct used in the Rac complex. Binding of Rac does not 
cause large structural rearrangements in p67phox, with the only difference between the two 
structures being a small additional helix that is present at the end of the loop that packs into 
the TPR groove. There is some inconsistency with affinity measurements for the Rac- 
p67phox interaction, with fluorescence titration determinations yielding affinities of 120 nM 
(Nisimoto et al., 1997), and 31 nM (Han et al., 1998) and ITC measurements giving 1.7 µM 
(Lapouge et al., 2000). 
Studies using various truncations of p67phox led to the identification of an activation domain 
(residues 199-210) that is essential for NADPH Oxidase activity (Han et al., 1998). As for 
the proline-rich region and N-terminal SH3 domain of p67phox, the identity of the respective 
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binding partners for these regions are still unknown. As mentioned earlier, the C-terminal 
SH3 domain of p67phox binds the C-terminal proline-rich region of p47phox (Leto et al., 1994; 
Finan et al., 1994; Leusen et al., 1995). 
The PB1 domain of p67phox has been shown to bind the PB1 domain in another oxidase 
protein, p40phox. PB1 domains are so named because they were originally found in Phox 
proteins and the budding yeast protein Bem1p (Ito et al., 2001). The crystal structure of this 
complex is also known (Wilson et al., 2003), and shows the mode of binding involves a 
front-to-back interaction of each PB1 domain mediated by electrostatic interactions, with 
the highly basic, concave back of PB1p67phox binding to the acidic, convex front of 
PB1p40phox. 
 
Figure 13. Ribbon diagram of the p40phox PB1 (yellow)/p67phox PB1 (blue) heterodimer. A short 
sequence found in some PB1 domains is highlighted in orange, and the D289p40phox, 
D293p40phox/K355p67phox electrostatic interaction is shown with stick representation. Figure from 
Wilson et al, 2003 (PDB Code 1OEY). 
 
p40 phox 
p40phox (339 amino acids) is an oxidase protein whose exact role is not entirely understood. 
It is constitutively associated with p67phox in resting neutrophils (Wientjes et al., 1996), 
mediated by the PB1 domains of each protein. This interaction is quite strong:  4 nM for the 
isolated PB1 domains of each protein (Wilson et al., 2003), and 10 nM for the full-length 
proteins (Lapouge et al., 2002). Similar to p47phox and p67phox, it is composed of protein-
protein interaction motifs:  an N-terminal PX domain, followed by a SH3 domain, and a C-
32 
Introduction  
 
terminal PB1 domain. Although much is known regarding the PX and PB1 domains, the 
binding partner and role of the SH3 domain has not been established yet. 
 
Figure 14. Domain structure of p40phox. 
In contrast to the PX domain of p47phox, the PX domain of p40phox binds 
phosphatidylinositol-3-phosphate (PI(3)P) (Kanai et al., 2001; Ellson et al., 2001b) which 
has been shown recently to stimulate NADPH Oxidase activity (Ellson et al., 2001b). Its 
structure has also been determined to 1.7 Å in complex with di-butanoyl-PI(3)P (Bravo et 
al., 2001). 
 
 
Figure 15. Left, Ribbon representation of the crystal structure of the p40phox PX domain in complex 
with di-butanoyl-PI(3)P (pink stick; Bravo et al, 2001, PDB Code 1H6H). Right, Ribbon 
representation of the crystal structure of full-length p40phox (Honbou et al , 2007, PDB Code 2DYB). 
The superposition of the two molecules in the asymmetric unit is shown, demonstrating the flexibility 
in the position of the SH3 domain. 
Recent cellular studies indicate that p40phox can enhance NADPH Oxidase activation, the 
degree of which seems to depend on the stimulus used (Kuribayashi et al., 2002). The full-
length p40phox has recently been crystallized (Honbou et al., 2007), and gives insight into 
another form of autoinhibition when the oxidase is not active. In vivo studies confirmed that 
the PB1 domain inhibits interaction of the PX domain with its membrane lipid target PI(3)P 
(Honbou et al., 2007), a lipid that is enriched in phagosomal membranes (Kanai et al., 2001; 
Ago et al., 2001; Ellson et al., 2001a). The structure of the full-length protein indicates the 
interaction occurs at another region of the PB1 domain, which leaves the PB1p67phox - 
PB1p40phox interaction undisturbed. In this way, p40phox may help in the recruitment of 
p67phox to the membrane upon stimulation. 
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Rac  
Rac is a small (21 kDa) GTP-binding protein that belongs to the Rho (Ras homology) 
family of small GTPases. These proteins cycle between inactive GDP-bound and active 
GTP-bound forms, regulating signal transduction cascades that affect actin cytoskeletal 
organization, cell growth, endocytosis and secretion (Hall, 1994; Ridley, 1996). Rac 
undergoes prenylation at its C-terminal tail with the 20-carbon geranylgeranyl isoprenoid, 
which enables it to target to membranes (Zhang and Casey, 1996). In its inactive form, 
prenylated Rac•GDP is bound by its cytosolic chaperone, Rho GDP dissociation inhibitor 
(RhoGDI) (Abo et al., 1991; Chuang et al., 1993; Abo et al., 1994), which prevents 
unsignaled exchange to GTP and sequesters the geranylgeranyl group, maintaining 
prenylated Rac in a soluble form (Gregg et al., 2003). Stimuli-induced Rac activation 
targets the complex near the membrane, with subsequent dissociation of prenylated 
Rac•GDP from RhoGDI for Rac membrane localization. Guanine nucleotide exchange 
factors (GEFs) accelerate the dissociation rate of GDP (Vetter and Wittinghofer, 2001), 
allowing Rac to bind GTP, which is normally present at a ~10-fold higher concentration 
than GDP inside the cell. This active form of Rac is available to interact with many different 
effector molecules to transduce the desired signal. The duration of this signal is regulated by 
GTP hydrolysis. Rac, like all small GTPases, has a slow intrinsic GTPase activity, which is 
accelerated by GTPase activating proteins (GAPs) (Moon and Zheng, 2003), and returns 
Rac to the GDP-bound state. The cycle is completed with the extraction of prenylated 
Rac•GDP from the membrane by RhoGDI.  
In addition to its roles in cytoskeleton rearrangement and cell growth, Rac is also required 
for NADPH Oxidase activation, with both Rac1 (Abo et al., 1991) and Rac2 isoforms 
(Knaus et al., 1991) capable of supporting oxidase activity in cell-free studies. In human 
neutrophils, Rac2 is the predominant Rac isoform (Knaus et al., 1991), whereas Rac1 is 
expressed ubiquitously (Bokoch and Zhao, 2006) and has been used in many of the studies 
investigating the role of Rac in NADPH Oxidase. The two isoforms share 92% sequence 
identity, with the main differences found in the composition of their C-terminal tails 
(residues 183-188) that are involved with membrane association (Bokoch and Zhao, 2006).  
All small GTPases have two characteristic regions termed Switch I and Switch II, which are 
involved in nucleotide binding and undergo conformational changes with respect to GDP 
and GTP binding (Vetter and Wittinghofer, 2001). Many downstream effector molecules 
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regulated by GTPases recognize these changes and form complexes with the active GTP-
bound form that involve one or both of the Switch regions (Vetter and Wittinghofer, 2001). 
In the case of the phagocytic NADPH oxidase complex, the TPR region of p67phox binds 
Rac via the Switch I region (residues 26-45) (Diekmann et al., 1994; Freeman et al., 1994; 
Xu et al., 1994; Lapouge et al., 2000) (Figure 12). Two residues of Switch I, Ala 27 and Gly 
30, mediate the specificity of p67phox interaction with Rac (Lapouge et al., 2000). 
Like all members of the Rho family, Rac contains an additional 12 residue “insert region” 
(residues 124-135) relative to other GTPases. The exact function of this region is not clear, 
with some reports implicating its involvement in NADPH oxidase activation (Freeman et 
al., 1996; Joneson and Bar-Sagi, 1998; Diebold and Bokoch, 2001) and Rac-induced DNA 
synthesis leading to cell proliferation (Joneson and Bar-Sagi, 1998), while others finding no 
effect on oxidase activity (Toporik et al., 1998; Alloul et al., 2001). Translocation 
experiments have suggested a direct interaction of Rac with cytochrome b558 via the insert 
region (Diebold and Bokoch, 2001), with only 25% of Rac translocated to the membrane in 
X chromosome-linked CGD neutrophils deficient in cytochrome b558 (Heyworth et al., 
1994).  
 
Phagocytic NADPH Oxidase activation 
Due to its role in the destruction of pathogens and its high catalytic output, the phagocytic 
NADPH oxidase is tightly regulated such that superoxide production occurs only when 
pathogens have been phagocytosed to avoid injury to normal cellular tissues. Therefore, 
neutrophils must be stimulated to signal the assembly of the cytosolic regulatory proteins to 
the phagosome membrane. By-products from bacterial protein secretion, like the N-
formylated peptide N-formyl-Met-Leu-Phe, or opsonized particulate stimuli bind to cell 
surface receptors and stimulate neutrophils (Bokoch and Zhao, 2006). Many researchers use 
the phorbol ester, PMA (phorbol 12-myristate 13-acetate), a soluble protein kinase C 
agonist (Nauseef, 2004) to stimulate cells since PKC is responsible for the phosphorylation 
of several serines in the AIR of p47phox, a key event in phagocytic NADPH oxidase 
activation. Additionally, phospholipase A2 generation of intracellular arachidonic acid 
seems to be required for phagocytic oxidase activation (Dana et al., 1994; Dana et al., 
1998), although the precise mechanism of this action is still unknown. 
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Cell stimulation leads to translocation of all three cytosolic oxidase components p47phox, 
p67phox, and p40phox to the membrane (Wientjes et al., 1993). Phosphorylation of the 
autoinhibitory region in p47phox releases autoinhibition, allowing its tandem SH3 domains to 
bind to the proline-rich region in p22phox, and its PX domain to bind phosphoinositides in the 
membrane. p47phox carries p67phox to the membrane via a tail-to-tail interaction between the 
C-terminal SH3 domain of p67phox and the C-terminal proline-rich region of p47phox.  
Translocation of p67phox to the membrane is further enhanced by interactions of p40phox with 
membrane phosphoinositides via its N-terminal PX domain. Once positioned at the 
membrane, p67phox requires interaction with the small GTPase Rac to initiate electron 
transfer in gp91phox for superoxide production. Rac translocates to the membrane 
independently from the cytosolic oxidase proteins (Heyworth et al., 1994) after  dissociation 
from RhoGDI. Membrane associated GEFs exchange GDP for GTP, and prenylated 
Rac•GTP binds the TPR domain of p67phox, enabling the activation domain of p67phox to 
activate superoxide production through gp91phox.  
 
1.3.3 Nox1 
Nox1 was the first discovered homologue of gp91phox and was initially considered to be 
mitogenic, based on subsequent tumor formation when NIH-3T3 cells overexpressing Nox1 
were injected into nude mice (Suh et al., 1999). This was later found to be caused by a 
mutant form of Ras present in these cells (Lambeth, 2004). Although Nox1 is present in 
colon cancer cell lines, its suppression does not affect cell proliferation (Geiszt et al., 
2003a). Instead, Nox1 expression is increased in more differentiated colon tumors, 
suggesting another role which at present remains to be characterized.  
Nox1 is most abundant in the colon, and is believed to participate in host defense in the 
digestive tract based on findings that specific microbial components recognized in innate 
immune responses induce Nox1 expression and subsequent ROS generation. For example, 
lipopolysaccharides from the pathogenic Helicobacter pylori (a Gram-negative bacterium 
which infects the stomach) can elicit increased ROS release by activation of Nox1 in guinea 
pig gastric pit cells (Kawahara et al., 2001). Lipopolysaccharides are components in the cell 
wall of Gram-negative bacteria that allow pathogenicity. Nox1 is similarly induced in 
human colon cancer cells in response to recombinant flagellin from Salmonella enteriditis, 
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which increases ROS release as well as ROS-dependent release of the inflammatory 
cytokine interleukin-8 (IL-8) (Kawahara et al., 2004). 
Nox1 is 58% identical to gp91phox and of all the Nox homologues it is the most functionally 
similar to gp91phox, as indicated by its ability to rescue gp91phox deficiency in CGD 
neutrophils (Geiszt et al., 2003a). It can be activated by p47phox and p67phox, although 
superoxide production is only marginally increased (Takeya et al., 2003). Nox1 possesses 
its own regulatory proteins, termed Noxo1, for Nox organizer 1 (the equivalent of p47phox) 
and Noxa1, for Nox activator 1 (the equivalent of p67phox), both of which are expressed in 
the colon (Banfi et al., 2003; Geiszt et al., 2003b). Nox1 produces little or no superoxide on 
its own (Takeya et al., 2003), and this can be significantly increased through interaction 
with Noxo1 and Noxa1 (Takeya et al., 2003; Banfi et al., 2003; Geiszt et al., 2003b).  
 
Comparison of regulatory proteins for Nox1 and the phagocytic oxidase  
Noxo1 and Noxa1 share a majority of the motifs found in p47phox and p67phox, respectively, 
with some exceptions. Noxo1 lacks the autoinhibitory region present in p47phox, while 
Noxa1 lacks the N-terminal SH3 domain of p67phox.  
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Figure 16. Domain structure of Noxo1 and Noxa1, with comparison to p47phox and p67phox, 
respectively. Figure after Takeya and Sumimoto, 2003. 
 
Both proteins show relatively low overall sequence identity to their phagocytic counterparts 
(23% identity of Noxo1 to p47phox and 28% identity of Noxa1 to p67phox), yet they both are 
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capable of most of the interactions seen for phagocytic oxidase proteins. Site-specific 
mutations that define the molecular interactions of the phagocytic oxidase components have 
confirmed this. The tandem SH3 domains of Noxo1 recognize the proline-rich C-terminus 
of p22phox, confirmed with a loss of interaction with a P156Q mutation, a naturally occurring 
mutation in p22phox from a CGD patient. Similarly, the SH3 domain of Noxa1 binds the C-
terminal proline-rich region of Noxo1, with disruption of the interaction when Trp 436 of 
the Noxa1 SH3 domain is mutated to Arg. Additionally, the TPR domain of Noxa1 binds 
Rac•GTP, with loss of interaction when Arg 103Noxa1 is substituted by Glu (Takeya et al., 
2003).  
Noxo1 and Noxa1 do not exclusively regulate Nox1. They have been found to regulate 
Nox3 in a Rac-independent manner, as well as in mixed complexes with p47phox and p67phox. 
They can additionally activate gp91phox, although they activate Nox1 more efficiently 
(Takeya and Sumimoto, 2006). In contrast to gp91phox, Nox1 and Nox3, Nox4 is capable of 
generating superoxide without the need for additional regulating proteins like p47phox, 
p67phox, Noxo1 or Noxa1 (Geiszt et al., 2000; Shiose et al., 2001; Ambasta et al., 2004; 
Martyn et al., 2006). 
Alternative splice forms of Noxo1 have also been found, designated Noxo1α, β, γ, and δ 
(Cheng and Lambeth, 2005; Takeya and Sumimoto, 2006). Noxo1β is the predominant form 
expressed in most tissues, like the colon. Noxo1α and Noxo1δ each have a single amino 
acid deletion of Lys 50 in the PX domain with respect to Noxo1β, and exhibit weaker ability 
to activate Nox1. Both splice forms are found in much lower abundance in tissues such as 
testis, fetal liver and the human colon cancer cell line T84, and therefore may have little 
biological relevance. Noxo1γ, on the other hand, possesses a five amino acid insertion in the 
PX domain with respect to Noxo1β, and is expressed in the testis at similar levels as 
Noxo1β. This insertion apparently allows Noxo1γ to localize primarily in the cytoplasm, in 
contrast to the exclusive membrane association of Noxo1β in resting cells. The activity of 
Noxo1γ is still controversial, with some reports of equal activation as Noxo1β (Cheng and 
Lambeth, 2005), and others observing lower activation (Takeya et al., 2006). The 
subsequent use of the term Noxo1 in this writing refers to Noxo1β, the first published form 
without insertions or deletion. 
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Regulation of Nox1 
The Nox1 oxidase shares several aspects analogous to the regulatory mechanisms of the 
phagocytic NADPH oxidase (Ueyama et al., 2006). Nox1 functionally associates with 
p22phox in the plasma membrane and exhibits enhanced superoxide production when p22phox 
is coexpressed (Takeya et al., 2003; Ambasta et al., 2004; Hanna et al., 2004). Both proteins 
have mutually stabilizing effects on each other, as evidenced by increased protein 
expression when the other is coexpressed (Hanna et al., 2004). Like p47phox, Noxo1 interacts 
with the proline-rich region of p22phox and interacts in a tail-to-tail fashion with Noxa1 to 
recruit it to the membrane. Noxa1 also binds Rac•GTP via the TPR region, and both 
proteins (like p67phoxand Rac) can support Nox1 superoxide generation in the absence of 
Noxo1 (Ueyama et al., 2006). 
Although Nox1 shares many features of the phagocytic oxidase, there are several important 
differences in the regulation of Nox1, most notably with respect to Noxo1. In contrast to 
p47phox, Noxo1 is localized in the membrane, independent of cell activation. Since it lacks 
the region homologous to the autoinhibitory region in p47phox, it is constitutively associated 
with the membrane via its PX domain (Cheng and Lambeth, 2004). A consequence of this 
feature is seen in the ability of Nox1 to spontaneously produce superoxide once Noxo1 and 
Noxa1 are coexpressed, without the requirement for PMA stimulation (Takeya et al., 2003; 
Geiszt et al., 2003b). PMA is still capable of slightly increasing Nox1 superoxide 
production (Takeya et al., 2003). A second area of difference lies with Noxa1. Despite 
possessing a PB1 domain like p67phox, it does not interact with p40phox, due to the 
substitution of a conserved Lys at position 355 by Glu within this domain, which is essential 
for this interaction (Takeya et al., 2003). 
Recent studies on Nox1 with regards to host defense have demonstrated that Nox1 is 
additionally regulated at the transcriptional level. In gastric mucosal cells of guinea pigs, 
lipopolysaccharides from Helicobacter pylori activate Rac1 and transcription of Nox1 and 
Noxo1 mRNA (Kawahara et al., 2005). Interestingly, Noxa1 mRNA is constitutively 
expressed in these cells, indicating that activation of Rac1 and induction of Nox1 and 
Noxo1 serve as triggers to activate oxidase activity in these cells. Once activated, these cells 
continuously and spontaneously produced superoxide at a rate of ~100 nmol·mg protein-1·h-1 
for more than 24 hours. Although this oxidative output is not sufficient to kill H. pylori, 
compared to 348 nmol·mg protein-1·min-1 for the phagocytic oxidase (Cross et al., 1985), 
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Nox1 may serve as an initial signal for the cell to mount immune and inflammatory 
responses against such pathogens.  
 
Role of Nox1 in disease 
This inducible nature of Nox1 has captured the attention of many researchers with regards 
to factors that can induce Nox1 expression and which have been found to promote vascular 
disease. Angiotensin II (Lassegue et al., 2001), growth factors like PDGF (Lassegue et al., 
2001), LDL (Holland et al., 1996; Holland et al., 1997), and mechanical stimuli (Grote et 
al., 2003; Castier et al., 2005; Jo et al., 2006) have all been found to upregulate Nox1 
mRNA. In the case of mechanical stimuli, hemodynamic forces have been shown to 
profoundly affect the vasculature. Normal blood flow in straight portions of the artery is 
uni-directional and is termed laminar shear stress. Disturbed blood flow, which includes 
oscillatory shear stress, is found in areas such as branched and curved regions in the artery, 
which are more likely to develop atherosclerotic lesions (Zarins et al., 1983; Ku et al., 
1985). Interestingly, laminar shear stress stimulates eNOS production of NO., whereas 
oscillatory shear stress activates Nox oxidases in endothelial and vascular smooth muscle 
cells. Disturbed blood flow increases Nox-derived superoxide, leading to reaction with NO. 
and the production of ONOO-, thereby decreasing the bioavailability of NO., which in turn 
leads to increased endothelial dysfunction. In some cases, like high pressure in some models 
of hypertension, mechanical stimuli do not alter Nox mRNA expression but rather increase 
Nox oxidase activity (Ungvari et al., 2006). This mechanosensitivity may derive from 
increases in intracellular Ca2+ concentration, as well as phosphorylation and activation of 
the kinase PKC-α (Ungvari and Koller, 2000; Ungvari and Koller, 2001; Ungvari et al., 
2004). 
Oscillatory shear stress additionally stimulates inflammation through the induction of 
adhesion molecules and subsequent monocyte adhesion to endothelial cells, which has been 
found to depend on a Nox1 and p47phox containing oxidase in endothelial cells (Hwang et 
al., 2003; Sorescu et al., 2004). This involves the cell adhesion molecule, ICAM-1 (Chiu et 
al., 1997), a molecule involved in monocyte adhesion and transendothelial migration, 
through the actions of the potent inflammatory cytokine, bone morphogenic protein 4 
(BMP4), a member of the transforming growth factor-β (TGF-β) super family (Jo et al., 
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2006). As mentioned earlier, induction of adhesion molecules plays a critical role in the 
pathogenesis of atherosclerosis and lesion development.  
Mechanical forces have also been recently shown to affect Nox1 with regards to matrix 
remodeling. Vascular smooth muscle cells from mice respond to mechanical stretch with 
rapid ROS formation which correlates with p47phox translocation to the membrane, an 
increase in Nox1 mRNA, and an increase in both mRNA and activity of the matrix 
metalloproteinase, MMP-2. Each of these effects were dependent on p47phox (Grote et al., 
2003). Recent studies using mice deficient in gp91phox or p47phox have also implicated Nox1 
as the oxidase that responds to chronic increase in blood flow with increased superoxide 
generation (Castier et al., 2005). This study confirmed the subsequent production of  
ONOO-, and demonstrated MMP activation in carotid arteries. Superoxide production, 
expression of MMP-9 and upregulation of MMP-2 were all found to depend on p47phox, but 
not gp91phox, implicating a role for Nox1. Thus, Nox1 containing oxidases may mediate 
flow-induced vascular remodeling, which has important implications with regards to 
atherosclerosis in lesion formation, development, and plaque rupture.  
It is important to note that multiple Nox isoforms exist in the vasculature, which adds 
additional layers of complexity. Three Nox proteins, gp91phox, Nox1 and Nox4 have 
emerged as key sources of superoxide in the vasculature.  All are expressed at the mRNA 
level in all three layers of human arteries to distinctly varying degrees (Sorescu et al., 2002). 
gp91phox mRNA is found most in endothelial cells, with much lower levels in smooth 
muscle cells and adventitial fibroblasts. Nox4 mRNA is abundant in all cells of the 
vasculature, with the highest expression in endothelial cells, followed by adventitial 
fibroblasts and smooth muscle cells. Conversely, Nox1 mRNA is expressed in low levels in 
each of these cells. Levels of mRNA, however, do not necessarily equate with protein 
levels, as seen by the localization of these Nox proteins in human coronary arteries. gp91phox 
was found mostly in the adventitia, to a lesser degree in the intima, and was nearly absent 
from the media. In contrast, Nox4 protein was found abundantly in the media, with a weaker 
presence in adventitial fibroblasts and the intima. Although Nox4 is abundant in the medial 
layer of the vessel wall, many of the agonist-induced superoxide production in VSMCs has 
been found to depend on p47phox, which is not required for Nox4 activity. In fact, p47phox has 
been found to play a pivotal role with regards to early stages of atherosclerosis. In an animal 
model of atherosclerosis, mice deficient in p47phox demonstrated a 75% reduction in the total 
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lesion area of descending aortas (where early lesions appear), regardless if fed a normal or 
high fat diet. gp91phox-deficiency did not affect the level of agonist-induced superoxide 
production, implicating the involvement of Nox1 (Barry-Lane et al., 2001). Despite its low 
mRNA expression, Nox1 has been found to be the major oxidase in vascular smooth muscle 
cells, based on studies using Nox1 antisense mRNA and anti-Nox1 ribozymes which 
decreased the agonist-induced superoxide production in VSMC (Lassegue et al., 2001; 
Katsuyama et al., 2002; Lassegue and Clempus, 2003). Often only information regarding 
Nox1 mRNA expression is available, due to a lack of an appropriately specific Nox1 
antibody (Lassegue et al., 2001; Bedard and Krause, 2007). Other oxidase proteins such as 
p22phox, p47phox, and p67phox are also expressed at both the mRNA and protein level in all 
cells of the vessel wall (Lassegue and Clempus, 2003). At present, there is little information 
regarding the presence of Noxo1 and Noxa1 in vascular cells. Recent work describes the 
localization of Noxa1 protein in the medial layer of mouse arteries and the translocation of 
Noxa1 and p47phox in response to the proliferative agonist epidermal growth factor, 
suggesting that Nox1 is activated by the combination of one classical and one novel 
regulatory protein in vascular cells (Ambasta et al., 2006).   
Not only can a single Nox isoform affect many processes in vascular pathologies, multiple 
Nox isoforms can also collectively contribute to a single pathology. The recent use of 
animals deficient in a particular Nox isoform are beginning to delineate the individual 
contributions of different Nox proteins, suggesting specific roles of Nox isoforms in 
vascular disease development. One example is the role of Nox proteins in angiotensin II-
induced hypertension. Hypertension can lead to smooth muscle hypertrophy (an increase in 
the size of smooth muscle cells) and increased vascular cross-sectional area, as a 
consequence of pressure-induced and pressure-independent mechanisms. In addition to its 
direct effects on blood pressure, angiotensin II can additionally induce medial smooth 
muscle hypertrophy in culture, and this was found to depend on NADPH Oxidase-derived 
ROS (Griendling et al., 1994; Liu et al., 2004).  Nox1 deficiency in vivo was found to affect 
blood pressure, with Nox1-deficient mice retaining the ability of endothelium-dependent 
vasodilation. In contrast, mice containing a functional Nox1 showed significantly decreased 
cGMP levels, indicating that elevated blood pressure in response to angiotensin II occurs 
through NO. depletion by Nox1-derived superoxide. Nox1 deficiency, however, did not 
affect hypertrophy of VSMCs in the media of mice aortas (Matsuno et al., 2005). 
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Conversely, in vivo deficiency in gp91phox did not affect blood pressure, but did reduce 
hypertrophy of VSMCs in the media (Wang et al., 2001). gp91phox-deficient mice exhibited 
significant reduction of ROS production in the endothelium and adventitia, which supports 
other data that suggests paracrine signaling of endothelial and adventitial ROS on the media 
(Liu et al., 2004). With regards to hypertension, the causes of which are complex and often 
varied from individual to individual, these findings are significant because they allow for 
the possibility of specific therapies for different underlying causes.  
The participation of NADPH Oxidases in multiple aspects of atherosclerosis makes them 
attractive targets for therapeutic intervention.  Inhibitors directed at the responsible sources 
of ROS may be more effective than unspecific treatment with antioxidants, which have the 
potential to perturb normal cellular ROS signaling without effectively hindering 
dysregulated ROS production in pathological settings. Nox isoform-specific inhibitors may 
allow for targeted intervention at a particular cell, tissue, or pathway, which may enable 
custom therapies for individuals with different pathological backgrounds.  
 
In addition to their roles in vascular diseases, there is an increasing appreciation for the role 
of NADPH Oxidases in cell proliferation and the pathogenesis of neurodegenerative 
diseases. Many human tumors constitutively produce large amounts of hydrogen peroxide, 
which can be inhibited by the flavoprotein inhibitor, diphenyleneiodonium (DPI), a known 
inhibitor of NADPH Oxidase (Szatrowski and Nathan, 1991). Normal cells also produce 
hydrogen peroxide in response to peptide growth factors such as epidermal growth factor 
(EGF) and PDGF. Growth factors bind their respective receptor tyrosine kinases, leading to 
phosphorylation of the receptors and other signaling molecules. This process is normally 
regulated by protein tyrosine phosphatases (PTPs), which remove phosphates, thus ensuring 
a limited duration of the growth signal. Hydrogen peroxide promotes growth signaling by 
inactivating PTPs through the oxidation of a key cysteine residue that must remain reduced 
to form a thiol-phosphate intermediate in the catalytic mechanism (Maehama et al., 2001).  
A second action of growth factor signaling is the transient activation of phosphatidylinositol 
(PI) 3-kinase to produce phosphatidylinositol 3,4,5-triphosphate (PIP3). This lipid second 
messenger activates many downstream targets, such as the protein kinase Akt, which is 
involved in cell proliferation and cell survival. Levels of PIP3 are regulated by lipid 
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phosphatases, such as the phosphatase with sequence homology to tensin (PTEN), which is 
a PIP3 3-phosphatase. PTEN is a tumor suppressor and belongs to the PTP family of 
phosphatases. It has been found to undergo reversible inactivation by hydrogen peroxide 
through active site cysteine oxidation in growth factor stimulated cells stably expressing 
Nox1 or a dominant negative peroxidase, either of which results in elevated intracellular 
hydrogen peroxide levels. Increased PIP3 levels observed in cells overexpressing Nox1 can 
further activate Nox1 by activating βPix, a guanine nucleotide exchange factor for Rac. Like 
all GEFs, βPix contains a pleckstrin homology domain which is activated by PIP3 or 
PI(3,4)P2 (Kwon et al., 2004). Hydrogen peroxide production in growth factor stimulated 
cells has been found to require PI 3-kinase activation, with formation of a ternary complex 
between Rac, βPix, and Nox1 (Bae et al., 2000; Park et al., 2004). Other studies that suggest 
a role for Nox1 in cell proliferation include studies using RNA interference of Nox1 which 
demonstrated a requirement for Nox1 in Ras activated ROS production, oncogenic 
transformation, and tumor growth (Mitsushita et al., 2004). Nox1 expression in lung 
epithelial cells was also found to promote cyclin D expression in a dose dependent manner. 
Cyclin D is a critical regulatory protein that controls progression of cells into the cell cycle 
for division. Thus, Nox1 may be a novel target for antitumor therapies. 
Increasing evidence indicates a role for NADPH Oxidases in neurodegenerative diseases 
like Alzheimer’s and Parkinson’s disease, where chronic oxidative stress contributes to 
neuronal death, protein aggregation and pathogenesis (Giasson et al., 2002; Klein and 
Ackerman, 2003; Norris and Giasson, 2005; Infanger et al., 2006). The oxidase proteins 
p47phox and p67phox have been found to accumulate in post-mortem brain tissue of 
Alzheimer’s disease patients (Shimohama et al., 2000), and fragments of β-amyloid from 
Alzheimer’s disease patients can stimulate superoxide production in rat microglial cells in a 
NADPH Oxidase-dependent manner (Bianca et al., 1999). Microglial cells act as immune 
cells of the central nervous system. While many of these studies have focused on the role of 
gp91phox/Nox2, Nox1 and Nox4 are also detected with gp91phox/Nox2 in fore-, mid-, and 
hind-brain (Infanger et al., 2006). Nox1 mRNA levels are the lowest of the three isoforms, 
but as seen in the vasculature where it can be subject to stimulus-induced activation, this 
does not necessarily negate its potential role in normal neuronal functions like long term 
potentiation, or possible roles in neurodegenerative diseases. 
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1.4 AIMS OF WORK 
While significant progress has been made unraveling the intricate and complex roles of 
NADPH Oxidases at the cell biological level, limited information is available with regards 
to the enzyme at the molecular level, in particular for the membrane-associated Nox 
proteins. Molecular details on the mechanism of electron transfer would enable us to 
understand how these enzymes produce superoxide, which may shed light on ways to 
prevent this by therapeutic intervention. Specifically, information about the three-
dimensional structure of the catalytic Nox proteins would assist in the design of novel, 
isoform-specific inhibitors, which may have significant therapeutic importance. Nox1 plays 
important roles in many facets in atherosclerosis, such as endothelial dysfunction, 
hypertension, induction of cell adhesion molecules and vascular remodeling, with additional 
potential roles in cell proliferation and neurodegenerative disease. Inhibitors of Nox1 in 
these pathological settings may provide a way of early intervention to prevent disease 
progression. This work aimed to structurally characterize human Nox1, either as a 
holoenzyme or only the cytosolic domain, by X-ray crystallography to gain insight into the 
mechanistic details of electron transfer. A prerequisite for structural studies is the ability to 
produce the protein of interest relatively pure and in appreciable amounts. A method was 
therefore developed to heterologously overexpress and purify four different constructs of 
human Nox1. Additionally, it is important to verify the biological integrity of the 
recombinant proteins. This can be accomplished by measuring a specific enzymatic activity 
if the protein performs an enzymatic function. In the case of human Nox1, a NADPH-
dependent activity assay was used to determine if the recombinant proteins were indeed 
active. Characterization of interactions with biological binding partners is another way to 
address biological integrity. Biochemical and biophysical methods were employed to 
determine if the recombinant proteins were capable of biologically relevant interactions with 
regulatory oxidase proteins. These, together with the structural characterization of human 
Nox1, could provide insights into the mechanism of electron transfer of human Nox1 and 
molecular details on how regulatory proteins enhance this activity, which can be used to 
develop novel inhibitors as potential therapeutic agents.  
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Characterization of human Nox1 
 
 
If you faint in the day of adversity, 
your strength is small. 
Prov. 24:10 
 
 
 
  
Results and Discussion  
 
2. RESULTS AND DISCUSSION    
 
2.1 GENETIC ENGINEERING AND DEVELOPMENT OF EXPRESSION AND 
PURIFICATION METHODS FOR CONSTRUCTS OF HUMAN NOX1 
Previous work (Woo, 2003, unpublished results) to establish a procedure to heterologously 
express and purify constructs of human Nox1 from E. coli involved initially two types of 
constructs:  one that encompassed the entire sequence of human Nox1 and another 
consisting of only the cytosolic C-terminal domain based on sequence alignment analysis 
from the original work that first described the Nox homologues (Cheng et al., 2001) (Figure 
17). These preliminary expression studies indicated that a construct containing an N-
terminal thioredoxin tag (to improve protein solubility) and the cytosolic C-terminal domain 
of human Nox1 could be expressed in low levels in the soluble fraction when a low 
temperature (20°C) was used for induction. Different E. coli cell strains such as BL21(DE3) 
Codon Plus RP, Origami and C41(DE3) were used for protein expression. BL21(DE3) 
Codon Plus RP contains rare tRNAs for the amino acids arginine and proline. Origami cells 
are recommended by the manufacturer for use with the expression vector (pET32a) in which 
the cytosolic C-terminal Nox1 domain was subcloned. C41(DE3) is a derivative of the 
commonly used BL21(DE3) strain, and was found to improve expression of problematic 
globular and membrane proteins (Miroux and Walker, 1996). Of these, utilization of the 
strain C41(DE3) improved soluble expression of the cytosolic domain of human Nox1. Co-
expression of the molecular chaperones GroEL/GroES did not improve soluble expression 
of the cytosolic domain of human Nox1. Other N-terminal tags were tested and an N-
terminal NusA tag was found to greatly improve soluble expression of the cytosolic domain 
of human Nox1. However, the NusA tag could not be easily removed with chromatographic 
measures after proteolytic cleavage, which decreased the utility of this construct for 
crystallization studies. This is a known disadvantage of the NusA tag (Ermolova et al., 
2003). In contrast to the cytosolic domain of human Nox1, initial trials of expression of full-
length human Nox1 with an N-terminal GST tag in Rosetta competent cells (which contain 
plasmids for rare tRNAs), and in C41(DE3) cells with and without the molecular chaperone 
system GroEL/GroES did not result in any noticeable target protein expression.  
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Figure 17. Sequence alignment of human Nox proteins (gp91phox, Nox1, Nox3, Nox4 and Nox5). Filled circles indicate candidates for heme ligation. 
Predicted transmembrane α-helices are represented by heavily hashed boxes. The lightly shaded hashed box is a transmembrane helix that lies within a 
predicted signal peptide motif for gp91phox, Nox1, Nox3, Nox4, but not Nox5, with arrows indicating the site of cleavage. FAD and NADPH binding sites are 
also indicated. Figure from Cheng et al, 2001. Red arrows indicate the start of the cytosolic domain of Nox1 used in the present work. 
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2.1.1 Full-length human Nox1 
Two factors were tested to see whether they could promote expression of human Nox1 in E. 
coli. One addressed cofactor incorporation of the heme prosthetic group as a potentially 
limiting factor. Other heme containing eukaryotic proteins expressed in E. coli have been 
found to require inclusion of the heme precursor, δ-aminolevulinic acid for expression 
(Mulrooney and Waskell, 2000). The second examined whether providing an internal 
membrane environment in E. coli for overexpressed membrane proteins to accumulate could 
promote expression. Studies on overexpression of the subunit b of E. coli F1Fo ATP 
synthase in the E. coli strains C41(DE3) and C43(DE3) were found to concomitantly 
produce intracellular membranes, and coexpression of subunit b with a target membrane 
protein was suggested as a potential strategy to promote overexpression of a desired 
membrane protein (Arechaga et al., 2000).  
 
Coexpression of human Nox1 and subunit b of E. coli F1Fo ATP synthase 
To determine if coexpression of the subunit b of E. coli F1Fo ATP synthase could promote 
expression of full-length human Nox1, cells of the strain C41(DE3) were transformed with 
both a plasmid containing the gene for subunit b (a kind gift from Prof. John E. Walker, 
MRC, Cambridge, UK) and a plasmid containing the gene for human Nox1 inserted into the 
vector pET 41a via the restriction sites NcoI and XhoI (a kind gift from Prof. Dr. H.H.W. 
Schmidt, Monash University, Melbourne, Australia). Control cells transformed with each 
single plasmid were additionally prepared. Protein expression was induced with the addition 
of a final concentration of 0.7 mM IPTG, and two induction conditions were tested:  3 hours 
at 37°C and 18 hours at 25°C. Moderate expression of subunit b could be obtained in all 
cells transformed with this plasmid. However, no overt overexpression of human Nox1 
(expected molecular weight of ~97 kDa for the construct) was seen at either induction 
condition, which was independent of the cell density at the time of induction. 
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Influence of δ-aminolevulinic acid in the coexpression of human Nox1 and subunit b 
of E. coli F1Fo ATP synthase 
The effect of including the heme precursor, δ-aminolevulinic acid was tested in conjunction 
with coexpression with subunit b on human Nox1 protein expression. To allow the cells 
time to incorporate heme into the protein, the induction conditions were adjusted to 20°C 
over 2 days. Due to the reduced induction temperature, a cold-adaption protocol (Dr. 
Konstanze von König, personal communication) was used where cultures were allowed to 
grow to cell density at 25°C instead of 37°C prior to induction. In this study, inclusion of δ-
aminolevulinic acid did not improve expression of human Nox1. One factor that could have 
affected this result was the use of the media 2YT (from the protocol for subunit b 
expression) and not the richer TB (Terrific Broth) media, which can allow for sustained 
growth over several days.  
In any case, protein expression of full-length human Nox1 in E. coli may be limited  by 
other factors like mRNA secondary structure or the fact that the lipid composition of E. coli 
membranes differs from those of eukaryotic cells. Thus, continuing efforts to heterologously 
express a eukaryotic membrane protein in a prokaryotic system may prove less successful. 
Other eukaryotic expression systems such as yeast, dictyostelium, or baculovirus might 
prove to be more useful, especially if expressed with p22phox. With regards to baculovirus, 
there has been a report of recombinant expression of the phagocytic cytochrome b558 using 
recombinant baculovirus (Rotrosen et al., 1992). This seems, however, to be limited in 
utility since no subsequent work following this isolated report has been published, 
suggesting the overall level of difficulty of overexpressing the membrane-bound Nox 
proteins in general. Additionally, the authors admit that the system produced relatively low 
amounts of recombinant cytochrome b558 protein, which precludes its usefulness for 
providing the amount of protein required for structural studies.  
 
2.1.2 The cytosolic domain of human Nox1 
As mentioned earlier, previous work involved an extensive search for conditions that would 
promote soluble expression of the cytosolic portion of human Nox1 (residues 290-564). Of 
the two initial constructs tested, one that contained an N-terminal thioredoxin tag to promote 
solubility, was found to overexpress the fusion protein, although a majority of this protein 
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was insoluble. At the time of these studies, the protease required to cleave off the 
thioredoxin tag (should it prove to be necessary for crystallization) was a limiting factor. 
One way to remedy this would be to exchange the protease cleavage site with that of 
tobacco etch virus (TEV) protease, which can be easily produced recombinantly. In addition 
to this, the cytosolic domain can be cloned into a vector that possesses a simple N-terminal 
His-tag, followed by a TEV cleavage site. In this work, two such constructs were cloned, 
expressed, and purified to determine their usefulness for structure-function studies. An 
additional His-tagged construct, which includes the cytosolic domain and at least one 
transmembrane helix, was also produced and characterized. These three constructs along 
with the original thioredoxin tagged construct are discussed below.  
 
TrxE-Nox1cyt 
Of the constructs containing the cytosolic domain of human Nox1, the original thioredoxin-
tagged construct was found to overexpress to the largest extent and the most reproducibly. 
Hence initial biochemical work was carried out with this construct to determine a template 
purification scheme that could then be used for the other constructs. In addition, preliminary 
characterizations could be made to see, for example, if the thioredoxin tag interfered at all. 
In the best case, the tag could provide additional crystal contacts and more importantly, 
could provide a method for obtaining phases via molecular replacement, should 
crystallization prove to be successful. This construct will be referred to as TrxE-Nox1cyt:  
Trx indicates an N-terminal thioredoxin tag, the italicized subscript refers to the protease 
which cleaves off the tags (in this case, enterokinase), and  Nox1cyt indicates the cytosolic 
domain of human Nox1 (residues 290-564). 
 
Figure 18. Schematic of the Trx
E
-Nox1cyt construct. To encourage protein solubility, this construct 
contains an N-terminal thioredoxin (Trx) tag followed by a 6-His Tag for affinity purification. These 
tags can be removed by the protease enterokinase to produce the cytosolic domain of human Nox1 
(residues 290-564) which contains the putative binding sites for FAD and NADPH. The additional 
amino acids alanine, methionine and glycine are inserted before the start of the Nox1 cytosolic domain 
as a consequence of using the NcoI restriction site. 
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Conditions for the expression of TrxE-Nox1cyt were determined in a previous work (Woo, 
2003, unpublished results). Briefly, C41(DE3) competent cells were transformed with the 
plasmid pET32a containing residues 290-564 of human Nox1 inserted via NcoI and XhoI 
restriction sites (a kind gift from Prof. Dr. H.H.W. Schmidt, Monash University, Melbourne, 
Australia). An overnight culture was made from a single colony in Standard 1 (ST1) or TB 
media supplemented with ampicillin, and used to inoculate larger cultures, typically 5-10L. 
Cells were grown to an optical density of 0.35-0.5 at 37°C and protein expression was 
induced with the addition of IPTG to a final concentration of 0.1 mM, and further incubated 
at 20°C overnight.  
Chromatographic measures used previously to purify TrxE-Nox1cyt indicated that Ni-NTA 
affinity chromatography and size exclusion chromatography were insufficient to purify the 
fusion protein to homogeneity (Woo, 2003, unpublished results). Subsequent purifications 
employed additional chromatographic steps that proved to be effective. The entire 
purification was made at 4°C. Initial capture proceeded via Ni-NTA affinity 
chromatography, and crude separation was achieved with a linear gradient of 5-800 mM 
Imidazole in 150 ml over two 5 ml HiTrap Ni-Chelating columns (Amersham 
Biosciences/GE Healthcare) connected in series (Figure 19). 
 
Figure 19.  Initial purification of Trx
E
-Nox1cyt with Ni-NTA chromatography. The supernatant, S, of 
clarified lysate from E. coli C41(DE3) cells expressing Trx
E
-Nox1cyt was loaded via a peristaltic pump 
onto two 5ml HiTrap Ni-Chelating Sepharose columns connected in series. The columns were pre-
equilibrated with Buffer Ni-A (20 mM Tris-HCl, pH 8, 300 mM NaCl, 5 mM Imidazole, 10% 
glycerol, 2 mM β-mercaptoethanol). Flow thru, FT, was collected and the column was washed with 
Buffer Ni-A until the absorbance reading at 280 nm returned to baseline and remained constant. The 
columns were then transferred to an ÄKTA Prime (Amersham Biosciences/GE Healthcare) and 
elution was made with a 0-80% Buffer Ni-B (20 mM Tris-HCl, pH 8, 300 mM NaCl, 1M Imidazole, 
10% glycerol, 2 mM β-mercaptoethanol) linear gradient over 150 ml. A single elution peak was 
obtained and fractions (3 ml) were analyzed on SDS-PAGE. M represents molecular weight markers. 
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An initial trial using anion exchange chromatography (Resource Q, Amersham 
Biosciences/GE Healthcare) was moderately successful to provide intermediate separation 
after Ni-NTA chromatography. A gradient from 25 mM-1M NaCl over 300 ml was set up 
and the gradient was held at 190.75 mM NaCl, allowing weakly binding proteins to elute 
until the absorbance reached baseline and remained constant. The gradient was then allowed 
to run to completion. TrxE-Nox1cyt eluted predominantly in the first peak from the hold at 
190.75 mM NaCl, with many of the contaminating proteins preferentially binding the resin. 
Although the Resource Q resin provided some separation from contaminants, its 
improvement was limited, as can be seen in Figure 20. 
 
Figure 20. Purification of Trx
E
-Nox1cyt with Resource Q chromatography. Fractions containing TrxE-
Nox1cyt pooled from Ni-NTA chromatography were desalted over 5x 5ml HiTrap Desalting columns 
(Amersham Biosciences/GE Healthcare) connected in series, and then applied to a 6ml Resource Q 
column pre-equilibrated with Buffer Res Q-A (20 mM Tris-HCl, pH 8, 25 mM NaCl, 10 % glycerol, 
and 2 mM β-mercaptoethanol). A linear gradient from 0-100% Buffer Res Q-B (20 mM Tris-HCl, pH 
8, 1M NaCl, 10 % glycerol, and 2 mM β-mercaptoethanol) was run over 300 ml, and the gradient was 
initially held at 17% Buffer B (190.8 mM NaCl) to elute weakly binding proteins. M represents 
molecular weight markers, and an orange bar indicates fractions containing Trx
E
-Nox1cyt pooled for 
further purification. 
 
The cytosolic domain of human Nox1 is predicted to contain putative binding sites for the 
cofactors FAD and NADPH, and this second binding site was exploited with a second 
affinity chromatography step using 2’5’ADP Sepharose 4B (Amersham Biosciences/GE 
Healthcare). This resin selectively binds NADP+-dependent dehydrogenases, and elution 
can proceed with a simple salt gradient for weakly binding proteins, or competitively with 
NAD+ or NADP+. In the case of TrxE-Nox1cyt, binding was weak and the fusion protein 
could be eluted with step gradients of NaCl. The separation achieved from this 
chromatographic step was so effective, it was found that anion exchange chromatography 
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could be completely omitted and a similar level of purification was seen. (Figure 21A and 
B). Western blot analysis using both antibodies against the His tag and against the C-
terminus of human Nox1 (a kind gift from Prof. Dr. H.H.W. Schmidt, Monash University, 
Melbourne, Australia) confirmed the purified protein as the desired fusion protein, TrxE-
Nox1cyt (Figure 21C). 
 
Figure 21. A, Purification of Trx
E
-Nox1cyt from 2’5’ADP Sepharose 4B. Pooled fractions containing 
Trx
E
-Nox1cyt from Resource Q chromatography were applied to a column containing 4 ml of 2’5’ADP 
Sepharose 4B resin pre-equilibrated with Buffer ADP-A (10 mM NaH2PO4, pH 7.3, 150 mM NaCl, 
10 % glycerol, and 2 mM DTT). The column was washed by gravity with two column volumes of 
Buffer ADP-A, and a series of step gradients were made with 4 ml of Buffer ADP-A containing 200 
mM, 300 mM, 400 mM, 500 mM, 700 mM and 1M NaCl, respectively. Competitive elution was made 
with 4 ml of 8 mM NADP+. Flow through, FT, and elution fractions were analyzed on SDS-PAGE. B, 
Comparison with 2’5’ADP Sepharose 4B purification of Trx
E
-Nox1cyt fractions pooled after Ni-NTA 
chromatography. Colored bars indicate peaks and respective fractions analyzed on SDS-PAGE. 
Arrowhead indicates Trx
E
-Nox1cyt. C, Western Blot analysis of purified TrxE-Nox1cyt. M represents 
molecular weight markers. 
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MALDI-TOF (matrix-assisted laser desorption ionization- time of flight) analysis (Dr. 
Robert Shoeman) additionally confirmed the correct molecular mass, with a calculated 
value of 48,616.46 Da versus the expected 48,684.55 Da for the fusion protein construct, 
which is within error of the instrument (Figure 22).  
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Figure 22. MALDI spectrum of purified Trx
E
-Nox1cyt, with a measured mass of 48,616.46 Da.  
 
Although it was possible to purify TrxE-Nox1cyt under native conditions from the soluble 
portion of E. coli lysate, the typical yields were significantly lower than typical yields 
normally obtained from proteins that overexpress well. Yields ranging from less than 0.5 
mg/107 g of cells (10 L TB) to 1.2 mg/84g (7L TB)  cells were not uncommon, and thus 
became a limiting factor for structural studies on the protein. 
At the time of this work, an article was published describing the expression and purification 
(under denaturing conditions) of various truncations of the cytosolic domain of gp91phox 
from E. coli (Nisimoto et al., 2004). The authors also found predominant expression of the 
proteins in the insoluble fraction, and used a denaturing/renaturing protocol that employed 
replacement of the denaturing agent with either of two detergents, Triton X-100 or Genapol 
X-80. This purification method was tested with TrxE-Nox1cyt to determine if larger 
quantities of more stable protein could be obtained in like fashion.  
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Pellets of insoluble material (corresponding to the amount of cells from approximately 1L of 
induced culture) from cells lysed previously were homogenized with buffer containing 6M 
guanidinium hydrochloride. This is in contrast to the 8M urea used by Nisimoto, et al, due 
to a lack of solubility of TrxE-Nox1cyt in urea after initial fractionation (Woo, 2003, 
unpublished results). The clarified supernatant was then applied to a 10 ml Ni-NTA 
(Qiagen) column and washed with a denaturing buffer containing 40 mM Imidazole until a 
stable baseline absorbance was reached. The column was then washed with a linear gradient 
of 0-100% Refolding buffer over 100 ml, where the denaturing agent was replaced with 
0.3% Triton X-100 and supplemented with 30 µM FAD. Elution was made in this Refolding 
buffer with 250 mM Imidazole. As noticed in pilot denaturing trials made previously (Woo, 
2003, unpublished results), the denatured TrxE-Nox1cyt is not captured 100% by the Ni-NTA 
resin, and significant amounts were seen in the Flow through and Wash fractions (Figure 
23). In addition, exclusive binding of the refolded TrxE-Nox1cyt was not observed, with a 
considerable amount of contaminants present in the elution fractions. This indicates that 
further chromatographic measures would be required to purify the protein to homogeneity, 
which differs from what was described for the recombinant C-terminal truncations of 
gp91phox. In spite of this, a denaturing/renaturing purification method for TrxE-Nox1cyt could 
provide a more substantial protein yield, if the renatured protein was shown to retain native 
properties. 
 
Figure 23. Denaturing/renaturing purification of Trx
E
-Nox1cyt after Nisimoto et al, 2004. Insoluble 
material after lysis was homogenized in denaturing buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 20 
mM Imidazole, 6 M guanidinium hydrochloride). The supernatant, S, was applied to 10 ml of Ni-NTA 
resin. The column was washed with 10 column volumes of denaturing buffer containing 40 mM 
Imidazole. Refolding buffer (50 mM NaH2PO4, pH 7.4, 150 mM NaCl, 30 µM FAD, 0.3% Triton X-
100) was introduced by a linear gradient over 100 ml. Renatured protein was step eluted with 
refolding buffer containing 250 mM Imidazole. P, insoluble fraction from homogenization under 
denaturing conditions; FT, flow through; M, molecular weight markers. 
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H6-Nox1220-564  
In light of the work done on the cytosolic domain of gp91phox (Nisimoto et al., 2004), a 
truncation construct of human Nox1 was cloned that encompassed the homologous regions 
of their longest and most active construct (residues 221-571). This corresponds to residues 
220-564 of human Nox1. Although affirmed by the authors as a construct defining the 
cytosolic domain of gp91phox, the construct includes the sixth predicted transmembrane helix 
in its entirety and the last three residues of the fifth predicted transmembrane helix (Figure 
17). 
To have a direct comparison, this was cloned into the same vector (pET 30a, Novagen) 
using the same restriction sites (EcoRI and XhoI) as was used for gp91phox. The cloning of 
the construct was made by Monika Berthel and will be referred to as H6-Nox1220-564, for N-
terminally His-tagged human Nox1 containing residues 220-564.  
 
Figure 24.  Details of the H6-Nox1220-564 construct. This construct includes the last three residues from 
transmembrane helix 5, the entire transmembrane helix 6 (TM6) and the cytosolic portion of human 
Nox1. It contains an N-terminal His-tag removable by the protease enterokinase, and a nine-residue 
insertion (in italics) as a consequence of the vector and EcoRI restriction site. 
 
Expression studies in both BL21(DE3) and BL21(DE3) Codon Plus RIL cells showed 
significant overexpression of H6-Nox1220-564 in the insoluble fraction (Monika Berthel) 
(Figure 25). Attempts to purify under denaturing conditions according to Nisimoto et al, 
resulted in very low amounts of H6-Nox1220-564 retained on the Ni-NTA column (Monika 
Berthel, personal communication). A simple, fast native purification method based on a 
protocol presented at a course on membrane proteins (NCCR course, 2004) was employed 
to determine the potential usefulness of this construct. Lysis was performed in a buffer 
containing 2% Triton to simultaneously solubilize membranes. Clarified lysate from 1L of 
induced cells was applied to 100 µl of Ni-NTA resin (Qiagen) pre-equilibrated with lysis 
buffer and washed with step gradients of lysis buffer containing 20 mM, 40 mM and 60 mM 
Imidazole, respectively, and with a reduced concentration of Triton (0.3%). Elution 
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proceeded with lysis buffer containing 300 mM Imidazole, and 0.3% Triton. SDS-PAGE 
and Western Blot analysis were used to determine the progress of the purification. 
 
Figure 25. Overexpression of H6-Nox1220-564 in BL21(DE3) or BL21(DE3) Codon Plus RIL cells 
(Monika Berthel). Cells were grown at 37°C to a cell density of 1.2 or 1.4, respectively and induced 
with a final concentration of IPTG of 1mM for 3 hours at 37°C. P, stands for pellet, S, for supernatant, 
and M, for molecular weight markers. 
 
 
Figure 26. Native purification of H6-Nox1220-564 with Ni-NTA chromatography and corresponding 
Western blot of flow through (FT) and elution (E) fractions. P, stands for pellet, S, for supernatant, 
FT, for flow through, W for lysis buffer wash, and M, for molecular weight markers. Arrows indicate 
H6-Nox1220-564. 
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As can be seen in Figure 26, there are significant N-terminal proteolytic fragments from H6-
Nox1220-564 which are present to a higher degree than the desired protein. The anti-Nox1 
antibody is directed against the C-terminus of Nox1, and notably reacts only with the larger 
molecular weight species. In contrast, the anti-His tag antibody additionally recognizes 
many of the lower molecular weight protein species seen in the SDS-PAGE of the elution 
fractions. These results spotlight initial concerns over the usefulness of this longer construct. 
In the original work using gp91phox, the authors mention this extreme susceptibility of 
gp91C (the equivalent construct) to proteolysis even in the presence of protease inhibitors 
(which was likewise observed with H6-Nox1220-564 in this work). This process was time 
dependent during dialysis at 3°C for 16 h, and after one week the 46 kDa protein was 
completely proteolyzed into two fragments. If one desires to perform structural 
characterization of a protein, clearly this kind of behavior is not desirable, and will make 
crystallization of the entire construct near to impossible.  
It should be noted here that a recent article, published after this work, described the 
expression of several C-terminal truncations of Nox1, including a construct similar to H6-
Nox1220-564 that includes three additional residues of TM5 and lacks the last 14 residues 
from the C-terminus (residues 217-550) (Park et al., 2006). The authors describe the use of 
the vector pGEX4T1 with expression in E. coli DH5α cells, and demonstrate reasonable 
expression for the purpose of pull-down experiments, although smaller molecular weight 
species of ~28-30 kDa (possible proteolytic fragments) are also capable of binding the 
glutathione resin. Perhaps this vector and cell combination affords better heterologous 
overexpression of Nox1 proteins than those used in this work. None of the designed 
constructs by Park et al contain the last 14 residues of Nox1, perhaps suggesting that these 
residues destabilize the resulting proteins. While this deletion might be justified for the 
purposes of their study, it may not be advantageous for use in studies on the electron 
transfer mechanism of Nox1. As mentioned earlier, Nox proteins belong to the family of 
ferredoxin-NADP+-reductase (FNR) proteins, which have a characteristic NADPH binding 
fold where the last aromatic residue of the C-terminus packs against one side of the 
isoalloxazine rings of FAD (Taylor et al., 1993). In Nox proteins, this residue is a 
phenylalanine, which is strictly conserved in all five Nox proteins. Removal of this residue 
(and neighboring residues) may affect the ability of the enzyme to bind and transfer 
electrons to the FAD cofactor. Other studies on C-terminal truncations of gp91phox support 
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this, with a reduced NADPH-dependent  activity observed with constructs bearing deletions 
of the last 13 or 20 residues from the C-terminus (Nisimoto et al., 2004) (although the 
authors view these reductions as negligible). Interestingly, the article that describes binding 
interactions of Nox1 (residues 217-550) does not report any data on the activity of this 
construct (Park et al., 2006). 
 
Figure 27. Domain structure of gp91phox and activity of various C-terminal truncations, with the 
longest construct and equivalent constructs containing truncations of the last 13 and 20 residues boxed 
in red. Figure from Nisimoto et al, 2004. 
 
H6-Nox1cyt 
As mentioned earlier, alternative constructs were designed in case the thioredoxin tag was 
found to interfere. A vector containing an N-terminal His-tag followed by a TEV protease 
site (kindly provided by Dr. Kirill Alexandrov, MPI of Molecular Physiology, Dortmund) 
was used to produce a simple His-tagged construct of the cytosolic domain of human Nox1, 
here referred to as H6-Nox1cyt. In order to subclone the ∆1-289 human Nox1 insert into the 
vector, a Nde I site was introduced through PCR using ∆1-289 human Nox1 in pET 32a (the 
plasmid for TrxE-Nox1cyt) as a template. Vector and insert were each digested with Nde I 
and Xho I, and ligated after treating the digested vector with calf intestinal alkaline 
phosphatase to prevent vector re-ligation. Ligated plasmids were then transformed into 
competent XL1-Blue cells and positive clones were identified through agarose gel 
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electrophoresis of restriction enzyme digests and PCR reactions of isolated plasmids. 
Sequences were verified with DNA sequencing. 
 
Figure 28. Schematic of the H6-Nox1cyt construct. This construct contains an N-terminal His-tag 
removable by TEV protease, followed by a three amino acid insertion (which results from the TEV 
protease site and the NdeI restriction site) that directly precedes the cytosolic portion (residues 290-
564) of human Nox1.  
 
H6-Nox1cyt was expressed in C41(DE3) competent cells, according to guidelines worked out 
previously for TrxE-Nox1cyt. Cells were induced at low cell density (0.3-0.5) with low 
amounts of IPTG (0.05 mM or 0.1 mM final concentration) and overnight incubation at 
20°C. Reasonable and reproducible expression was only obtained from freshly transformed 
cells grown in rich media such as TB or ST1, with ST1 as the preferred media. TB media 
tended to produce twice as much cells for similarly sized cultures, which made the 
purification more cumbersome and time-consuming, without necessarily providing more 
protein in the end. Similar to TrxE-Nox1cyt, H6-Nox1cyt showed predominant expression in 
the insoluble fraction, although some amount of protein could be purified from the soluble 
portion. 
 
Figure 29. Comparison of H6-Nox1cyt expression in TB vs. ST1 media. 1L cultures were grown to 
OD600 of ~0.52 for each media and protein expression was induced with a final concentration of 0.1 
mM IPTG overnight at 20°C. The amount of harvested cells from TB media (15.12g) was more than 
twice that from ST1 (1, 6.48 g; 2, 7.42g; 3, 6.51g; 4, 6.69g; 5, 6.36g). Arrowheads indicate H6-Nox1cyt 
expression, which is more obvious from ST1 cultures and predominantly in the pellet. They also 
indicate the variability of expression often observed, even with equivalent cell amounts (compare 1 
with 3). 
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H6-Nox1cyt was purified via Ni-NTA chromatography and the enhanced binding capability 
of this construct allowed for improved separation from impurities in a single 
chromatographic step by lengthening the linear gradient from the original 70 ml to 250 ml. 
This proved to be necessary in light of the greater instability of H6-Nox1cyt and the 
preclusion of many chromatographic techniques that require low salt binding conditions. 
  
Figure 30. Enhanced binding of H6-Nox1cyt and improved separation with Ni-NTA chromatography. 
SDS-PAGE analysis of fractions from H6-Nox1cyt and TrxE-Nox1cyt Ni-NTA chromatography with 
equivalent linear gradients revealed the greater binding capacity of H6-Nox1cyt. This property was 
exploited to maximize the extent of purification over a single chromatographic step through an 
extension of the gradient to 250 ml. FT stands for Flow through, S stands for supernatant, M stands for 
Markers, and numbers indicate fraction numbers. Arrowheads indicate Trx
E
-Nox1cyt and H6-Nox1cyt, 
respectively. 
 
Attempts to further purify H6-Nox1cyt over 2’5’ ADP Sepharose 4B revealed the particular 
sensitivity of the cytosolic domain of human Nox1, and its requirement of high 
concentrations of salt in the buffer. Any attempt to reduce the NaCl concentration (either by 
dialysis or simple dilution with a buffer not containing NaCl) for application on 2’5’ ADP 
Sepharose 4B resin resulted in the prompt precipitation of the protein. One trial also tested 
the possibility of directly loading the Ni-NTA fractions onto 2’5’ ADP Sepharose 4B resin, 
but only 7% of the loaded protein bound the column, reducing the usefulness of this effort 
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(data not shown). This sensitivity to salt was not noticed initially with TrxE-Nox1cyt possibly 
because the thioredoxin tag (pI = 4.67) might have interacted favorably with the basic (pI = 
8.45) cytosolic domain of human Nox1. Additionally, these samples contained many 
contaminating proteins that may have interacted with the cytosolic domain of human Nox1, 
shielding the areas that would normally precipitate if isolated. It should be noted that the 
higher the purity of the construct, the greater the instability of the protein and the tendency 
for it to precipitate (including later purifications of TrxE-Nox1cyt which showed improved 
separation from impurities after Ni-NTA affinity chromatography). Early purifications of 
either TrxE-Nox1cyt or H6-Nox1cyt from Ni-NTA chromatography with substantial amounts 
of contaminating proteins did not show the same sensitivity to reduction in the NaCl 
concentration (Figure 31). An alternative approach to a single Ni-NTA chromatographic 
step might be to use a short gradient during the Ni-NTA chromatography, in order to 
increase the presence of stabilizing contaminating proteins, followed by 2’5’ ADP 
Sepharose 4B chromatography, since H6-Nox1cyt  should be stabilized in the high salt 1M 
NaCl elution.  
 
Figure 31. Purification of H6-Nox1cyt with 2’5’ ADP Sepharose 4B chromatography using a sample 
from a single step elution from Ni-NTA resin, that had also been purified with size exclusion 
chromatography. Load, indicates the sample loaded onto the column; green bars identify the elution 
peak and respective fractions on the SDS-PAGE. Arrowhead indicates H6-Nox1cyt. M, molecular 
weight markers.  
 
The greater sensitivity of H6-Nox1cyt necessitated a few adjustments as to how it was 
handled, in contrast to TrxE-Nox1cyt. The H6-Nox1cyt protein not only required high salt for 
stability, but also had a greater tendency to be retained on the membranes of most 
63 
human Nox1 
 
conventional centrifugal concentration devices. To remedy this, static concentrators 
(Vivapore, Sartorius, Göttingen), which use solvent absorption to concentrate the sample of 
interest, proved to be more effective at concentrating H6-Nox1cyt without large losses in 
protein yield. It was important to not over-concentrate the protein, since this increased the 
likelihood for soluble aggregates to form. Additionally, standard methods for determining 
the protein concentration could not be used due to the presence of a high concentration of 
imidazole still present in the pooled fractions after Ni-NTA chromatography (which 
interferes with most standard methods such as Bradford assay and absorbance determination 
at 280 nm). Attempts to reduce the imidazole concentration by dialysis also resulted in 
prompt precipitation of the protein. Therefore, the Ni-NTA protein fractions were diluted 
until the imidazole concentration was between 200-300 mM and then concentrated. The 
high glycerol content (10%) in the buffer also interfered with the Ehresmann protein 
concentration determination method. For these reasons, SDS-PAGE analysis was used in 
lieu of standard methods to estimate protein concentration. This was done by running a 
series of known amounts of a low molecular weight marker (Amersham Biosciences/GE 
Healthcare) alongside various amounts of H6-Nox1cyt and comparing these with the 
chymotrypsin marker at 30 kDa in the known series. The general solubility limit of H6-
Nox1cyt was 1-1.4 mg/ml, with typical yields of 3.15 mg/3L to 7.7 mg/5L. Western blot 
analysis confirmed the purified protein to be H6-Nox1cyt. 
 
Figure 32. A, Determination of H6-Nox1cyt protein concentration by SDS-PAGE analysis. Defined 
amounts of a low molecular weight marker were loaded in series alongside various amounts of H6-
Nox1cyt (red arrowhead). The amount of H6-Nox1cyt protein loaded was estimated by visual 
comparison with the 30 kDa molecular weight marker (black arrowhead). Protein concentration was 
calculated as µg/µl loaded. B, Western Blot confirmation of the Ni-NTA purified protein as H6-
Nox1cyt with Anti-His tag and Anti-Nox1 antibodies. M stands for Markers, T (black arrowhead) 
indicates Trx
E
-Nox1cyt used as a positive control for the Anti-His tag antibody since H6-Nox1cyt 
stained more weakly.  
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TrxT-Nox1cyt 
As a second alternative, a construct similar to TrxE-Nox1cyt was made containing a different 
protease site for removal of the N-terminal tags. This construct contains a TEV protease site 
instead of the enterokinase protease site. Although the thioredoxin tag was later found to 
interfere with the NADPH-dependent activity assay (see Section 2.2.1), this construct may 
provide a way to stabilize the cytosolic domain during purification, while retaining the 
ability for removal of the tags with TEV protease for subsequent characterization 
experiments. 
 
Figure 33. Details of the Trx
T
-Nox1cyt construct. This fusion protein has the identical structure as the 
Trx
E
-Nox1cyt construct, with the exception that the enterokinase protease cleavage site has been 
replaced with that of TEV protease, which adds an additional glycine to the short insertion before the 
beginning of the cytosolic domain of human Nox1.  
 
Site directed mutagenesis was used to exchange the enterokinase protease cleavage site to 
that of TEV protease. This was done using the QuikChange® Site-Directed Mutagenesis Kit 
(Stratagene) in two sequential reactions:  the first deleting the enterokinase site, and the 
second introducing the TEV site. The plasmid encoding the TrxE-Nox1cyt construct was used 
as the initial template for the first deletion reaction. DNA sequencing identified positive 
clones, and this resulting plasmid was in turn used as the template for the second insertion 
reaction. DNA sequencing confirmed clones containing the TEV protease site. 
Protein expression conditions worked out previously for the construct TrxE-Nox1cyt were 
again employed for TrxT-Nox1cyt. These included transformation in C41(DE3) competent 
cells, early induction with 0.1 mM IPTG when the cell density reached approximately 0.3-
0.45, and overnight incubation at 20°C. Initial expression of TrxT-Nox1cyt proved to be 
reasonable and purification proceeded over Ni-NTA resin using step gradients containing 
50, 100, and 250 mM Imidazole for elution. TrxT-Nox1cyt began to elute primarily at 100 
mM Imidazole and these fractions were pooled and further purified over size exclusion 
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chromatography containing 300 mM NaCl in the elution buffer. This chromatographic step 
proved to be quite effective, and although purified just short of homogeneity, this step may 
be an alternative to 2’5’ ADP Sepharose 4B chromatography for protein preparations that 
are more sensitive to low salt conditions. Western blot analysis confirmed the ~ 45 kDa 
band to be Nox1 (Figure 34). 
 
Figure 34.  A, Ni-NTA purification of Trx
T
-Nox1cyt. Fractions from different step elutions with the 
indicated amounts of Imidazole in the elution buffer are shown. An arrow highlights Trx
T
-Nox1cyt, 
which runs slightly above the 45 kDa molecular weight marker. S, supernatant loaded on the column; 
FT, flow through; M, molecular weight markers. B, Chromatographic trace of further purification of 
Trx
T
-Nox1cyt with size exclusion chromatography and SDS-PAGE of corresponding fractions. Load, 
indicates the sample loaded onto the column; M, molecular weight markers. Numbers indicate elution 
peaks and identify respective fractions on the SDS-PAGE. Western blot of boxed fraction using Anti-
Nox1 antibody. 
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2.2 ASSESSMENT OF THE BIOLOGICAL INTEGRITY OF RECOMBINANT 
HUMAN NOX1 CONSTRUCTS 
While determining the three dimensional structure of a new protein is significant in and of 
its own, it is additionally important to confirm that the purified protein is capable of native 
biological functions, and to relate the new structural insights to the functional role of the 
protein of interest. Of the four constructs, the two most promising constructs, namely TrxE-
Nox1cyt and H6-Nox1cyt, were further characterized with biochemical and biophysical 
methods. Biological activity was assessed with a NADPH-dependent diaphorase activity 
assay, which measures the electron transfer step from NADPH to FAD, using an artificial 
terminal electron acceptor. Of interest was whether the C-terminal truncation of human 
Nox1 was active and whether it contained the necessary regions to bind FAD and interact 
productively with cytosolic regulatory proteins.  
Since the purification of TrxE-Nox1cyt under denaturing conditions had the potential to 
generate more protein, the refolded TrxE-Nox1cyt protein was characterized to determine if 
the refolding procedure resulted in a protein with native properties. The refolded TrxE-
Nox1cyt was found to have a slightly higher experimental pI, ~6.9 as determined by 
isoelectric focusing (Figure 35), compared to the calculated value of  6.35 using the 
ExPASy Proteomics Server (Gasteiger et al., 2003).  
 
Figure 35. Isoelectric focusing gel of refolded Trx
E
-Nox1cyt. The left gel shows a SDS-PAGE of the 
sample loaded onto an IEF gel (right). M represents molecular weight markers. 
 
Unfortunately, the Triton X-100 detergent was found to interfere with many of the methods 
used for characterization of the refolded TrxE-Nox1cyt. DLS measurements were performed 
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to determine if the sample was monodisperse, but the inclusion of Triton X-100 at a 
concentration 20 times the CMC (CMC = 0.015%, Anatrace Product Catalogue) meant that 
the machine detected the micelles (74 kDa) of the detergent, and could not distinguish 
between these and micelles containing a 48 kDa protein. This is a well known disadvantage 
of using DLS to determine the monodispersity of membrane proteins which require the 
presence of detergents, and is no longer routinely used to assess this property (NCCR 
course, 2004). While DLS is very useful to measure the size of detergent micelles, it cannot 
distinguish between two species if the difference in their molecular weights is less than 8-
fold. To underscore this point, the manufacturer of DynaPro (Wyatt Technologies) admits 
that a mixture of standard proteins such as BSA (64 kDa) and lysozyme (14.7 kDa), which 
have a mass ratio of 4.4, cannot be resolved by DLS even at the highest resolution. Instead, 
the device measures the average radius for both particles 
(http://www.wyatt.com/solutions/hardware/DynaProTitan.cfm). Triton X-100 also 
interfered with standard protein concentration determination assays, such as Bradford. 
Additionally, it was found that an average lab stock of Triton X-100 was capable of 
reducing the terminal electron acceptor in the activity assay without the presence of the 
fusion protein. One disadvantage of using polyoxyethylene detergents such as Triton X-100 
and Genapol X-80 is their ability to form peroxides from their reaction with oxygen, which 
is accelerated upon exposure to light (Lever, 1977; Miki and Orii, 1985; Jaeger et al., 1994). 
Although purer grades can be commercially obtained that contain less than 200 µM 
peroxides (Calbiochem), any peroxide can interfere with the NADPH-dependent diaphorase 
activity assay, potentially giving false positives.  
In contrast to the apparent stabilizing effects of 0.3% Triton X-100 or Genapol X-80 on C-
terminal truncations of gp91phox, significant precipitation was observed in the refolded TrxE-
Nox1cyt protein sample after only 2 days at 4°C. This prompted a small screen of a range of 
detergents from different classes to see whether there might be another more stabilizing 
detergent. This protocol was based on one which involved incubation of equal volumes of 
the target protein with a buffer containing approximately 10 times the CMC of a desired 
detergent and allowed to remain at 4°C for one week (NCCR course, 2004). This was done 
individually with a variety of detergents and the samples were then centrifuged after the 
incubation. Protein stability was determined by analyzing the amount remaining soluble 
after this procedure via SDS-PAGE. In this study, eight different detergents were tested: n-
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Dodecyl-β-D-maltopyranoside (DDM), n-Decyl-β-D-maltopyranoside (DM), n-Octyl-β-D-
glucopyranoside (OG), CHAPS, CYMAL-5, Fos-Choline-12, Triton X-100, and Genapol 
X-80. Of these, only Fos-choline-12 and the buffer control containing no detergent did not 
have any visible precipitation after centrifugation of the incubated samples. SDS-PAGE 
analysis of these samples indicated that the TrxE-Nox1cyt fusion protein remained in the 
soluble fraction at levels similar to a freshly thawed control (Figure 36). Interestingly, both 
samples with either Triton X-100 or Genapol X-80 contained small but visible precipitation 
after centrifugation of the incubated samples, and at least with regards to the TrxE-Nox1cyt 
fusion protein, these detergents may not stabilize the protein as effectively as was observed 
for the C-terminal truncations of gp91phox.  
 
 
Figure 36. Stability of Trx
E
-Nox1cyt and H6-Nox1cyt in different classes of detergents. Detergent 
solutions containing 10 mM Tris-HCl, pH 7.5, 100 mM NaCl, and the following detergent 
concentrations were incubated 1:1 v/v with Trx
E
-Nox1cyt for 9 days or H6-Nox1cyt for 7 days at 4°C:  
0.2% DDM, 2% DM, 5% CHAPS, 1.2% CYMAL-5, 0.5% Fos-choline-12, 0.15% Triton X-100, and 
0.083% Genapol X-80. Due to solubility issues, OG was used as a 10% aqueous solution without 
buffer or NaCl. A non-detergent control was also made: using the storage buffer for Trx
E
-Nox1cyt, 10 
mM NaH2PO4, 500 mM NaCl, 10% glycerol, 2 mM DTE, pH 8.0; for H6-Nox1cyt, using 10 mM Tris-
HCl, pH 7.5 and 100 mM NaCl. Total protein amount is indicated by a gel sample made just before 
running the SDS-PAGE from freshly thawed protein (Fresh control). All gel samples (excluding 
markers) were made without boiling at 100°C. Arrowheads point to Trx
E
-Nox1cyt and H6-Nox1cyt 
respectively. M represents molecular weight markers. 
 
A similar detergent screen was performed on H6-Nox1cyt, which also identified Fos-choline-
12 as the only detergent of those tested that was able to maintain  H6-Nox1cyt in the soluble 
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fraction (Figure 36). H6-Nox1cyt appears to be more sensitive than TrxE-Nox1cyt to many 
common detergents, with very little of the protein remaining soluble after incubation. This 
includes Triton X-100 and Genapol X-80. These results explain the lack of improved 
stability observed when 0.3% Triton X-100 was included in a purification of H6-Nox1cyt. 
Park et al have included 1% Triton X-100 in buffers used for pull down assays, where 
various Nox1 truncations were bound to GST resin to serve as bait for investigations of 
various protein-protein interactions (Park et al., 2006). Although in the present work, 2% 
Triton X-100 was found to effectively extract all of H6-Nox1cyt from the pellet fraction after 
lysis, the protein precipitated once it was eluted from the Ni-NTA column (data not shown). 
The stability of truncated Nox1 in a detergent may therefore be less obvious when the 
protein is still retained on the resin, as opposed to being free in solution.  
 
2.2.1 NADPH-dependent diaphorase activity of recombinant human Nox1 
constructs 
Intrinsic activity 
Nox proteins catalyze the one-electron reduction of molecular oxygen using the two-
electron donor NADPH as an electron source: 
2 O2   +   NADPH   Æ   2 O2 . -   +   NADP+   +   H+ 
It was additionally discovered that cytochrome b558 is capable of a NADPH-dependent 
diaphorase activity, which was independent from superoxide production (Cross et al., 1994). 
Diaphorase refers to a flavoprotein capable of oxidizing NADPH. This diaphorase activity 
has been utilized to measure the intrinsic activity of various recombinant C-terminal 
truncations of gp91phox, as well as the effect of cytosolic regulatory proteins on this activity 
in vitro (Han et al., 2001; Nisimoto et al., 2004). The first step of electron transfer involving 
NADPH and FAD can be studied using an artificial terminal electron acceptor such as the 
dye nitroblue tetrazolium (NBT) or cytochrome c, which, upon reduction, undergoes a 
spectrophotometric change that can be monitored over time. This work utilized NBT as the 
final electron acceptor since studies made on C-terminal truncations of gp91phox 
demonstrated higher turnover rates using NBT (Han et al., 2001; Nisimoto et al., 2004). 
NBT is a dye that changes color from yellow to purple upon reduction, and can be 
monitored spectrophotometrically at 595 nm.  
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Determination of the NADPH-dependent diaphorase activity of the natively purified TrxE-
Nox1cyt revealed some inherent limitations of this construct. The activity of the recombinant 
TrxE-Nox1cyt protein was assayed using a cell-free assay developed for cytosolic truncations 
of gp91phox (Han et al., 2001; Nisimoto et al., 2004). Unfortunately, low amounts of 
DTE/DTT used in the buffer for TrxE-Nox1cyt (18 µM) were enough to reduce NBT at a rate 
similar to the intrinsic rate of H6-Nox1cyt (see below). Since the thioredoxin tag itself is also 
capable of sulfhydryl redox chemistry, it would interfere with the assay as well. It should be 
noted that the authors who studied the C-terminal truncations of gp91phox also began with N-
terminally tagged thioredoxin fusion proteins of their constructs and also found that DTT 
interfered with the assay (Han et al., 2001). Their subsequent work (Nisimoto et al., 2004) 
utilized N-terminal His-tagged fusion proteins instead.  
To determine if H6-Nox1cyt possessed the necessary regions of the protein to be biologically 
active, its activity was also tested using this NADPH-dependent diaphorase activity assay. 
Performing the assay in 1 ml cuvettes, H6-Nox1cyt was found to possess a low intrinsic 
NADPH-dependent diaphorase activity of 0.19 mol reduced NBT/min/mol H6-Nox1cyt. Due 
to the large consumption of protein for these spectrophotometric activity measurements, the 
assay was modified for microtiter format. This had the additional advantage that several 
samples could be assayed simultaneously, including all necessary buffer controls. All 
samples could be rapidly (within 5 minutes) and uniformly heated, which simplified the 
cumbersome handling experienced with the 1ml assay version. In the microtiter format, the 
protein concentration used for the 1 ml spectrophotometric format was too low to generate 
absorbance signals at 595 nm with a satisfying signal-to-noise ratio. Therefore, the protein 
concentration was increased in the microtiter format. Both 5-fold (2.3 µM) and 10-fold (4.6 
µM) increases in protein concentration produced acceptable signals. Due to limitations in 
protein yields, a concentration of 2.3 µM was used in subsequent assays.  
The measured intrinsic NADPH-dependent diaphorase activity of H6-Nox1cyt was found to 
depend on the amount of soluble aggregation in the purified sample. A protein batch that 
was later found to contain a large percentage of soluble aggregates (Figure 37, see next 
section) showed a low activity (0.22 mol reduced NBT/min/mol H6-Nox1cyt). A second 
batch of mostly non-aggregated H6-Nox1cyt (Figure 38, see next section) displayed a 
markedly higher activity (0.95 mol reduced NBT/min/mol H6-Nox1cyt). This activity is 
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roughly 4-fold higher than that of a truncated gp91phox protein of roughly similar length 
(residues 304-570), and is similar in magnitude to the activity of a longer truncated gp91phox 
(residues 221-570) (Table 1) which showed the highest activity in a series of truncated 
gp91phox constructs (Nisimoto et al., 2004).  
 
Table 1. Comparison of in vitro NADPH-dependent diaphorase activity of purified H6-Nox1cyt (this 
work) to truncated gp91phox proteins and intact cytochrome b558, as well as to in vivo values. 
Calculations of electron flow assume that NBT is a 4 electron acceptor.   
Protein  Truncation Assay format Activity electron flow 
   (mol reduced NBT/min/mol Nox) (electrons/min/molecule Nox)
in vitro (present work)     
     
     Nox1 290-564 spectrophotometric 0.19 0.76 
     Nox1 mostly aggregated 290-564 microtiter 0.22 0.88 
     Nox1 290-564 microtiter 0.95 3.8 
     
in vitro (literature values)     
     
gp91phox 304-570 spectrophotometric 0.24 a 0.96* 
gp91phox 266-570 spectrophotometric 0.41 a 1.64* 
gp91phox 221-570 spectrophotometric 0.92 a 3.68* (0.92 a ‡) 
cytochrome b558 none NR NR 6.5 a 
cytochrome b558, 
solubilized from 
phorbol-stimulated pig 
neutrophils 
none spectrophotometric 782 mol O2
. - /min/mol cyt b558 b * 30.4* 
     
in vivo   
Protein Activity  
 (mol O2
. - /min/mol Nox)  
   
Nox1, unstimulated VSMCs 0.21 c * 0.21* 
Nox1, Angiotensin II stimulated VSMCs 0.77 c * 0.77* 
Nox1, unstimulated gastric guinea pig cells 0.011 d * 0.011* 
Nox1, LPS stimulated gastric guinea pig cells  0.11 d * 0.11* 
   
aNisimoto et al, 2004; bCross et al, 1985; cGriendling, et al, 1994; dKawahara et al, 2005. LPS, 
lipopolysaccharides from Helicobacter pylori. *Calculated from values reported in the literature. ‡For 
this value, the authors appear to have assumed that NBT is a single electron acceptor. NR, not 
reported. 
 
Although the intrinsic activity of H6-Nox1cyt is low if compared to the catalytic output of the 
phagocytic oxidase, it is consistent with the biological function of Nox1 as a source of low-
level constitutive superoxide production, observed from in vivo studies (Table 1). Even with 
roughly 50% homology, many of the nonphagocytic Nox proteins produce superoxide at 
levels 10% or less than that of the phagocytic oxidase. The electron transfer rate of 
3.8 electrons/min/molecule H6-Nox1cyt is higher than that calculated from in vivo superoxide 
production by Nox1 in various tissues, which suggests that electron transfer by the truncated 
protein may occur via a different mechanism in vitro. 
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Effect of Fos-choline-12 on the intrinsic NADPH-dependent diaphorase activity of H6-
Nox1cyt 
The microtiter-format activity assay was exploited to address whether the detergent Fos-
choline-12 was able to increase the intrinsic activity of H6-Nox1cyt through increased 
stabilization of the protein. NADPH-dependent diaphorase activity was measured with and 
without Fos-choline-12 at various multiples of the CMC. Fos-choline-12 was capable of 
slightly increasing the activity of H6-Nox1cyt at a concentration 2x the CMC (3 mM), but 
this effect was found to depend strongly on the protein batch, and the extent of soluble 
protein aggregation in the sample. In one batch, where a majority of the protein was present 
as soluble aggregates, this slight enhancement in activity was observed (Figure 37). In 
contrast, when another predominantly monomeric H6-Nox1cyt batch was assayed, Fos-
choline-12 actually decreased the intrinsic activity of H6-Nox1cyt (Figure 38). These results 
indicate that while 3 mM Fos-choline-12 may improve re-solubilization of soluble 
aggregates of H6-Nox1cyt, it may not necessarily be required for optimal activity in 
monodisperse preparations. 
It is important to note that freshly prepared solutions of Fos-choline-12, in contrast to Triton 
X-100, was not capable of reducing NBT, and thus does not interfere with the assay under 
the conditions tested (60 minutes at 37°C). Solutions made from an aqueous 10% stock 
solution of Fos-choline-12 (although stored at 4°C under Argon) were, however, capable of 
partially reducing NBT to its half-reduced form which is magenta pink in color (Altman, 
1974), emphasizing the importance of making the detergent solutions fresh from solid if 
they are to be included. 
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Figure 37. Analytical gel filtration of a batch of H6-Nox1cyt with a large amount of aggregation in the 
sample (inset). H6-Nox1cyt (33.5 kDa) was incubated with a 50-fold molar excess of FAD at 4°C for at 
least 1 hour. 95 µg was injected over an analytical Superdex 75 column pre-equilibrated with 20 mM 
NaH2PO4, pH 7.3, 300 mM NaCl, 250 mM Imidazole, and 10% glycerol. Arrowheads indicate elution 
profile of gel filtration standards. Corresponding effects of various concentrations of Fos-choline-12 
(FC) on the intrinsic NADPH-dependent activity of this sample.  
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Figure 38. Analytical gel filtration of a more monomeric batch of H6-Nox1cyt (inset). H6-Nox1cyt (33.5 
kDa) was incubated with a 25-fold molar excess of FAD at 4°C for at least 1 hour. 264 µg was 
injected over an analytical Superdex 75 column pre-equilibrated with 20 mM NaH2PO4, pH 7.3, 300 
mM NaCl, 250 mM Imidazole, and 10% glycerol. Arrowheads indicate elution profile of gel filtration 
standards. Effect of 2x CMC Fos-choline-12 on the intrinsic NADPH-dependent activity of this 
sample. 
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2.2.2 Interaction of recombinant human Nox1 constructs with regulatory 
oxidase proteins 
An important question to address was whether the C-terminal truncation of human Nox1 
contained all the necessary regions of the protein to interact with regulatory proteins. 
Although Nox1 possesses its own cytosolic regulators, Noxo1 and Noxa1, the human 
proteins were found to be much more difficult to work with than their phagocytic oxidase 
counterparts (Dr. Yvonne Groemping, personal communication). In light of the high degree 
of difficulty in handling the Nox1 constructs alone and the ability of Nox1 to interact with 
phagocytic oxidase regulatory proteins, a recent description of a recombinant fusion of 
p67phox and Rac that acts as a minimal activator of cytosolic truncations of gp91phox in a cell-
free assay (Miyano et al., 2001; Nisimoto et al., 2004) was selected as a more realistic tool 
to probe this question. This fusion protein, p67N-Rac, contains the N-terminal Rac-binding 
TPR domain and activation domain (residues 1-210), followed by a three amino acid linker 
(Ser-Glu-Phe), and Rac1 containing a point mutation (C189S) in a cysteine that undergoes 
prenylation, maintaining Rac in a soluble form (Kreck et al., 1994). p67N-Rac containing a 
constitutively active Rac1 mutation (Q61L) was also described and both proteins were used 
in these studies. 
 
Expression and purification of p67N-Rac fusion proteins 
Plasmids containing the two fusion proteins, p67N-Rac and p67N-Rac(Q61L) were a kind 
gift from Dr. Minoru Tamura (Ehime University, Japan). Since the description of the 
expression and purification of the fusion proteins was very general, the detailed procedures 
were also experimentally developed. p67N-Rac and p67N-Rac(Q61L) were expressed in the 
E. coli strain BL21(DE3), and although described as being expressed at 37°C for 2.5 hours 
after the addition of IPTG, little soluble expression was actually observed under these 
conditions. For this reason, lower temperature (20°C) and a reduced IPTG concentration 
(0.05mM final) were employed and found to remedy this problem (Figure 39). Protein 
expression was normally determined using Bug Buster® Protein Extraction Reagent 
(Novagen) for lysis of analytical cell amounts, and although this often revealed little soluble 
expression, substantial amounts of both p67N-Rac and p67N-Rac(Q61L) were observed in 
the soluble fraction after lysis with a microfluidizer. 
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Figure 39.  A, Expression of p67N-Rac following published protocols (37°C), and with adjustments in 
the expression conditions (20°C). Arrows indicate p67N-Rac. M, molecular weight markers, N, non-
induced, I, induced, S, supernatant, P, pellet, Slysis, supernatant after lysis. B, SDS-PAGE of the final 
purified p67N-Rac and p67N-Rac(Q61L) fusion proteins. 
 
Since p67N-Rac and p67N-Rac(Q61L) are expressed as GST fusion proteins, they were 
purified with glutathione sepharose affinity chromatography. The high level of expression 
of both fusion proteins allowed for nearly exclusive binding to the affinity resin. Elution of 
p67N-Rac or p67N-Rac(Q61L) was initially performed with thrombin digestion as 
described, which cleaves after the GST tag. However, the digestion was not every efficient 
on the column, with a majority of the GST-fusion protein still bound to the resin. Thrombin 
digestion after elution of the GST-fusion proteins from the glutathione sepharose proved to 
be more effective, but required a week for complete digestion at 4°C. Thrombin was 
removed with Benzamidine chromatography and p67N-Rac or p67N-Rac(Q61L) was 
collected after a second glutathione chromatographic step to capture any uncut protein and 
GST tag. Purification was completed with size exclusion chromatography. MALDI-TOF 
analysis confirmed the expected molecular mass of the purified p67N-Rac (45,976.67 
expected, 46,359.2 measured). The yields of both p67N-Rac (85 mg/1L medium) and p67N-
Rac(Q61L) (70 mg/1L medium) after these adjustments were found to be substantially 
better than published yields (1-2 mg/L medium). 
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Figure 40. MALDI spectrum of purified p67N-Rac, with a measured mass of 46,283.3 Da. 
 
To ensure that the constitutively active Rac1 mutant did not hydrolyze GTP under the 
conditions to be used in the NADPH-dependent diaphorase assay, the intrinsic GTPase 
activity of p67N-Rac(Q61L) was measured at 37°C over several days. As can be seen in 
Figure 41, the amount of GTP bound did not change significantly even after 5 hours 
incubation at 37°C. 
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Figure 41. Intrinsic GTPase activity of p67N-Rac(Q61L) at 37°C. Aliquots were removed at the 
indicated times and analyzed in triplicate by HPLC. 
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Probing protein-protein interactions  
Several methods were used to determine whether the truncated Nox1 protein was capable of 
interactions with cytosolic regulatory proteins. A pull-down assay using GST-p67N-
RacQ61L•GTP as bait was made to determine if H6-Nox1cyt could be captured from E.coli 
lysate. High salt in the H6-Nox1cyt lysis buffer, however, could have prevented any 
interaction, revealing the shortcomings of using this method due to the major instability of 
H6-Nox1cyt in low salt buffers. Other methods were tested to see if they would report 
directly on a possible interaction. Previous studies by others on the interaction of p67phox 
with Rac utilized fluorescence changes as reported by mantGppNHp, a fluorescent, 
nonhydrolyzable analogue of GTP. Fluorescence was found to increase upon binding of 
p67phox to Rac•mantGppNHp (Nisimoto et al., 1997). These experiments were extended in 
this work to determine if any interaction between the p67N-Rac fusion protein and Nox1cyt 
also produced a change in fluorescence. Due to a lack of stability in the buffer used for 
fluorescence measurements (which was identical to that used in Nisimoto et al., 1997), 
TrxE-Nox1cyt was used instead of H6-Nox1cyt. Initial fluorescence measurements indicated a 
slow, substantial increase (46.7%) in the fluorescence emission at 445 nm upon the addition 
of p67N-Rac•GDP to mantGppNHp, representing the exchange of the Rac-bound GDP for 
the fluorescently labeled GTP analogue. In contrast, a small (1.4%), immediate increase was 
observed upon the addition of TrxE-Nox1cyt to p67N-Rac•mantGppNHp (Figure 42).  
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Figure 42. Interaction of Trx
E
-Nox1cyt with p67N-Rac as measured by fluorescence. mantGppNHp 
(0.12µM) in 20 mM Tris-HCl, pH 7.45, 3 mM NaCl, 50 mM KCl, and 0.1 µM MgCl2, was excited 
with a wavelength of 355 nm and the emission at 445 nm was monitored over 5 minutes. p67N-
Rac•GDP was added to this solution at a final concentration of 0.25 µM and the emission was 
monitored for 30 minutes. TrxE-Nox1cyt was then added at a final concentration of 0.35 µM and the 
emission monitored for 20 minutes. 
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These observations were further investigated using stopped flow kinetic methods in order to 
resolve the time scale of the interaction and increase the sensitivity of the measurement. 
However, these measurements gave inconsistent results, suggesting that other factors might 
be involved which complicate interpretation of the data. Additionally, the low magnitude of 
increase upon the addition of TrxE-Nox1cyt to p67N-Rac•mantGppNHp may reflect the 
possibility that the mant moiety might be physically distant from the site of interaction and 
thus may not be able to report effectively on an interaction between Nox1cyt and the p67N-
Rac complex. The NADPH-dependent diaphorase assay was therefore favored as a more 
likely indicator of any functional interaction of p67N-Rac with Nox1cyt due to effects on 
activity. 
 
Effect of p67-Rac fusion proteins on the intrinsic NADPH-dependent diaphorase 
activity of H6-Nox1cyt 
High concentrations of p67phox or only the N-terminal region of p67phox (residues 1-210) in 
combination with Rac have been shown to fully activate the phagocytic oxidase in a cell-
free reconstitution assay without the requirement for p47phox (Koshkin et al., 1996; Han et 
al., 1998). The p67N-Rac and p67N-Rac(Q61L) fusion proteins were also found to be 
capable of activating NADPH oxidase activity and recombinant C-terminal truncations of 
gp91phox in a cell-free assay, with a 2-fold higher activation compared to activation by the 
individual p67phox and Rac proteins (Miyano et al., 2001; Miyano et al., 2003; Nisimoto et 
al., 2004).  
Preliminary studies in this work indicate that both fusion proteins, either as native p67N-
Rac bound with the nonhydrolyzable GTP analogue, GppNHp, or p67N-Rac(Q61L)•GTP, 
slightly enhance the intrinsic activity of H6-Nox1cyt (Figure 43). The activation is minimal, 
with p67N-Rac•GppNHp producing a 1.3-fold higher activity, and p67N-Rac(Q61L)•GTP, 
a 1.4-fold higher activity. This slight enhancement of activity is not due to DTT present in 
the buffer used to store p67N-Rac(Q61L) since volumes of each protein storage buffer 
equivalent to the volume of that protein used in the assay were also assayed in the same 
assay buffer used to assay the proteins, and the change in absorbance at 595 nm over time 
recorded for the respective buffer samples were subtracted from the activity measured from 
the corresponding protein-containing samples. The sample of p67N-Rac•GppNHp used did 
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not contain DTT in the storage buffer. Although the assay buffer for this measurement did 
not contain extra 4 mM MgCl2 (which was present in the assay buffer for the p67N-
Rac(Q61L)•GTP measurement), MgCl2 was present in the storage buffer of p67N-Rac, 
which gives a final concentration of 90 µM MgCl2 in the 1ml assay sample. According to 
fluorescence measurements made by Nisimoto, et al., a concentration of 0.1 µM MgCl2 is 
still sufficient to observe nucleotide exchange of GDP for mantGppNHp by Rac (Nisimoto 
et al., 1997). p67N-Rac•GDP was also capable of exchanging GDP for mantGppNHp in a 
buffer with 0.1 µM MgCl2 in fluorescence measurements made in this work (Figure 42). 
Therefore, this lower concentration of MgCl2 in the p67N-Rac•GppNHp assay sample is not 
expected to disrupt efficient binding of GppNHp to Rac.  
It should be noted that the p67N-Rac•GppNHp measurement was made using the 
spectrophotometric assay format, while the p67N-Rac(Q61L)•GTP measurement was made 
in the microtiter format, yet both yield similar levels of activation. When compared to the 
roughly 1.8-fold increase in activity using a truncated gp91phox of roughly comparable 
length (306-569) (Han et al., 2001), this low level of activation is consistent with this length 
of truncation. To determine whether the measured level of activation is statistically 
significant, the performed measurements could be repeated. In any case, the effect of the 
p67N-Rac fusion proteins on these shorter truncated proteins is less significant when 
compared to the more than 16-fold enhancement seen for the longest recombinant C-
terminal truncated (221-570) gp91phox. This could indicate that the truncated human Nox1 
does not contain all of the necessary regions for optimal interaction to occur. A recent 
article describes GST fusion proteins of two constructs of Nox1, one containing residues 
217-550 and one containing residues 336-550, with both constructs capable of Rac1 
association when each GST fusion was incubated with lysates of the human colon cancer 
cell line Caco-2 (Park et al., 2006). They noted that the longer Nox1 construct associated 
with Rac1 to a larger extent than that containing residues 336-550, suggesting that the 
membrane-proximal region of Nox1 is required for Rac1 binding. H6-Nox1cyt contains this 
region, but lacks the sixth transmembrane helix, and perhaps these residues strengthen this 
interaction. 
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Figure 43. Effect of p67N-Rac and p67N-Rac(Q61L) on the intrinsic NADPH-dependent diaphorase 
activity of H6-Nox1cyt. Top, H6-Nox1cyt (4.5 µM) was pre-incubated with 12.3 µM of p67N-Rac pre-
loaded with GppNHp at 4°C for 15 minutes. 100 µl of this solution was assayed in a final volume of 
1ml in a Beckman DU®640 spectrophotometer alongside H6-Nox1cyt alone at 37°C. Activity was 
calculated from the slopes obtained from the linear region. Bottom, H6-Nox1cyt (11 µM) was pre-
incubated with 39 µM of p67N-Rac(Q61L)•GTP at 4°C for 15 minutes. 21 µl of this solution was 
assayed in a final volume of 100 µl in a Labsystem iEMS Reader MF microtiter plate reader alongside 
H6-Nox1cyt alone and in the presence and absence of 2x CMC Fos-choline-12 at 37°C. Activity was 
calculated from the slopes obtained from the linear region. 
 
Additionally, these results could reflect the minimal activation of Nox1 observed when 
mixed with phagocytic oxidase regulators, in contrast to the large activation seen with 
Noxo1 and Noxa1 (Takeya et al., 2003; Geiszt et al., 2003b). This is in spite of a 39% and 
64% identity for the TPR and activation domains of p67phox and Noxa1, respectively. A 
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recent study has demonstrated that Nox1 is regulated by p47phox and Noxa1 in vascular cells 
(Ambasta et al., 2006). The lack of significant activation by p67N-Rac may therefore reflect 
the lower ability of p67phox to activate Nox1. Studies in human colon cancer cell lines T84 
and Caco2 confirm the lower ability of p67phox to elicit a marked increase in Nox1-
dependent superoxide production. Transduction of p67phox mRNA or overexpression of 
Noxa1 alone did not augment spontaneous or PMA-stimulated superoxide release by T84 
cells, whereas cells overexpressing Noxo1 significantly increased their superoxide 
generation when stimulated with PMA. This output was not altered by transfection of 
p67phox, but was further increased with overproduction of Noxa1 (Kawahara et al., 2004).  
With regards to the effect of detergent on the level of activation by the p67N-Rac fusion 
proteins, inclusion of the detergent Fos-choline-12 at a concentration 2x the CMC did not 
significantly enhance the activation by p67N- Rac(Q61L)•GTP, with a tendency to reduce 
the effect of p67N-Rac(Q61L)•GTP on H6-Nox1cyt (Figure 43). Again, this suggests that 
detergents may have a destabilizing effect on the proteins, which is in contrast to what was 
observed for truncations of gp91phox (Nisimoto et al., 2004). 
 
2.2.3 Assessment of cofactor binding 
Although all Nox proteins require the cofactor FAD to generate superoxide, early studies on 
cytochrome b558 indicated that the binding of FAD to the enzyme is quite labile. Human 
neutrophils lost the ability to produce superoxide in the presence of 0.045% Triton X-100, 
but full activity could be restored if 0.2 mM FAD was added in the presence of the detergent 
(Babior and Kipnes, 1977). The ability to differentially fractionate the FAD containing 
portion from cytochrome b558 led some to believe that the oxidase contained an additional 
flavoenzyme component (Gabig, 1983) before it was evident that the flavin-binding protein 
was indeed gp91phox itself (Rotrosen et al., 1992). FAD is lost during the purification of 
cytochrome b558 (Knoller et al., 1991; Rotrosen et al., 1992), with the dependence on 
exogenous FAD for cell-free superoxide production correspondingly increasing with the 
level of cytochrome b558 purity (Sumimoto et al., 1992). 
Consistent with these observations, retention of FAD by H6-Nox1cyt after purification was 
not visually obvious, with no overt absorbance maxima detected in the visible region 
expected for FAD binding proteins. In contrast, characterization of the longest truncated 
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gp91phox protein (residues 221-570) by Nisimoto et al, found this truncation to be the only 
one capable of binding FAD in a nearly 1:1 molar ratio. An absorption spectrum of the re-
flavinated gp91phox protein (residues 221-570) contains two absorbance maxima typical for 
flavoproteins at 383 nm and 452 nm, although the relative intensities of these peaks is 
roughly 1/5 the intensity of the corresponding protein absorbance at 275 nm. This suggests 
that the last transmembrane helix may be involved in the stable association of FAD with 
Nox proteins, which is lacking in H6-Nox1cyt. Reflavination of cytochrome b558 has been 
shown to be sensitive to phospholipid composition (Koshkin and Pick, 1993; Koshkin and 
Pick, 1994), with reflavination of cytochrome b558 in an optimal mixture of PC, PE, PI, SM, 
and cholesterol (4:2:1:3:3 w/w) demonstrating 70% the activity measured in native plasma 
membranes (Nisimoto et al., 1995). H6-Nox1cyt is capable of transient, functional binding of 
FAD, as inferred from the ability of the enzyme to reduce NBT in the presence of excess 
FAD in the assay buffer used for the NADPH-dependent diaphorase assay. This diaphorase 
activity was still observed after subtracting the change in absorbance at 595 nm that was 
measured for the H6-Nox1cyt protein storage buffer assayed in the same assay buffer and in 
the same manner as the H6-Nox1cyt protein sample. Further characterization should be done 
to determine if H6-Nox1cyt is able to retain FAD after reflavination by using HPLC methods 
to quantify the amount of FAD in H6-Nox1cyt elution fractions after removal of excess FAD 
by size exclusion chromatography using a buffer that does not include FAD. Additionally, 
the NADPH-dependent diaphorase activity assay could be used to determine the affinity of 
FAD for H6-Nox1cyt by varying the FAD concentration in the assay and determining any 
effects on activity.  
 
2.3 SUMMARY AND PERSPECTIVES 
Studies were made to heterologously overexpress human Nox1 in E. coli, either as the full-
length protein or as C-terminal truncations containing the cytosolic domain, for the purpose 
of structural characterization by X-ray crystallography. Coexpression of full-length human 
Nox1 with subunit b of E. coli F1Fo ATP synthase in the absence or presence of the heme 
precursor, δ-aminolevulinic acid, did not promote Nox1 expression in C41(DE3) E. coli 
cells. Eukaryotic expression systems such as yeast, dictyostelium, or baculovirus may prove 
to be more effective, especially if Nox1 is coexpressed with p22phox to enhance the stability 
84 
Results and Discussion  
 
of each protein. Of these, dictyostelium may be the preferred expression system, since it 
naturally expresses three Nox homologues, NoxA, NoxB, and NoxC, with NoxA showing 
homology to the Nox1-4 proteins (Kawahara et al., 2007). 
Heterologous overexpression of C-terminal truncations containing the cytosolic domain of 
human Nox1 in E. coli proved to be more successful. Three constructs, TrxE-Nox1cyt, TrxT-
Nox1cyt, and H6-Nox1cyt, containing human Nox1 (residues 290-564) were solubly 
expressed at low levels in C41(DE3) E. coli cells under induction conditions using low cell 
density, low temperature, and low concentrations of IPTG. Purification procedures were 
established for each construct, which include initial capture by Ni-affinity chromatography, 
followed by a second affinity step using 2'5' ADP Sepharose. H6-Nox1cyt, was found to be 
less tolerant of low salt conditions, and therefore was purified over a single Ni-affinity 
chromatography step. Although the N-terminal thioredoxin tag present in TrxE-Nox1cyt and 
TrxT-Nox1cyt was found to interfere with the NADPH-dependent diaphorase assay used to 
assess the activity of the truncated Nox1, these constructs may still be useful in structural 
studies if the tag does not hinder crystallization. A fourth construct, H6-Nox1220-564, 
containing the cytosolic domain of human Nox1 as well as the sixth transmembrane helix 
and the last three residues of the fifth transmembrane helix, was also cloned and expressed 
in BL21(DE3) and BL21(DE3) Codon Plus RIL E. coli cells. Unfortunately, H6-Nox1220-564 
was found to be prone to severe proteolysis, even in the presence of protease inhibitors, 
which limits its utility for structural studies.  
In spite of its difficulty in handling, H6-Nox1cyt does possess an intrinsic NADPH-dependent 
diaphorase activity of 0.95 mol/min/mol H6-Nox1cyt, which is consistent with its biological 
function of low-level, constitutive superoxide production. This activity suggests that H6-
Nox1cyt is capable of transient, functional interaction with the cofactor FAD (present in 
excess in the assay buffer), and the assay can be used to determine the affinity of this 
interaction. Additionally, preliminary studies suggest that H6-Nox1cyt can functionally 
interact with fusion proteins of the phagocytic oxidase regulators p67phox and Rac1, resulting 
in a modest activation of 1.3 to 1.4-fold. This low level of activation may indicate the 
importance of the sixth transmembrane helix in strengthening the interaction between Nox1 
and phagocytic regulatory proteins, which is lacking in H6-Nox1cyt. Additionally, it may 
reflect the ability of Nox1 to discriminate between different cytosolic regulators, as was 
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seen in in vivo experiments (Kawahara et al., 2004). Of interest would be the creation of an 
equivalent Noxa1N-Rac1 fusion protein to examine its ability, if any, to significantly 
enhance the intrinsic activity of H6-Nox1cyt. Interestingly, detergents such as Fos-choline-
12, may not be required to stabilize H6-Nox1cyt as long as the protein is maintained in high 
salt conditions and is not subjected to conditions that would promote soluble aggregation, 
such as overconcentration. Thus, H6-Nox1cyt may serve as a minimal active fragment that 
can be used in future structural studies either alone or in complex with a variety of other 
proteins to aid in the understanding of how auxiliary proteins can modulate its intrinsic 
activity. Such proteins include the proposed Noxa1N-Rac1 fusion protein and βPix, a GEF 
for Rac. If Noxa1N-Rac1 is found to significantly activate H6-Nox1cyt, structural 
characterization of the complex could provide molecular details on factors that promote 
electron transfer, as well as insights into mechanisms to disrupt this for therapeutic reasons. 
The role of βPix in EGF-induced ROS generation by Nox1 has been recently described 
(Park et al., 2004; Park et al., 2006), and indicates that Nox1 (residues 217-550) forms a 
ternary complex with Rac•GTPγS and βPix. Domain mapping of βPix revealed that its PH 
domain interacts with the FAD binding region (residues 335-360) of Nox1. Structural 
characterization of a complex between H6-Nox1cyt, active Rac1 and the PH domain of βPix 
may offer some insights as to how a GEF can modulate the activity of Nox1. 
Complexes of H6-Nox1cyt with small molecule inhibitors may directly shed light on 
mechanisms to inhibit Nox1. Several experimentally used inhibitors such as 
diphenyleneiodonium (DPI) or aminoethyl benzenesulfono fluoride (AEBSF) lack the 
appropriate specificity for therapeutic consideration. DPI is a general flavoenzyme inhibitor, 
inhibiting NOS (Stuehr et al., 1991), xanthine oxidase (Doussiere and Vignais, 1992), and 
cytochrome P450 reductase (McGuire et al., 1998). Inhibition of NADPH oxidase occurs 
via a radical mechanism, where DPI abstracts an electron from a reduced redox center in the 
oxidase and subsequently reacts with FAD, forming covalent adducts (O'Donnell et al., 
1993). AEBSF inhibits the binding of p47phox to cytochrome b558 during oxidase assembly 
(Diatchuk et al., 1997) but is also a well known serine protease inhibitor. Currently, 
NADPH oxidase inhibitor design has relied on high-throughput screening due to a lack of 
structural information (Tegtmeier et al., 2005). A novel inhibitor identified by such high-
throughput screening, VAS2870 (3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-
d]pyrimidine) from vasopharm BIOTECH GmbH (Würzburg), has been found to have an 
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IC50 value of 10.6 µM when assayed with membranes of human neutrophils. Additionally, 
preincubation of 10 and 20 µM VAS2870 abolishes PDGF-induced NADPH Oxidase 
activation and ROS generation in VSMC homogenates, preventing PDGF-dependent VSMC 
migration via Src (ten Freyhaus H. et al., 2006). Structural characterization of a complex of 
VAS2870 with H6-Nox1cyt may provide avenues for rational drug design to increase 
specificity for human Nox1, the major oxidase in VSMCs.  
With regards to a detailed understanding of the overall catalytic mechanism of Nox proteins 
at the molecular level, analysis of multiple homologues in other organisms may be another 
alternative to identify more stable Nox proteins that retain the basic features of the human 
Nox proteins. A recent, comprehensive taxonomic analysis of the Nox and Duox proteins 
has yielded many possible candidates that could be screened to find one that might be more 
amenable to heterologous expression and isolation than the human Nox proteins (Kawahara 
and Lambeth, 2007). These include Nox1 homologues present in frog and zebrafish, as well 
as NoxA homologues found in dictyostelium and fungi, which contain the basic domain 
structure of Nox1-4 proteins.  
In conclusion, methods have been developed to heterologously express and purify an active 
form of the cytosolic domain of human Nox1, which may be capable of biologically 
relevant interactions. Structural characterization of this active fragment alone and in 
complex with activating proteins may provide deeper insights into the first electron transfer 
step towards the production of superoxide by these unique enzymes, whose roles in human 
pathologies are increasingly recognized.  
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3. INTRODUCTION 
As highlighted by the difficulties experienced with the characterization of the cytosolic 
domain of human Nox1, many proteins of interest lack the inherent stability outside of their 
natural cellular environment to be able to address questions at the biochemical and 
molecular level. Factors that can increase protein stability are thus of considerable interest. 
Since the discovery of naturally occurring circular proteins and peptides, peptide backbone 
cyclization of linear proteins and peptides has become a biotechnical method for protein 
stabilization. These circular proteins and peptides are characterized by high thermal and 
chemical stability, as well as resistance to proteolysis (Eisenbrandt et al., 1999; Jennings et 
al., 2001; Felizmenio-Quimio et al., 2001). Such properties are attractive for industrial 
applications, with regard to enzyme catalysis, or in pharmaceutical drug design. 
Additionally, cyclization may facilitate structural determination of proteins by X-ray 
crystallography through stabilization of inherently flexible regions of proteins which are 
often not observed in the calculated electron density, or which may hinder or prevent 
efficient packing of the protein in a crystal lattice. 
 
3.1 PROTEIN CYCLIZATION VIA EXPRESSED PROTEIN LIGATION 
Several examples of engineered cyclic proteins and peptides have taken advantage of a 
technique called expressed protein ligation (Iwai and Pluckthun, 1999; Scott et al., 1999; 
Iwai et al., 2001; Williams et al., 2002). This method utilizes protein splicing via inteins 
(internal proteins) to catalytically generate the circular products. Inteins are protein domains 
that excise themselves out of a precursor polypeptide chain. This self-splicing reaction 
results in the formation of a new peptide bond between the flanking ends of the precursor 
polypeptide chain (the exteins). Such splicing can occur post-translationally on nascent 
polypeptide chains, and is termed cis-splicing. Alternatively, inteins can be divided into two 
inactive N- and C-terminal fragments, which are either fused to two different exteins, or a 
single extein. Plasmids containing the divided intein-extein construct(s) are transformed into 
E. coli cells. When the two intein fragments are expressed, they are able to form a functional 
intein independent of covalent linkage between the fragments, and perform a trans-splicing 
reaction inside the E. coli cells. The reaction results in ligation between the two different 
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exteins, or ligation of a single polypeptide chain, as is the case in cyclization (Figure 44) 
(Paulus, 2000).  
Inteins are generally single protein sequences about 400-500 amino acids long, and consist 
of a protein splicing domain and an endonuclease domain. Mini-inteins are roughly 150 
residues long and contain only a protein splicing domain. The cyanobacterium 
Synechocystis sp. strain PCC6803 (Ssp) possesses a naturally split intein, Ssp DnaE intein 
(Wu et al., 1998a), which has been used to produce cyclic peptides and proteins. Generation 
of a circular product involves a precursor with the structure IC-extein-IN, where IC and IN are 
the C- and N- terminal intein domains, respectively, and the extein is the linear sequence of 
the target peptide or protein (Scott et al., 1999; Evans, Jr. et al., 2000; Iwai et al., 2001). 
Inteins that exist as a single, continuous sequence have also been engineered to be split, and 
retain the ability to perform trans-splicing after reconstitution. Examples of this include the 
Psp Pol-1 intein (Southworth et al., 1998), PI-PfuI intein from Pyrococcus furiosus (Iwai et 
al., 2001), and the Ssp DnaB mini-intein (Wu et al., 1998b). The Ssp DnaB mini-intein has 
the advantage that the trans-splicing reaction occurs efficiently in vivo in E. coli cells, 
without the need for a denaturation/renaturation step required by the separately purified 
fragments of the Psp Pol-1 intein. It requires neither a spacer sequence nor the presence of 
native exteins for efficient splicing. The superior performance of the Ssp DnaB mini-intein 
compared to other inteins in heterologous systems has led to its use in protein engineering 
applications, and is used in this work to produce a cyclized Rab7 protein. 
The mechanism of intein-mediated protein splicing occurs in four steps. (1) Nucleophilic 
attack by the side chain of cysteine or serine/threonine at the IN–target junction on the 
carbonyl of the adjacent peptide bond results in a N-S or N-O acyl shift, creating a 
(thio)ester. (2) Transesterification, with nucleophilic attack on the (thio)ester by the side 
chain of the first residue at the IC-target junction, producing a branched (lariat) intermediate. 
(3) Cyclization of a conserved asparagine at the intein C-terminus involving attack by the β-
amide nitrogen on the carbonyl of the peptide bond, which cleaves at the carboxyl terminal 
splice junction, releasing the cyclized target. (4) A final N-S or N-O shift in the circularized 
target, producing a peptide bond and completing the splicing reaction (Figure 44) (Paulus, 
2000; Perler and Adam, 2000). 
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Figure 44. Schematic of a split intein and mechanism of protein splicing to produce a circularized 
target. Generation of a circular product involves a split intein precursor with the structure IC-extein-IN, 
where IC and IN are the C- and N- terminal intein domains, respectively, and the extein is the linear 
sequence of the target peptide or protein. Association of IC and IN produces a fully functional intein 
that catalyzes the circularization of the target in four steps. Figure after Perler and Adam, 2000.  
 
3.2 THE MODEL SYSTEM:  RAB7 GTPASE 
3.2.1 Rab GTPases 
Rab GTPases (Ras genes from rat brain) represent the largest branch of Ras related small 
GTPases, with 11 yeast proteins (Ypt proteins, yeast protein involved in transport) and over 
60 mammalian members identified thus far. They regulate major steps in intracellular 
vesicular membrane transport during cellular processes such as exocytosis and endocytosis. 
Nascent proteins destined for secretion and integral membrane proteins are sorted to their 
appropriate locations by exocytosis, passing from the endoplasmic reticulum, through the 
Golgi, to the plasma membrane. Extracellular nutrient uptake and recycling of membrane 
proteins and receptors via internalization is accomplished through endocytosis. Cargo is 
transported to the early endosome and moves onto either recycling endosomes to be 
recycled, or to late endosomes and then lysosomes for degradation. Rab GTPases mediate 
steps in this transport such as vesicle budding, vesicle delivery via molecular motors along 
microtubules or actin filaments, vesicle tethering close to the target membrane, and vesicle 
fusion with the membrane of the target compartment (Zerial and McBride, 2001; Pfeffer, 
2001; Grosshans et al., 2006). 
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Rab GTPases are posttranslationally modified at two cysteines in their C-terminus with a 
20-carbon geranylgeranyl lipid moiety that allows them to anchor to membranes. Some Rab 
proteins (such as Rab8 and Rab13) are geranylgeranylated at a single cysteine. In contrast to 
other GTPases, Rab prenylation requires Rab escort protein (REP) to present it to the 
cytosolic heterodimeric Rab geranylgeranyltransferase (Rab GGTase or GGTase type II). 
Mammalian cells contain two REP isoforms (REP-1 and REP-2) that bind Rab in its GDP 
form. Once prenylated, REP sequesters the lipid modification, keeping inactive prenylated 
Rab •GDP soluble, and delivers it to the membrane.  
Figure 45. The Rab7 •GDP(monoprenylated):REP-
1 complex (PDB Code 1VG0, Rak et al, 2004). 
Rab7 (blue)•GDP(salmon stick) prenylated with a 
single geranylgeranyl group (GG, magenta stick) 
interacts with three main regions in REP-1 (white). 
The globular core of Rab7 mainly interacts with the 
Rab binding platform (RBP, red) of REP-1 through 
its Switch II region (SW2, salmon). The extended 
C-terminal tail (green) of Rab7 •GDP interacts 
with the C-terminal binding region (CBR, yellow 
orange) of REP-1. A mobile effector loop (MEL, 
dark blue) lies between Domain 1 and Domain 2 of 
REP-1, with Domain 2 sequestering the 
geranylgeranyl moiety. Switch I (SW1, blue-green) 
is not well-defined in this structure. 
 
 
Like all small GTPases, Rab GTPases cycle between an inactive GDP-bound and an active 
GTP-bound state. Guanine nucleotide exchange factors (GEFs) increase the dissociation rate 
of GDP, allowing GTP to bind, which is present at concentrations 10 times that of GDP in 
the cell. This leads to the active Rab •GTP state, which is recognized by a myriad of effector 
proteins that participate in the various steps of vesicular transport. GTPase activating 
proteins (GAPs) regulate the duration of this signal by accelerating the normally slow 
intrinsic GTPase activity, which returns Rab •GTP to the inactive Rab •GDP state. Rab 
proteins are then extracted out of the membrane by Rab GDP dissociation inhibitor 
(RabGDI), and are recycled back to the cytosol where they can repeat the cycle (Goody et 
al., 2005) (Figure 46).  
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Figure 46. Rab GTPase cycle. 1 and 2, In the cytosol, newly synthesized Rab•GDP GTPases are 
escorted by REP to GGTase II for geranylgeranylation. 3, REP delivers prenylated Rab•GDP to the 
membrane for use in vesicular transport. 4, GEFs accelerate GDP dissociation from Rab, allowing 
GTP to bind. 5 and 6, Active prenylated Rab•GTP is recognized by effector molecules that participate 
in various steps of vesicular transport. 7, GAPs accelerate Rab's intrinsic GTPase activity, returning it 
to the inactive GDP form. 8, GDI retrieves prenylated Rab•GDP from the membrane through Rab 
recycling factor (RRF), recycling it back into the cytosol, 9, where it can repeat the cycle. 
Corresponding crystal structures of Rab7∆C22•GDP:REP-1 (PDB Code 1VG9) and REP-
1:GGTaseII:isoprenoid (PDB Code 1LTX) are shown, with a dashed circle indicating the hypothetical 
position of Rab7 based on superposition of the two structures. Additionally, the crystal structure of 
doubly geranylgeranylated (green stick) Ypt1•GDP (a yeast homologue, cyan; PDB Code 2BCG) in 
complex with GDI (white) is shown. Figure modified from Alory and Balch, 2001.  
 
Sequence alignment of Rab proteins led to the identification of regions that are specific to 
the Rab family (Figure 47). These regions (RabF1-5) lie in or around the Switch regions, 
which change conformation depending on whether GDP or GTP is bound, and together with 
conserved regions for phosphate/Mg2+ and guanine nucleotide binding (PM/G) motifs 
define the Rab family of proteins. Additional regions of high conservation were observed 
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within Rab subfamilies, and these areas (RabSF1-4) are proposed to confer effector 
specificity (Pereira-Leal and Seabra, 2000).  
 
3.2.2 Rab7 GTPase 
Rab7 regulates late endocytic transport from early to late endosomes, from late endosomes 
onto lysosomes, as well as lysosome biogenesis (Feng et al., 1995; Meresse et al., 1995; 
Bucci et al., 2000). It is additionally involved in cellular response to the withdrawal of 
growth factors, contributing to the initiation of apoptosis (Edinger et al., 2003). Two Rab7 
effectors have been identified, Rab7-interacting lysosomal protein (RILP) (Cantalupo et al., 
2001) and Rabring7 (Mizuno et al., 2003), both of which are recruited to late 
endosomes/lysosomes by Rab7•GTP. The three-dimensional structure of a constitutively 
active Rab7 mutant in complex with RILP indicates that both the Switch regions and two 
Rab specific regions (RabSF1 and RabSF4) are involved in the interaction interface (Wu et 
al., 2005). 
 
Figure 47. Rab7 protein sequence with secondary structure shown above, and RabF (red, bold) and 
RabSF (yellow highlight) regions indicated below. A blue line underlines Switch I, and a purple line 
underlines Switch II. Conserved nucleotide binding (PM/G) motifs are shown in green. The two C-
terminal cysteines that undergo prenylation are indicated by *. Ribbon representation of the Rab7 
(dark green):REP-1 (white) complex (PDB code 1VG0) with RabF and RabSF regions indicated in 
red and yellow, respectively, and PM/G motifs in light green. Geranylgeranyl is shown in red stick 
representation. Ribbon representation figure taken from Leung et al, 2006. 
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3.3 AIMS OF WORK 
Rab7 was selected as a model system to study the effects of cyclization on protein stability 
and in stabilization for crystallization. Fluorescence and circular dichroism spectroscopy 
were used to assess the extent of thermal stabilization imparted by cyclization. Native 
biological function was evaluated by measurement of the intrinsic GTPase activity and 
interaction with a yeast homologue of REP-1 (Mrs6) to determine if cyclization of Rab7 
disturbed its biological activity. Finally, structural characterization by X-ray crystallography 
was made on cyclized Rab7•GDP and cyclized Rab7•GppNHp to determine (1) if 
cyclization improved the ability to crystallize both inactive and active forms of Rab7, and 
(2) if cyclization could stabilize flexible protein loops and allow for their structure 
determination.  
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3.4 RESULTS AND DISCUSSION 
3.4.1 Protein expression and purification 
The generation of cyclized Rab7 took advantage of split-intein mediated protein ligation. 
Rab7 truncated to residues 7-185 flanked by linker residues (Figure 48A) was inserted via 
EcoRI and MluI restriction sites into a plasmid containing the split Ssp DnaB mini-intein 
under a thermally controlled promoter (Williams et al., 2002) (a kind gift from Prof. Nick 
Dixon, University of Wollongong, New South Wales, Australia). This plasmid was 
transformed into BL21(DE3) E. coli cells. Protein expression was induced via heat shock, 
and found to be sensitive to the cell density at the time of induction. Reasonable expression 
was found when the cell density reached an optical density at 600 nm of at least 0.7 but not 
above 0.8 absorbance units. Although overexpression was not obvious from SDS-PAGE 
analysis (Figure 48B), further purification resulted in typical yields of 12 mg of cyclized 
Rab7 per 5L of cell culture. Prior to harvesting the cells, cyclization was promoted by 
incubating the cultures for at least 2 hours at 4°C.  
 
Figure 48. A, Design of cyclized Rab7: a truncated version of Rab7 containing residues 7-185 (bold) 
was used with a 9 residues linker (red) that becomes covalently linked upon cyclization. Two other 
constructs used in this work, Rab7∆C2 and Rab7∆C22, are also shown aligned with excerpts of the 
protein sequence of wild type Rab7. B, Expression pattern of cyclized Rab7 in BL21(DE3) E. coli. M, 
Markers; S, cyclized Rab7 standard; N, non-induced cells; I, cells after thermal induction; and C, 
induced cells after promotion of cyclization at 4°C for 2 hours. 
 
Since the construct lacks affinity tags, a traditional purification scheme was employed with 
crude fractionation via ammonium sulfate, followed by initial separation over DEAE-
Sepharose, a weak anion exchange resin. Higher molecular weight contaminants were 
removed by size exclusion chromatography, and a final run over Porous HQ resin, a strong 
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anion exchanger, allowed for the final polishing step (Figure 50A). A previous protocol 
using a linear gradient from 0-1M NaCl over 100 ml for the final elution showed significant 
amounts of contaminating proteins, in spite of a single peak in the elution profile (Nathalie 
Bleimling, unpublished results, Figure 49A). It was noted that cyclized Rab7 was the first 
species to elute, with other proteins following later on in the elution peak. This protocol was 
modified in two ways: 1) the gradient volume was extended to 300 ml, and 2) the gradient 
was held once the absorbance at 280 nm began to increase from baseline to allow selected 
elution of weaker binding proteins. When the first elution peak began, the gradient was held 
at 80 mM NaCl, allowing improved separation of different protein species (Figure 49B). As 
the absorbance reading at 280 nm reached a plateau, the gradient was then allowed to 
continue until the next elution peak began (at 110 mM NaCl), and again held until no further 
elution was seen. This was continued until the gradient reached 500 mM NaCl, at which 
point the elution was stepped to 1 M NaCl, since all of the protein had eluted before 
500 mM NaCl in the original 100 ml linear gradient. SDS-PAGE analysis on fractions from 
this modified elution scheme indicated that most of the contaminating proteins were 
retained longer on the anion exchanger with respect to cyclized Rab7, allowing cyclized 
Rab7 to elute nearly exclusively. 
 
Figure 49. Optimization of cyclized Rab7 purification over Porous HQ chromatography. A, 
Chromatographic profile of a single linear gradient over 100 ml and respective SDS-PAGE on elution 
fractions. Arrowhead indicates cyclized Rab7. L, sample loaded; FT+W, flow through and wash 
samples; M, Markers; St, cyclized Rab7 standard. B, Chromatographic profile of the modified elution 
method and corresponding SDS-PAGE analysis of respective fractions. Load, loaded sample; numbers 
indicate fractions. 
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This modified protocol was successful to produce pure cyclized Rab7 as judged by SDS-
PAGE (Figure 50A). Cyclization was confirmed with ESI-MS, with a measured mass of 
21,353 Da, indicating a loss of 18 Da due to a water molecule upon cyclization (expected 
mass for the linear form:  21,373.20 Da) (Figure 50B).  
 
Figure 50. A, Purification of cyclized Rab7. S, supernatant after protein induction; M, markers; St, 
cyclized Rab7 standard. B, ESI-MS spectra of the final purified protein, confirming successful 
cyclization. 
 
3.4.2 The effect of cyclization on the secondary structure of Rab7 
Circular dichroism measurements were made on cyclized Rab7•GDP and compared to a 
linear version missing the equivalent 22 residues from the C-terminus (Rab7∆C22•GDP), 
as well as wild-type Rab7 missing the last two amino acids from the C-terminus 
(Rab7∆C2•GDP). As can be seen from Figure 51 and Table 2, cyclization does not 
significantly alter the percentage of secondary structural elements, and is actually more 
similar to the nearly full-length Rab7∆C2 protein than the linear truncated Rab7. These are 
in good agreement with the values of 37% α-helix and 19% β-sheet calculated from the 
crystal structure of human Rab7(Q67L)•GTP (PDB code 1T91) (Wu et al., 2005), and 41% 
α-helix and 19% β-sheet for rat Rab7•GppNHp (PDB code 1VG8) (Rak et al., 2004). The 
percentage of α-helix varies from the two crystal structures based on the fact that more of 
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the C-terminal helix is visible in the Rab7•GppNHp structure as compared with the 
Rab7(Q67L)•GTP structure. 
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Figure 51. Overlay of circular dichroism spectra of Rab7∆C2, Rab7∆C22, and cyclized Rab7. 
 
Table 2. Percent secondary structure of different Rab7 constructs determined by circular dichroism. 
Protein % α-helix % β-sheet % β-turns % Unordered 
Rab7∆C2•GDP 29.1 16.4 19.3 35.1 
Rab7∆C22•GDP 22.5 21.5 20.8 35.0 
Cyclized Rab7•GDP 30.6 18.2 16.0 35.1 
 
 
3.4.3 The effect of cyclization on protein stability:  Temperature-dependent 
fluorescence and circular dichroism measurements 
To determine whether cyclization conferred additional thermal stability, both cyclized 
Rab7•GDP and a linear version, Rab7∆C22•GDP, were monitored by fluorescence and 
circular dichroism with increasing temperature. Fluorescence measurements were made 
monitoring the intrinsic tryptophan fluorescence using an excitation wavelength of 290 nm. 
Thermal recovery of the respective proteins was checked after the last temperature by 
cooling the sample to 20°C and re-measuring its fluorescence emission. In the case of the 
cyclized Rab7•GDP, the fluorescence emission measured at 20°C was lower than that at 
30°C, even though the same sample and cuvette were used and the measurements performed 
on the same day. Therefore, the measurement at 20°C has been excluded from Figure 52. 
Cyclized Rab7•GDP appears to retain more fluorescence than its linear counterpart (Figure 
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52A), and even demonstrated an apparent ability to regain intrinsic tryptophan fluorescence 
after re-cooling to 20°C (data not shown).  
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Figure 52. A, Comparison of the intrinsic tryptophan fluorescence emission of Rab7∆C22 and 
cyclized Rab7 upon thermal denaturation. B, Fluorescence at 344 nm with respect to temperature. 
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Figure 53. Comparison of circular dichroism spectra of Rab7∆C22 and cyclized Rab7 upon thermal 
denaturation. 
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The nature of this effect was clarified with subsequent circular dichroism measurements 
(Figure 53). With increasing temperature, both proteins increase their β-strand content, with 
cyclized Rab7 demonstrating a more pronounced alpha to beta transition. In contrast to the 
recovery of fluorescence of cyclized Rab7 observed upon re-cooling, the protein did not 
regain any secondary structure when the 85°C sample was re-cooled to 20°C. Rab GTPases 
have a conserved 6-stranded β-sheet core that is surrounded by 4 α-helices. For the cyclized 
protein, thermal denaturation causes the surrounding α-helices to unfold but the protein is 
prevented from melting further possibly by the constraints of the covalent attachment of the 
N- and C-termini. Thus the final denatured protein is “trapped” with some elements of β-
sheet remaining. Since Rab7 contains a tryptophan in the β-sheet core (W62), the apparent 
retention and recovery of tryptophan fluorescence may be due to an enhanced hydrophobic 
environment upon denaturation that prevents quenching of the fluorescence by water.  
The extent of thermostability imparted by cyclization was quantified by determining the 
melting temperature for cyclized Rab7 and Rab7∆C22. This was measured using the 
temperature dependence of the CD signal at 210 nm (α-helix) and 220 nm (β-sheet) (Figure 
54). Cyclization modestly increased the melting temperature by 3.7°C (210 nm), which falls 
short of the typical 5°C increase in thermostability observed for cyclization of other proteins 
such as β-lactamase and subunit IIA of the E. coli glucose transporter (Iwai and Pluckthun, 
1999; Siebold and Erni, 2002), and is less significant when compared with the ~14°C 
increase in melting temperature obtained with cyclized DnaB-N (Williams et al., 2002). 
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Figure 54. Melting temperature of Rab7∆C22 and cyclized Rab7 determined by the CD signal at 
210 nm and 220 nm with increasing temperature. 
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3.4.4 The effect of cyclization on biological function 
As is the case with all modifications, it is important to determine whether they influence the 
native state of the protein of interest. In this regard, several measurements were made with 
cyclized Rab7 and its linear counterpart, Rab7∆C22 to see if they differed significantly from 
each other. 
 
GTPase Activity 
The intrinsic GTPase activity was measured by incubating either Rab7∆C22 •GTP or 
cyclized Rab7•GTP in 40 mM HEPES, pH 7.5 at 37°C in the presence of 10 mM MgCl2. 
Aliquots were collected every 20 seconds, flash frozen in liquid nitrogen to stop the GTPase 
reaction, and analyzed by HPLC to quantify the amounts of GTP and GDP. Cyclization 
caused a slight decrease in the hydrolysis rate, with a rate constant of 0.0032 s-1 compared to 
0.0054 s-1 for the linear form (Figure 55).  
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Figure 55. Intrinsic GTPase activity of cyclized Rab7 compared to Rab7∆C22. Cyclized Rab7•GTP 
or Rab7∆C22•GTP at a concentration of 150 µM in 40 mM HEPES, pH 7.5 was incubated at 37°C in 
the presence of 10 mM MgCl2. Aliquots were collected at the given time points, flash frozen in liquid 
nitrogen and analyzed on HPLC to quantify the amounts of GTP and GDP. The amount of GTP for 
each time point was normalized with the initial amount of GTP.  
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Effector binding and dissociation 
Association and dissociation kinetics were measured for both cyclized Rab7 and its linear 
counterpart, Rab7∆C22 to determine if cyclization affected the biological activity of Rab7. 
For association measurements, each Rab7 construct was complexed with a fluorescent 
analogue of GDP (mantGDP) at a final protein concentration of 0.5 µM and titrated against 
varying excess concentrations of Mrs6, the yeast homologue of REP-1. Fluorescence 
resonance energy transfer (FRET) was exploited by excitation of the intrinsic tryptophan 
fluorescence of the Rab7 protein and measurement of the emission of the mantGDP moiety. 
Binding was associated with an increase in the FRET signal over time, whereas 
displacement showed a decrease in the FRET signal over time. Cyclization of Rab7 did not 
drastically alter the association kinetics of Rab7 to Mrs6. Both cyclized Rab7 and 
Rab7∆C22 showed double exponential binding kinetics, with apparent KD’s of similar order 
of magnitude, 3.58 ± 0.75 µM and 1.36 ± 0.40 µM, respectively, using amplitude analysis 
(Figure 56). Each construct lacks the C-terminal tail, and therefore represents the globular 
core of Rab7. The affinity of these constructs to Mrs6 is decreased 40- to ~100-fold when 
compared to wild type Rab7 [c.f. KD = 35 ± 2 nM, (Constantinescu, 2001)]. Thus, the 
measured values can be regarded as the affinity of the globular core of Rab7 to REP-1.  
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Figure 56. Independent determination of the affinity of Rab7∆C22•mantGDP and cyclized 
Rab7•mantGDP, respectively, for Mrs6 using amplitude analysis. 
 
103 
cyclized Rab7 
 
The association of two proteins is a bimolecular process, and is therefore a second order 
reaction. Under certain conditions, a second order reaction can be made to approximate a 
first order reaction if one of the species is present in a large excess of the other. Although 
such conditions were employed in the studies presented here, simple exponential behavior 
expected from pseudo-first order conditions was not observed. Earlier measurements of 
REP-1 association with Rab7 also indicated double exponential behavior, and this was 
explained by a 2-step binding model with fluorescence changes in both steps (Alexandrov et 
al., 1998). Displacement measurements in the present work also showed biphasic behavior. 
Here, there was a clear difference in the behavior, with Rab7∆C22 being more obviously 
biphasic. 
 
Figure 57. Displacement of Rab7∆C22•mantGDP and cyclized Rab7•mantGDP, respectively, from 
Mrs6. Kinetic transients were fit to a double exponential equation. The fitted rate constants for 
Rab7∆C22 are k1=1.6 ± 0.022 s-1, k2= 0.083 ± 0.00052 s-1, and for cyclized Rab7, k1 = 0.87± 0.04 s-1, 
k2= 0.074 ± 0.00036 s-1. 
 
Biphasic kinetics suggests, but is not limited to, two binding steps, and in this case may 
represent the overall behavior of several different factors. It is interesting to note that Rab7 
contains three tryptophans, each of which are within 25 Å of the 3'-oxygen of the nucleotide 
ribose, which is the usual site of attachment for the mant moiety (PDB Code 1VG9: Trp 62, 
22.42 Å; Trp 102 ,17.96 Å; and Trp 142, 24.69 Å). Two of these lie in the vicinity of Switch 
I and II, with Trp 62 just below the interface between Switch I and the Rab binding platform 
of REP-1, and Trp 102 situated just behind the short helix in Switch II (Figure 58A and B). 
Switch II makes extensive contacts with the Rab binding platform in REP-1 (Figure 45). 
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Trp 62 additionally participates directly at the Rab7:REP-1 interface, and undergoes a 
rotation of 19.8° upon REP-1 binding (Figure 58C). It is thus conceivable that the observed 
fluorescence changes represent a combination of several conformational changes of Rab7 
upon REP-1 binding as sensed by the tryptophans, which may not all occur simultaneously 
with association. This would be consistent with the previously observed fast, concentration-
dependent phase, followed by a slower, concentration-independent phase of Rab7 
association with REP-1 (Alexandrov et al., 1998). In this case, the initial association of 
Rab7 to REP-1 would be concentration dependent, while the subsequent conformational 
changes would not depend on REP-1 concentration since the two proteins are already 
associated with each other.  
 
Figure 58. Location of tryptophans in the vicinity of Switch I and II in Rab7. A, Ribbon 
representations of cyclized Rab7•GDP (magenta) superposed on Rab7∆C22 •GDP (cyan) in complex 
with REP-1 (green). Trp 102 lies behind the short helix in Switch II that moves in toward Rab7 upon 
binding of the N-terminal region of Domain I in REP-1. B, View of Trp 62 at the Rab7:REP-1 
interface, below Switch I, and next to Switch II, which undergoes conformational changes upon REP-
1 complex formation. Arrows indicate the ends of the visible region of Switch I in the linear 
Rab7∆C22 •GDP structure. Bound GDP is shown as white stick representation. C, Rotation of Trp 62 
that must occur in cyclized Rab7•GDP (peach stick) upon Rab7:REP-1 complex formation (yellow 
stick).  
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As mentioned previously, although cyclization of Rab7 does not prevent Rab7 association to 
Mrs6, it does slightly lower its affinity. The similar dissociation rate constants for cyclized 
and linear Rab7 indicate that the difference in affinity is due to different association rate 
constants. A direct consequence of covalent linkage of the termini is a reduction of the 
degrees of freedom available for Rab7, which may affect its association with Mrs6. It is well 
known that Ras GTPase effectors bind Ras with an induced-fit binding mechanism (Sydor et 
al., 1998; Linnemann et al., 1999), and this has also been observed when Rab3A forms a 
complex with its effector, Rabphilin-3A (Ostermeier and Brunger, 1999). Superposition of 
the crystal structure of uncomplexed cyclized Rab7•GDP on the Rab7∆C22 •GDP in 
complex with REP-1 reveals that the short helix consisting of Arg 69, Phe 70, and Glu 71 in 
Switch II is compressed towards Rab7 upon REP-1 binding (Figure 59). In cyclized 
Rab7•GDP, Glu 71 would have to rotate approximately 180°C to avoid collision with 
Tyr 395 of REP-1, and form a hydrogen bond between its backbone carbonyl and the side 
chain of Arg 398 from REP-1. Covalent linkage of the termini may constrain the protein in 
such a way that this rotation is less favorable, which could contribute to the slight reduction 
in affinity measured for cyclized Rab7. Interestingly, in contrast to uncomplexed wild type 
Rab7•GDP, which possesses a different conformation of Switch II prior to REP-1 binding, 
cyclized Rab7•GDP alone and Rab7∆C22 •GDP in complex with REP-1 share a similar 
overall conformation in some areas of Switch II. In spite of this, REP-1/Mrs6 may require a 
different initial conformation of Rab7•GDP to induce the final bound conformation. It is 
worthy to note here that in most of the determined inactive GDP-bound Rab GTPase 
structures, the switch regions are largely disordered (Eathiraj et al., 2005). REP-1/Mrs6, 
thus, may require a more flexible Rab7•GDP in order to produce a productive binding 
event. The reduced degrees of freedom in turn may hinder the larger conformational 
changes required by cyclized Rab7•GDP for REP-1/Mrs6 association.  
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Figure 59. Rearrangement of the short helix (Arg69-Phe70-Glu71) of Rab7 with 180° rotation of 
Glu 71 upon REP-1 binding to Rab7. Superposed ribbon representations of cyclized Rab7•GDP 
(magenta) and Rab7∆C22•GDP (cyan) in complex with REP-1 (dark blue).  
 
3.4.5 Cyclization as an aid for crystallization 
 
Cyclized Rab7• GDP 
Rab7•GDP has been extensively structurally characterized. Both monoprenylated 
Rab7•GDP and Rab7∆C22•GDP each in complex with REP-1, as well as Rab7•GDP and 
Rab7•GppNHp alone have been crystallized and their structures have been determined by 
X-ray crystallography (Rak et al., 2004). Switch I and II were found to be largely disordered 
in the Rab7•GDP structure, in keeping with the inherent flexibility of these regions in the 
GDP form of Rab GTPases in general (Stroupe and Brunger, 2000; Eathiraj et al., 2005). 
Structures of Rab7∆C22•GDP and monoprenylated Rab7•GDP in complex with REP-1 
allowed for the visualization of Switch II, which makes key interactions with the REP-1 
molecule. In contrast, Switch I was disordered in each structure, arising from the minimal 
contact of this region with REP-1, which predominantly interacts with Switch II. With this 
motivation, Rab7 was cyclized to determine if this could stabilize the Switch I region 
enough to obtain structural information on this area. Indeed, cyclized Rab7•GDP 
crystallized readily, and diffracted to very high resolution (1.16 Å), resulting in a complete 
picture that includes Switch I (Dr. Olena Pylypenko, unpublished results).  
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The overall structures of Rab7•GDP and cyclized Rab7•GDP do not differ significantly 
from each other, with a rmsd of Cα atoms of 0.83 Å. The main difference lies in the ordering 
of Switch I and II in the cyclized version (Figure 60A). These regions are stabilized by 
several crystal contacts. Rab7•GDP and cyclized Rab7•GDP crystallized in different space 
groups, and therefore possess different crystal packing. The observed conformation of 
Switch I in cyclized Rab7•GDP is affected by hydrophobic contacts with the linker region 
of a symmetry related molecule. The side chain of Ile 4 in the linker packs against a 
hydrophobic environment created by the methylene groups of Gln 36 and Lys 38, as well as 
the aromatic ring of Tyr 37 in Switch I. A salt bridge between Arg 69 in Switch II and 
Glu 158 of a second symmetry related molecule allows for a second hydrophobic 
environment, with Ile 127 and Ile 160 of the same symmetry molecule packing against Tyr 
37 on the other side of its aromatic ring (Figure 60C). This stabilized conformation of 
Switch I allows Ala 39 to form key backbone hydrogen bonds to both the α-phosphate and 
an axial water which coordinates the Mg2+ ion (Figure 60D), thus stabilizing GDP binding. 
Cyclized Rab7 was found to require a more stringent nucleotide exchange protocol to fully 
exchange the endogenously bound GDP compared to wild type Rab7 (see next section), 
which suggests that these interactions between Ala 39 and GDP may also be present in 
solution. Knowledge of the conformation of Switch I in the apo-form of Rab7•GDP allows 
for comparative analysis with structures of Rab7 bound to effectors like REP-1 to 
understand the molecular details of Rab7 conformational changes upon binding (see 
Effector binding section).  
Switch II is also stabilized by interactions of neighboring symmetry related molecules as 
well as intramolecular interactions. The salt bridge between Arg 69 and Glu 158 of a 
symmetry related molecule provides one anchor point, which is enhanced with hydrophobic 
interactions between Phe 70 and the methylene groups of Glu 130 of the same symmetry 
related molecule. A second area, the extended loop region of Switch II, is ordered through a 
hydrogen bond between the side chain of Ser 72 and Gln 109, which further hydrogen bonds 
to the side chain of Glu 105. Additional hydrophobic interactions occur between the side 
chains of Leu 73 and Phe 77 (Figure 60B). 
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Figure 60. Stabilization of Switch I and II in cyclized Rab7•GDP. A, Superposition of ribbon 
representations of Rab7•GDP (navy) and cyclized Rab7•GDP (white). Black circles indicate the 
extent of the switch regions visible in Rab7•GDP, with Switch I and Switch II in cyclized Rab7•GDP 
highlighted in cyan and lilac. B, Stabilization of Switch II in cyclized Rab7•GDP through favorable 
interactions (dashes) between Arg 69 and Glu 158 of a symmetry related molecule (blue) on one end, 
and Ser 72 with Gln 109 on the other. Additional hydrophobic interactions occur between Leu 73 and 
Phe 77, as well as between Phe 70 and the methylene groups of Glu 130 of the same symmetry related 
molecule. C, Stabilization of Switch I in cyclized Rab7•GDP via interactions with symmetry related 
molecules. Glu 36, Lys 38, and Tyr 37 in Switch I surround Ile 4 of the linker region from one 
symmetry related molecule (green). A salt bridge between Arg 69 in Switch II and Glu 158 of a 
second symmetry related molecule (dark peach) allows Ile 127 and Ile 160 of the same symmetry 
molecule to pack against Tyr 37 on the other side of its aromatic ring. D, Ribbon representation of the 
nucleotide binding region of cyclized Rab7•GDP. Switch I is shown in cyan, with interactions made 
by Ala 39, Mg2+ (green sphere) and active site waters (red spheres) shown with dashes.   
 
Cyclized Rab7• GppNHp 
Additional structural studies were carried out to determine whether cyclization permitted 
crystallization of the GTP-state of Rab7 as well. Crystallization studies on cyclized 
Rab7•GDP highlighted two base conditions that promoted protein crystal growth: 1) 25% 
PEG 3350, 100 mM Tris-HCl, pH 8.5, and 2) 1.6 M ammonium sulfate, 100 mM HEPES, 
pH 7.4 with microseeding, each with a protein concentration of 7 mg/ml (Nathalie 
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Bleimling, unpublished results). These conditions were probed first as an initial screen for 
cyclized Rab7 in complex with GppNHp (a nonhydrolyzable GTP analogue) at a 
concentration of 5 mg/ml, and both produced crystals. Crystals appeared 3 days after setup 
without microseeding in the ammonium sulfate conditions, and these were probed further by 
varying the pH and concentration of precipitant to encourage single crystal growth suitable 
for X-ray diffraction studies. A pH value other than 7.4 only delayed the onset of 
crystallization, and did not improve crystal form. Different seeding techniques such as 
microseeding and streak seeding were employed, as well as varying the time the seeds were 
introduced to the crystallization drops. Though the crystal forms improved to rods, they 
remained striated and flawed even at the stage of initial crystal growth. These observations 
led to suspicions that there was an inherent problem with the protein samples used for 
crystallization.  
Though requiring a significantly longer time (months), crystals were also eventually 
observed in the PEG conditions. When these crystals were subsequently used to seed fresh 
drops, crystals appeared overnight, with successive “generations” of seeding producing 
crystals with greatly improved quality and form. The resulting crystals strikingly resembled 
the form obtained for cyclized Rab7•GDP, and these results strengthened the growing 
suspicions that these crystals and those obtained from ammonium sulfate contained GDP or 
GDP-like nucleotides. 
Crystallization proved to be somewhat sensitive to different batches of purified protein, and 
surprisingly insensitive to the nucleotide state of the protein. HPLC analysis on crystals 
obtained in 21-22% w/v PEG 3350 with 100 mM Tris-HCl, pH 8.5 showed occupancy for 
three different nucleotides: 59.6% GDP, 8.8% of a contaminant found in GppNHp used for 
nucleotide exchange (possibly GppNH2), and 31.6% GppNHp. Analysis of crystals obtained 
from ammonium sulfate also contained a significant amount of this GDP-like contaminant, 
with a putative GppNH2 content 8-fold higher than GppNHp (Table 3). These results 
demanded a more stringent nucleotide exchange protocol than the one typically used for 
wild type Rab7 to produce exclusively GppNHp-bound protein for the present 
crystallization studies. Inclusion of alkaline phosphatase (Simon et al., 1996) to ensure 
complete removal of GDP successfully produced 97.8% cyclized Rab7•GppNHp. It is 
interesting to note that with this procedure, the amount of bound GppNH2 was significantly 
reduced to 2.2%. 
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Table 3. Nucleotide identification and quantification using HPLC analysis of crystals of cyclized 
Rab7. Standards containing 10 µM GDP and 10 µM GppNHp were analyzed alongside samples under 
isocratic conditions using 50 mM potassium phosphate, pH 6.6, 10 mM TBAB and 8% Acetonitrile. 
Crystals from PEG 3350 conditions, AP treated cyclized Rab7, and their respective standards were 
analyzed using a buffer containing slightly less than 8% Acetonitrile. Retention times for the 
respective standards are shown in parentheses. 
Sample Retention Time (min) % nucleotide 
   
Crystals from PEG 3350 conditions:   
GppNH2 5.89 (5.92) 8.79 
GDP 10.10 (10.03) 59.60 
GppNHp 14.32 (14.26) 31.61 
   
   
Crystals from AmSO4 conditions:   
GppNH2 5.26 (5.27) 89.02 
GppNHp 11.61 (11.65) 10.98 
   
   
AP treated cyclized Rab7:   
GppNH2 5.94 (5.93) 2.22 
GppNHp 14.32 (14.31) 97.78 
   
 
This alkaline phosphatase prepared cyclized Rab7•GppNHp (10 mg/ml) produced initial 
crystals 2 days after set up in 1.6M ammonium sulfate and 100 mM HEPES, pH 7.4 without 
seeding. Several factors were optimized to produce crystals large enough for diffraction 
studies. These include streak seeding drops at the time of setup, decreasing the 
concentration of precipitant to 1.3M or 1.4M, and increasing the drop volume from 0.6 µl to 
1.4 µl. These measures resulted in a flat crystal approximately 60 x 100 microns large 
(Figure 61A). Unfortunately, it was discovered that this crystal consisted of a collection of 
tiny rods, which splintered during separation attempts from the rest of the crystal bundle.  
As mentioned earlier, PEG 3350 provided an alternative crystallization condition and 
parameters were also probed in parallel using the alkaline phosphatase generated cyclized 
Rab7•GppNHp. Two concentrations of protein (5.15 mg/ml and 10.3 mg/ml), several pH 
values (4.5 to 10.6), and varying PEG concentrations were scanned and tested with cross-
seeding from GDP-containing cyclized Rab7 crystals that were originally seen in PEG 3350. 
Crystals were more reluctant to form in PEG conditions than was observed with the 
ammonium sulfate conditions (Figure 61B and C). Crystals were rather sensitive to pH, and 
found only to form with 100 mM Tris-HCl, pH 8.5. In general, 5-7 days were required 
before crystals were observed, and although most had thin-plate morphology, there was 
considerable striation observed along the surfaces (Figure 61, E and F). Unfortunately, 
crystals grown from PEG 3350 proved to be less robust than their ammonium sulfate 
counterparts. Heat from a standard light microscope was enough to create a temperature 
gradient within the vapor diffusion wells, which effectively melted the crisp edged plates. In 
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addition, initial tests for diffraction showed weak reflections to 12 Å. To see whether other 
compounds could improve the form and quality, a commercially available PEG Suite Nextal 
screen composed of 96 conditions with different molecular weight PEGs, pHs and salts, was 
made. Long thin needles were found 5 days later in 20% PEG 3350 with 200 mM 
magnesium sulfate. When reproduced on a larger scale, 23% PEG 3350 with 100 mM Tris-
HCl, pH 8.5 and 200 mM magnesium sulfate produced very large clusters of striated plates 
5 days after setup without seeding (Figure 61D). When tested for diffraction, the crystals 
diffracted to 3Å, but the reflections were diffuse, and subsequent screening for diffraction 
did not identify any crystal that would be suitable for structure determination.  
 
 
Figure 61. Crystals grown from alkaline phosphatase-prepared cyclized Rab7•GppNHp. A, Crystals 
obtained from optimized conditions containing 1.4 M Ammonium sulfate, 100 mM HEPES, pH 7.4 
with seeding at a protein concentration of 10.3 mg/ml. A volume of 0.7 µl protein to 0.7 µl reservoir 
solution was used over a final reservoir solution of 500 µl. Arrow indicates the crystal described in the 
text. B and C, Initial crystals of cyclized Rab7•GppNHp obtained in 23% and 25% PEG 3350, 100 
mM Tris-HCl, pH 8.5. D, Striated plates obtained from 23% PEG 3350 with 100 mM Tris-HCl, pH 
8.5 and 200 mM MgSO4. E and F, Improved crystals obtained after streak seeding with crystals from 
B and C.  
 
In an effort to determine if other factors might improve the ammonium sulfate crystal form 
or provide new crystal forms, an additive screen (Hampton Research) of 96 different small 
molecules was made using 1.6M ammonium sulfate and 100 mM HEPES, pH 7.4 as a base 
solution. In this commercially available screen, 96 reagents ranging from various salts, 
small organic molecules to detergents, are diluted 10-fold with the base solution. Crystals 
were found in a few conditions containing monovalent salts one week after setup. One 
condition containing 200 mM NaCl produced a cluster of crystals, some of which were thin 
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plates (Figure 62A), which was subsequently used as a seed stock to reproduce the 
conditions on a larger scale. Streak seeded drops produced showers of small, sometimes flat, 
rods overnight (as opposed to the originally observed thin plates) and crystal formation was 
surprisingly insensitive to varying concentrations of NaCl (50-400 mM). The number of 
crystals formed was proportional to the concentration of ammonium sulfate used, with 1.3 
and 1.4 M ammonium sulfate providing slower equilibration to improve crystal growth. 
Sequential seeding, where nice looking crystals of a flat rod form were crushed and used as 
seeds in fresh drops, aided in producing “generations” of more desirable looking crystals. 
Drop sizes were also varied to additionally increase equilibration time and allow for more 
controlled crystal formation. Reproducibility was a continual problem, but conditions were 
optimized to a range of 1.3-1.44 M ammonium sulfate, 100 mM HEPES, pH 7.4 and 200-
300 mM NaCl, with 0.6 µl or 1µl total drop volume. Unfortunately these crystals either did 
not diffract or produced smeary reflections in the diffraction pattern when tested on a home 
X-ray generator source.  
Another condition containing 100 mM KCl was found to produce a cluster of predominantly 
thin plates 19 days after the original additive screen setup (Figure 62B). Two thin plates 
were isolated from this original drop and cryocooled in 70% saturated ammonium sulfate, 
100 mM HEPES, pH 7.4, and 10% glycerol. One of the crystals diffracted to 3.5 Å in house, 
the best diffraction from any ammonium sulfate grown crystal obtained thus far. Reflections 
were diffuse, but this result encouraged further optimization to improve diffraction quality. 
Crystals could be reproduced with seeding from this original crystal cluster, and similar 
optimization strategies employed for the NaCl conditions were made with the KCl 
conditions. These produced more consistently (though not exclusively) thin plates, albeit 
often with striated surfaces. One protein batch set up in the sitting drop format at 13 mg/ml 
with 1.3 M ammonium sulfate, 100 mM HEPES, pH 7.4, and 500 mM KCl, with an altered 
protein to reservoir ratio of 0.5 µl to 1 µl or 0.5 µl to 1.5 µl and microseeding, gave three 
clean, glass-like thin plates measuring 200 µm in the longest dimension (Figure 62C to E). 
This success, however, was limited by the fact that the plates were indeed very thin and 
manipulation with cryoloops to cryocool for diffraction testing was quite demanding. Many 
factors contributed to the difficulty of this task. The sitting drop pedestals that were used are 
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Figure 62. Flat plate crystals of alkaline 
phosphatase-prepared cyclized Rab7•GppNHp 
obtained in ammonium sulfate with NaCl and 
KCl. A, Crystal cluster found in the original 
additive screen with 200 mM NaCl. B, Initial 
crystal cluster found in the original additive 
screen with 100 mM KCl. C, D, and E, 
Improved crystals of cyclized Rab7•GppNHp, 
in ammonium sulfate, 500 mM KCl, and 100 
mM HEPES, pH 7.4.  
quite deep, and the need to add cryoprotectant solution at approximately 3 times the volume 
of the original drop results in a very narrow plane of focus for viewing through the light 
microscope. In addition, the few thin plates were often surrounded by a large network of 
rods, which made the technical aspect of crystal handling extremely problematic to 
coordinate this in a short period of time before ammonium sulfate salt crystals invaded the 
drop due to high vapor pressure. The nature of the thin plate morphology also makes 
uniform cryocooling of the crystals without bending at the edges quite tricky, especially if 
the plates are large. Thus many crystals were screened for diffraction to find any which 
would be suitable for structure determination. The most common problems encountered 
were clean diffraction in one direction, and streaky, diffuse diffraction at phi= 90°.  
 
Data collection and structure solution 
One such crystal was found, which surpassed all previously tested crystals, diffracting to the 
edge of the home source detector at 2.2 Å in one direction. Diffraction data were collected 
at the Swiss Light Source (SLS) synchrotron to 1.8 Å. Diffraction data were processed with 
XDS (Kabsch, 1993), which indicated that the highest possible symmetry of the diffraction 
pattern corresponded to an orthorhombic space group. The structure was solved with 
molecular replacement using MOLREP (Collaborative Computational Project Number 4, 
1994) with Rab7•GDP (PDB code 1VG1) as a search model, indicating a space group of 
P22121 with two molecules of cyclized Rab7•GppNHp in the asymmetric unit. This model 
was refined using REFMAC5 (Murshudov et al., 1997), but the R factors failed to converge 
to acceptable values. The data were re-examined, and it was discovered that the crystal was 
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actually twinned, with a true space group of P21 and four molecules in the asymmetric unit 
(Table 4).   
 
Table 4. Data collection and refinement statistics of cyclized Rab7•GppNHp. Data processed in the 
correct space group, P21, are compared to values from original processing in P22121. Values in 
parentheses are for the highest resolution shell, 1.85-1.80Å. 
   
Data collection   
   
  
X-ray source SLS beamline, Paul Scherrer Institute 
Wavelength (Å) 0.9796 
  
   
 Processing in P21 (correct space group) 
Processing in P22121 
(incorrect space group) 
   
   
Unit cell parameters (Å, °) a = 40.62, b = 47.15, c = 189.94 a = 47.07, b = 190.04, c = 40.55 
 α = 90.000, β = 89.991, γ = 90.000 α = 90.000, β = 90.000, γ = 90.000 
Resolution range 20-1.8 Å 20-1.8 Å 
No. of observations 156841 153872 
No. of unique reflections 62728 33970 
Rmerge (%) 12.2 (50.6) 9.1 (36.0) 
Completeness (%) 93.3 (83.3) 97.6 (92.2) 
Redundancy 2.5 (2.3) 4.5 (4.0) 
<(I/σ(I)> 11.1 (2.7) 12.9 (3.2) 
 
  
Refinement  
  
  
R factor (%) 18.4 
Rfree (%) 26.6 
Included residues  
    molecule 1 5-179 
    molecule 2 6-71, 74-175 
    molecule 3 6-178 
    molecule 4 5-71, 74-179 
No. protein atoms 5464 
No. ligand atoms 132 
No. solvent atoms 345 
Twinning operator -h,- k, l 
refined twinning fraction 0.49 
R.m.s.d. bond lengths (Å) 0.014 
R.m.s.d. angles (°) 2.1 
Average B values (Å2)  
     Overall 22.3 
     Main chain 21.6 
     Side chain 23.0 
     Mg-GppNHp 17.2 
     Solvent 28.0 
Ramachandran plot , % residing in  
     Core regions 87.2 
     Additional allowed regions 11.8 
     Generously allowed regions 1.0 
     Disallowed regions 0 
  
Rmerge =Σ | AI h, P – AI h, Q  | /(0.5 * Σ AI h, P +  AI h, Q ), a quality indicator of the final merged structure factor amplitudes. 
Multiple observations of reflection h are assigned to two disjoint sets, where Ih,P and Ih,Q are the partially averaged estimates 
of the intensity. AI  are pseudoamplitudes, which take the contribution of negative reflections into account. 
R = Σ | |Fo| – |Fc| | / Σ |Fo|, where Fo and Fc are the structure factor amplitudes of the data and the model, respectively. 
 Rfree is R using a 5.6% test set of  randomly chosen reflections with twinning taken into account. 
 
The complications of twinning in crystallography 
When molecules crystallize out of solution, they search for the lowest free energy state, 
which is most easily accomplished by packing in a regular fashion. A perfect crystal is a 
three-dimensional ordered array of molecules possessing identical conformations. 
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Molecules within the crystal are related to each other by symmetry relationships such as 
rotation about an axis, which if performed on one of the molecules will produce another 
molecule in the lattice. Thus, molecules which are related by crystallographic symmetry 
have identical crystallographic environments (Drenth, 1999). A phenomenon in 
crystallography that macromolecular crystallographers are becoming increasingly aware of 
is that of twinning. Twinning is a special type of crystal growth defect where molecules may 
pack together in a way that is more favorable, but which violates the crystal symmetry 
(Yeates and Fam, 1999). This creates two or more regions termed “domains” that relate to 
each other by a specific symmetry operation known as the twin law.  
The presence of these specially related domains gives rise to certain properties of the 
resulting diffraction patterns depending on the number of dimensions in which their 
respective lattices coincide (Yeates, 1997; Yeates and Fam, 1999). If the domains share a 
common interface, where only two of the three dimensions coincide, the resulting 
diffraction pattern will be a composite of the two lattices. Such twinning is referred to as 
epitaxial, or non-merohedral twinning, and usually does not present large obstacles for 
structure determination, since the two diffraction patterns can be identified at the data 
collection stage. If one lattice can be indexed, the reflections from the second can then be 
ignored as long as they do not lie close to reflections from the first lattice (Yeates, 1997). A 
more problematic form of twinning (for the crystallographer) is when all three dimensions 
of each domain coincide perfectly, termed merohedral twinning. In this case, the diffraction 
patterns from each domain superimpose and resemble that of a single crystal because the 
respective real space lattices superimpose exactly. They are, however, oriented differently 
toward one another inside the crystal. This means that although the reflections of each 
domain superimpose in reciprocal space, their intensities are actually made up of 
contributions from the respective intensities of each twin reflection. Every reflection Iobs(h1) 
will have a twin related reflection Iobs(h2) related by the twin law, and the resulting 
measured intensities will be a linear combination of the intensity of each twin reflection 
weighted by the relative volume of each domain present in the crystal (Rees, 1980; Larsen 
et al., 2002): 
Iobs(h1) = (1 - α ) I(h1) + α I(h2) 
Iobs(h2) = α I(h1) + (1 - α ) I(h2) 
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where α is called the twinning fraction. The complement (1 - α) and α describe the relative 
volumes of each domain to each other (Yeates and Fam, 1999). If α is 0.5, the twinning is 
termed perfect and if α is less than 0.5 it is termed partial twinning.  
Perfect merohedral twinning is particularly difficult to detect because it provides additional 
symmetry to the crystal lattice that is not found in the actual Laue space group of the crystal. 
Hence the space group is often misidentified as a higher symmetry group of the same Laue 
system. This is possible in tetragonal, trigonal, hexagonal, and cubic crystal systems 
(Yeates, 1997). It has also been found in highly twinned monoclinic crystals, which appear 
to have orthorhombic symmetry. Such twinning of monoclinic crystals requires certain unit 
cell parameters that happen to mimic those of an orthorhombic cell. This has been found to 
occur if the β angle approaches 90° (Larsen et al., 2002), or if unit cell lengths a and c 
approximate each other (Ito et al., 1995; Declercq and Evrard, 2001). If the twinned lattices 
overlap approximately in three dimensions, this is termed pseudomerohedral twinning, and 
the resulting diffraction pattern will show split reflections at high resolution. In the present 
work, β refined to 89.991°, with a≠b≠c, and α=γ=90°, emulating a primitive orthorhombic 
unit cell. Close inspection of the cyclized Rab7•GppNHp diffraction pattern revealed split 
spots, indicating pseudomerohedral twinning (Figure 63). 
 
Figure 63. Excerpt of cyclized 
Rab7•GppNHp diffraction pattern 
showing split spots indicative of 
pseudomerohedral twinning. 
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Confirmation of twinning and estimation of twinning fraction 
To confirm that twinning was present in the crystal, the program TRUNCATE (Collaborative 
Computational Project Number 4, 1994) was utilized to perform statistical analysis on the 
measured intensities, which can be a simple test of twinning without knowledge of the 
twinning law (Rees, 1980). Single crystals follow Wilson’s statistics (Wilson, 1942), which 
predicts a broad distribution of intensities. Twinned crystals, as mentioned above, have 
measured intensities which are made up of contributions from twin-related reflections, and 
this results in an averaging effect on the intensities (Barends et al., 2005). A plot of the 
cumulative intensity distribution of the measured intensities for cyclized Rab7•GppNHp 
showed clear sigmoidal behavior for the acentric case, indicative of this averaging effect.  
Other common indications of twinning include specific statistical trends based on the 
normalized intensities (E) of twinned data versus that obtained for single crystals. One such 
indication is if |E2-1|<<0.736. Since intensities of the twin domains overlap, they tend to 
have less extreme (very sharp or very weak) types of intensities 
(http://xrayweb.chem.ou.edu/notes/twin.html#indicators). The mean |E2-1| value calculated 
using ECALC (Collaborative Computational Project Number 4, 1994) was significantly 
lower than the value of 0.736 expected for acentric zones of an untwinned crystal (Table 5). 
Similarly the fourth moment of E, <E4>, was also found to be lower than what is expected 
for single crystals, again, demonstrating that the measured data do not have a broad 
distribution of intensities, which is typical of twinned crystals. 
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Figure 64. Cumulative Intensity 
distribution for cyclized 
Rab7•GppNHp data compared to 
the theoretical distribution for a 
single crystal. N(Z) represents the 
cumulative distribution function, 
i.e. the cumulative frequency of 
reflections that have an intensity 
of Z, with Z as the intensity 
relative to the mean intensity. 
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Table 5. Statistical values for experimentally measured intensities compared with those expected for a 
single and twinned crystal, respectively. 
Statistical quantity 
(for acentric data) cyclized Rab7• GppNHp data 
Theoretical single 
crystal 
Theoretical perfect 
hemihedral twin 
Mean first moment of E, <E> 0.93 0.89 0.94 
Mean third moment of E, <E3> 1.21 1.33 1.175 
Mean fourth moment of E, <E4> 1.741 2.00 1.5 
|E2-1| 0.590 0.736 0.541 
 
Structures from pseudomerohedrally twinned crystals can be refined using the program 
SHELXL (Sheldrick, 2008) with the addition of just two parameters that describe the 
twinning: an estimate of the twinning fraction and the twinning law. These two parameters 
can be obtained from SFCHECK (Collaborative Computational Project Number 4, 1994) 
and were found to be 0.441, with a twinning law of –h, -k, l. Refining with SHELXL has the 
advantage that refinement can be made against all of the data, and SHELXL will refine the 
twinning fraction as well. Taking this into account, molecular replacement was repeated 
using the refined model before twinning was diagnosed as the search model, and the true 
space group was found to be monoclinic P21 with 4 molecules in the asymmetric unit.  
 
Definition of a new test set and removing model bias  
Since the previously REFMAC5 refined model was refined using a test set that did not take 
into account twin-related reflections, two procedures were implemented first before 
proceeding with further refinement of the twinned data (Larsen et al., 2002; Barends and 
Dijkstra, 2003). First, a test set that considers the twinning was generated using the script 
make_cv_twin in CNS (Brunger et al., 1998). This ensures that twin-related reflections do 
not lie both in the working set (reflections that contribute to R) and the test set (reflections 
that contribute to Rfree), which would eliminate the purpose for having the test set as cross-
validation. Second, simulated annealing was performed on the model to erase any bias from 
refinement against a test set that did not take twinning into account. In this procedure, the 
molecule is heated up to high temperatures to randomize the positions of the atoms in the 
model (effectively erasing its memory) and then allowed to cool slowly. 
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Refinement against twinned data 
The resulting model was then further refined using SHELXL (Sheldrick, 2008) which allows 
refinement against the twinned data if the twinning fraction and twinning law are known. 
Using the twinning fraction of 0.441 obtained from SFCHECK and a twinning law of -h, -k, 
l, (corresponding to a twin axis parallel to c), 20 cycles of conjugated least squares 
refinement were performed on all of the data. Surprisingly, R and Rfree again failed to 
converge, and although R was reduced by ~2.5%, Rfree did not reduce significantly from 
values obtained from REFMAC5 where no twinning was accounted for (Table 6). 
Table 6. Comparison of different refinement strategies for the cyclized Rab7•GppNHp model. 
Refinement strategy R Rfree 
REFMAC5, P22121, 2 molecules in a.u., no twinning 21.5 27.3 
SHELXL, P21, 4 molecules in a.u., no twinning 25.3 32.4 
SHELXL, P21, 4 molecules in a.u., Twinning: -h,- k, l     
   BASF=0.441 19.1 28.2 
Iterative cycles of model building, SHELXL, P21,  
   4 molecules in a.u., Twinning: -h,- k, l BASF=0.49 18.4 26.6 
 
Refinement with SHELXL proved to be less straightforward than other typical examples of 
high resolution data that refined to respectable R factors without much effort. Of concern 
was the observation that in many of the molecules, the axial waters coordinating the Mg2+ 
ions were either slightly off-linear or had no electron density. To address this, both the 
nucleotide and magnesium ion for each of the four molecules in the asymmetric unit were 
removed from the model. The model was then fit to the resulting electron density maps, 
which returned positive density at 2.55σ (3σ is the standard for significant) for each 
nucleotide and magnesium ion. Indeed, the occupancy of the axial magnesium waters was 
highly variable among the four molecules, and this slightly distorted octahedral geometry 
was most prevalent in the difference density of the fourth molecule in the asymmetric unit. 
The lack of full occupancy for the axial waters of the Mg2+ ions often led to distortion by 
SHELXL of the octahedral geometry, and was found to be corrected when the Mg2+ and 
GppNHp were allowed to refine together as a rigid body. This was made using the 
command "AFIX 6" before the Mg2+ coordinates and "AFIX 0" after the GppNHp 
coordinates of each nucleotide in the refinement input file. The axial waters in the Mg2+ 
coordination sphere of the first molecule required inclusion within these rigid body 
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restraints, to prevent the generation of a distorted 1.48 Å bond to Mg2+ after refinement in 
SHELXL. 
In spite of refining the entire data set using the twin law and the twinning fraction, Rfree 
remained relatively high (28%). As recommended by the SHELXL manual, the global 
standard deviations (the DEFS command) for different aspects of geometry were 
systematically varied to see if they might lower Rfree. In general, all changes to the DEFS 
values indicated that the default settings were the most beneficial. It was noted in the 
resulting PDB files after SHELXL refinement that the temperature factors (B-factors) for 
each amino acid varied significantly, even for atoms belonging to the same residue. To 
remedy this, the current model at the time was refined with a single 20-cycle REFMAC5 
run, which, although it does not take twinning into account, was sufficient to average the B-
factors. All subsequent changes to the model (see below) were then made with this 
REFMAC5-refined model to produce an optimized "final" model, that was then refined in 
one 10-cycle SHELXL run with tighter SIMU restraints set to a value of 0.02. The most 
significant improvements (albeit gradual) to the Rfree resulted from many iterative cycles of 
omitting regions from the model and observing what positive density (if any) actually 
returned. In this way, it was soon discovered that each molecule varied in what was actually 
described by the data with regards to each termini, Switch I, Switch II, Loop 3 (residues 52-
55), and Loop 7 (residues 111-118). Through this procedure, it was observed that SHELXL 
has a tendency for model bias, often returning good electron density whatever the model 
may be. Such properties have been observed by others with lower resolution (2.2 Å) 
merohedrally twinned data sets that used SHELX for refinement (Esser, 2007), and may 
represent a limitation of using this program. With respect to refining twinned data sets, 
SHELX is at present one of the few programs that can refine against the entire twinned data 
set, but future users are highly advised to make extensive use of Fo-Fc maps to guide their 
model building to avoid the stall in refinement progress that was experienced with cyclized 
Rab7•GppNHp. The difficulties experienced in the refinement of cyclized Rab7•  GppNHp 
may also be due to the extremely high twinning fraction present in the crystal, with a final 
refined twinning fraction of 0.49. 
As mentioned earlier, twinning in the crystal was noticed only after refinement, when the R 
factors failed to converge. The near perfect twinning present in the crystal, which reduces 
the number of measured intensities by half of what would be expected at each resolution, 
121 
cyclized Rab7 
 
results in an observable-to-parameter ratio of 2.3. This is extremely low and examples like 
this ultimately lead to an effective lower resolution of the maps as compared to what would 
have been expected had twinning not been present (Rudolph et al., 2004). In the case of 
Rudolph et al, they report near perfect (α ~0.46) pseudomerohedral twinning with a data set 
collected to 2.5 Å, but with an information content equivalent to an untwinned data set 
collected to 3.1 Å. Their low observable-to-parameter ratio led to unstable refinement and 
suboptimal geometry of their resulting model, with 71.2% of all residues in the most 
favored regions of the Ramachandran plot. Other examples in the PDB include the 
structures of rat apo-Heme Oxygenase-1 (PDB code 1IRM) and human topoisomerase I 
covalently bound to double stranded DNA (PDB code 1K4S), both of which have lower 
percentages of residues in the most favored regions (Table 7) (Sugishima et al., 2002; 
Staker et al., 2002). When compared with these values, the final refined model of cyclized 
Rab7•GppNHp shows reasonable geometry with 87.2% of residues in the most favored 
region, close to the normally acceptable value of over 90%.  
 
Table 7. Comparison of the overall geometry of cyclized Rab7•GppNHp with that of other twinned 
structures. 
Protein/PDB Code α Resolution R Rfree % most favored Reference 
       
1R3H 0.46 2.5 Å 23.1% 27.2% 71.2 Rudolph et al, 2004 
1IRM 0.45 2.55 Å 20.4% 30.7% 69.9 Sugishima et al, 2002 
1K4S NR* 3.2 21.7% 22.2% 78.1 Staker et al, 2002 
1NJ9 0.43 2.35 18% 27% 81.2% Larsen et al, 2002 
cyclized 
Rab7•GppNHp 0.49 1.8 18.4% 26.6% 87.2 present work 
       
        *NR, not reported 
 
Structure of cyclized Rab7•GppNHp and comparison with wild type Rab7•GppNHp 
The overall structure of cyclized Rab7•GppNHp is quite similar to that of wild type 
Rab7•GppNHp, with an overall rmsd of Cα atoms of 0.52 Å. All four molecules in the 
asymmetric unit possess a similar overall fold, with differences in the extent of what is 
visible for each terminus, Switch II, Loop 3 and Loop 7. The first and fourth molecules 
contain the longest visible regions (residues 5-179), followed by the third molecule with 
residues 6-178 visible, while the second has the most disordered C-terminus (residues 6-175 
visible). This may result from the close proximity of this region to the side chains of Arg 69 
and Gln 71 in Switch II of a symmetry related molecule, which themselves have sparse 
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electron density as well as high Bfactors, an indication of mobility. This may affect the 
packing of the C-terminus and contribute to the poor electron density describing this area.   
 
 
Figure 65. Comparison of the overall structure of cyclized and linear Rab7•GppNHp (white). Each 
molecule of cyclized Rab7•GppNHp is colored (1, salmon; 2, orange; 3, green; 4, dull blue). The 
flexibility of Switch II is shown in the boxed inset, with residues displaying varied conformations 
circled for clarity and shown in stick representation against the white ribbon representation of linear 
Rab7•GppNHp. Ser 72 and Leu 73 are not clearly defined in molecules 2 and 4, and were therefore 
omitted from the final model. Stick representation of the overlay of GppNHp from each molecule is 
shown for comparison. 
 
Superposition of all four molecules of the asymmetric unit revealed the regions of flexibility 
for cyclized Rab7•GppNHp, which occur primarily at the surface in solvent exposed loops 
and the termini (Figure 65). Whereas the cyclized version of Rab7•GDP was found to 
stabilize the Switch I region such that it could actually be modeled, cyclized Rab7•GppNHp 
shows a high degree of flexibility in Switch II, as evidenced by the sparse electron density 
that returned as positive density when residues 72-76 were omitted from each of the four 
molecules in the asymmetric unit, as well as the conformational variability observed among 
the four molecules (Figure 65). In the second and fourth molecule, residues 72-73 were 
omitted from the final model because they could not be modeled with confidence. The 
residues in Switch II are also characterized by high B-factors, indicating conformational 
mobility. It is worthy to note that these regions are visible in the wild type uncyclized 
Rab7•GppNHp crystal structure (PDB code 1VG8) (Rak et al., 2004), with much more of 
the C-terminus visible (residues 7-190) compared to the cyclized Rab7•GppNHp structure. 
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Small shifts in Loop3 (Val 52-Arg 55) and Loop 7 (Ser 111-Asp 114) are also seen in the 
cyclized Rab7•GppNHp structure when compared to Rab7•GppNHp. The lack of electron 
density in regions otherwise visible in linear Rab7 suggest that cyclization of Rab7 may 
allow for increased mobility of certain regions in the GTP state. Superposition of several 
active Rab7 structures reveals that the choice of the site of truncation and length of the 
linker may add strain to the molecule, forcing it to adopt a conformation that is not identical 
to wild type Rab7•GppNHp. The number of residues for the linker of cyclized Rab7 is the 
same as the number of residues at the N- and C-termini observed in the structures, which 
point away from each other (Figure 66A). The linker, therefore, may not be long enough to 
really allow the protein to adopt the GTP conformation that uncyclized Rab7 can reach. This 
additional strain may slightly destabilize cyclized Rab7•GppNHp, which may allow for 
flexibility in Switch II because the protein cannot adopt the conformation it normally would 
in a “relaxed” state.  
Although the two termini point in opposite directions in the Rab7•GppNHp structure, they 
do lie close to each other in the Rab7•GTP:RILP complex structure (Wu et al., 2005). Rab7 
in this case was mutated to the constitutively active Q67L mutant (which impairs its 
intrinsic GTP hydrolysis). The Rab7 binding domain of RILP was found to form a coiled-
coil homodimer of four helices that binds two identical Rab7 molecules on either side. The 
Rab7 binding domain of RILP contacts Rab7 at two interfaces:  one involving the switch 
and interswitch regions which is typically observed in other complexes between Ras-like 
GTPases and their effectors, and another involving the RabSF1 and RabSF4 regions which 
correspond to the N- and C-terminal regions. Rab7 undergoes significant conformational 
changes in its C-terminus upon RILP binding. The C-terminal helix (residues 175-185) was 
found to unfold halfway to a short β-strand, which forms an antiparallel β-sheet with strand 
β1, and makes important contacts with RILP. Mutation or deletion of Leu 8, Lys 10 or 
Val 180 significantly reduced or abolished Rab7 binding to RILP, confirming their role in 
complex formation. Although the N- and C-termini are not structurally defined in the model 
of cyclized Rab7, the construct contains the residues necessary for RILP binding. It would 
be interesting to know whether covalent linkage of the termini still permits such a 
conformational change in the C-terminus upon RILP binding. Unfortunately for the present 
work, a well-behaved purified RILP sample could not be obtained, and these functional 
measurements could not be performed. 
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  SIEFVLLK       VIILGDSGVG…………………… RNALKQETEV  ELYNETRESG       cyclized Rab7 
 
    
Figure 66. A, Rab 7•GTP (1T91, red), and Rab 7•GppNHp (1VG8, purple) superimposed on 
Rab7•GTP (green) in complex with the Rab7 binding domain of RILP (1YHN, peach). For the 
purpose of the overlay, only one molecule of Rab7•GTP is shown from the Rab7•GTP:RILP 
heterodimer. The structure of the Rab7 C-terminus changes significantly upon RILP binding. B, 
Cyclized Rab7•GppNHp (white) superimposed on Rab7•GTP in complex with RILP (1YHN, green). 
Below, protein sequence alignment of the N- and C-termini of wild type Rab7 and cyclized Rab7. 
Residues visible from the ribbon representations are underlined, with the linker used in cyclized Rab7 
colored in blue. N- and C-terminal residues observed in the Rab7•GTP:RILP complex and 
Rab7•GppNHp structures are highlighted in yellow (as in the ribbon representation). Residues visible 
in the Rab7•GTP:RILP complex structure are colored green. C, Zoom of B showing residues of Rab7 
in the N- and C-termini that contact RILP. Cyclized Rab7•GppNHp maintains most of the binding 
site, and the flexible termini (unobserved in the structure) may allow for complete RILP binding. 
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3.5 SUMMARY AND PERSPECTIVES 
A cyclized version of Rab7 was produced via intein-mediated expressed protein ligation, 
and characterized to determine the effect of cyclization on protein stability, biological 
function, crystallization, and structure. Cyclization imparted a modest increase in the 
thermal stability of Rab7, with a 3.7°C increase in the melting temperature. Although 
cyclized Rab7 is not capable of C-terminal prenylation and membrane targeting, it does 
mimic a C-terminally truncated Rab7, displaying similar rates of GTP hydrolysis, effector 
binding and dissociation kinetics. Residues in the linker of cyclized Rab7 provided 
favorable crystal contacts that significantly stabilized the notoriously flexible Switch I loop 
in the GDP bound form. This stabilization allows interactions between the backbone of Ala 
39 and both the α-phosphate of GDP and an axial water, which coordinates the active site 
Mg2+ ion. Cyclization also permitted crystallization of the GppNHp bound form. Crystals in 
this form were found to be pseudomerohedrally twinned with a near perfect twinning 
fraction of 0.49. In contrast to the stabilization seen in cyclized Rab7•GDP, cyclized 
Rab 7 •GppNHp showed several regions of flexibility, most notably in Switch II. Structures 
of active Rab7 reveal that the N- and C-termini lie in opposite directions in the GTP form, 
in contrast to Rab7•GDP. The choice of linker length and site of truncation may strain the 
protein by forcing the two ends of the molecule together, allowing for more flexibility in 
Switch II.   
In general, cyclization is a useful method for increasing the stability of proteins of interest. 
It can also be a useful tool to aid in the crystallization of proteins, by reducing the inherent 
flexibility of loops that may have important roles in biological function. An important 
prerequisite is the close proximity of the termini to each other in the target protein, in all 
forms in which it will be studied, as well as the lack of interference of cyclization with its 
biological function. 
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4. MATERIALS AND METHODS 
4.1 MATERIALS 
4.1.1 Chemicals and enzymes 
acetonitrile Sigma-Aldrich, Munich
alkaline phosphatase (calf intestinal) Roche Diagnostics, Mannheim
ammonium sulfate Applichem, Darmstadt
ampicillin Gerbu Biotechnik, Gaiberg
anti-His antibody Roche Diagnostics, Mannheim; Santa Cruz Biotechnology, Santa Cruz, CA, USA
anti-mouse IgG conjugated with AP Pierce, Rockford, IL, USA
anti-rabbit IgG conjugated with AP Pierce, Rockford, IL, USA
CaCl2 Merck Biosciences, Darmstadt
chloramphenicol Genaxxon Biosciences, Biberach/Riß
Complete EDTA-free protease inhibitor  
     cocktail Roche Diagnostics, Mannheim
DNase, bovine pancreas, grade II Roche Diagnostics, Mannheim
DTE Gerbu Biotechnik, Gaiberg
DTT Gerbu Biotechnik, Gaiberg
EDTA Gerbu Biotechnik, Gaiberg
FAD Sigma-Aldrich, Munich
Fos-choline-12 Anatrace, Maumee, OH, USA
GDP Pharma Waldhof, Düsseldorf
gel filtration standards Bio-Rad, Munich
Genapol X-80 Merck Biosciences, Darmstadt
glutathione,  reduced Sigma-Aldrich, Munich
glycerol Gerbu Biotechnik, Gaiberg
GMP Pharma Waldhof, Düsseldorf
GppNHp Sigma-Aldrich, Munich
GTP Pharma Waldhof, Düsseldorf
guanidinium hydrochloride Gerbu Biotechnik, GaibergSigma-Aldrich, Munich
HEPES Sigma-Aldrich, Munich; Gerbu Biotechnik, Gaiberg
Imidazole Fluka, Deisenhofen; Merck Biosciences, Darmstadt
IPTG Gerbu Biotechnik, Gaiberg
kanamycin Gerbu Biotechnik, Gaiberg
low molecular weight marker Amersham Biosciences/GE Healthcare, Freiburg
mantGDP Invitrogen, Carlsbad, CA, USA
mantGppNHp Jena Biosciences, Jena; Invitrogen, Carlsbad, CA, USA 
MgCl2 
Merck Biosciences, Darmstadt; 
JT Baker, Deventer, Holland
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NADPH Sigma-Aldrich, Munich;
Serva Electrophoresis, Heidelberg
NBT Sigma-Aldrich, Munich
NBT/BCIP staining solution Pierce, Rockford, IL, USA
phosphodiesterase Sigma-Aldrich, Munich
popular detergent kit Anatrace, Maumee, OH, USA 
potassium chloride Merck Biosciences, Darmstadt
potassium phosphate, dibasic Merck Biosciences, Darmstadt
potassium phosphate, monobasic Merck Biosciences, Darmstadt
Pre-stained molecular weight marker Fermentas, St. Leon-Rot
restriction enzymes New England Biolabs, Frankfurt/Main
sodium chloride Merck Biosciences, Darmstadt; Fluka, Deisenhofen
sodium phosphate, monobasic Merck Biosciences, Darmstadt
sucrose Serva Electrophoresis, Heidelberg
T4-DNA ligase Roche Diagnostics, Mannheim
Tetra-n-butyl ammonium bromide Sigma-Aldrich, Munich
thrombin Sigma-Aldrich, Munich
Triton X-100 Merck Biosciences, Darmstadt
Trizma Base Sigma-Aldrich, Munich; Roth, Karlsruhe
tween Serva Electrophoresis, Heidelberg
urea Gerbu Biotechnik, Gaiberg
δ-aminolevulinic acid  Sigma-Aldrich, Munich
 
All chemicals used for crystallization were from Fluka, Deisenhofen. 
 
4.1.2 Bacterial strains and media 
XL1Blue (Stratagene, Heidelberg): 
 recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F'proAB lacI
q
Z∆M15 Tn10 (Tetr)] 
XL10 Gold (Stratagene, Heidelberg): 
 Tetr ∆(mcrA)183 ∆(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 
lac Hte [F’ proAB lacI
q
Z∆M15 Tn10 (Tetr) Amy Camr] 
BL21(DE3) (Merck Biosciences, Darmstadt): 
 F– ompT hsdSB (rB–mB–) gal dcm (DE3) 
BL21(DE3) Codon Plus RIL (Merck Biosciences, Darmstadt): 
 E. coli B F– ompT hsdS (rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte [argU ileY leuW Camr] 
C41(DE3) (Prof. Dr. Axel Scheidig, ZBM, Christian-Albrechts-Universität Kiel): 
 [E. coli F– ompT hsdSB (rB–mB–) gal dcm (DE3)] 
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Media 
LB, TB, ST1, and 2YT media and LB agar plates with the appropriate antibiotics were made 
by the media kitchens at the MPI of Molecular Physiology (Dortmund) and the MPI for 
Medical Research (Heidelberg). 
 
4.1.3 Vectors and primers 
Vectors 
pET 32a Novagen/Merck Biosciences, Darmstadt
pET 19b Novagen/Merck Biosciences, Darmstadt
pET 30a Novagen/Merck Biosciences, Darmstadt
pET 41a Novagen/Merck Biosciences, Darmstadt
pGEX 2T Amersham Biosciences/GE Healthcare, Freiburg
 
Sequencing primers: 
All non-commercially available primers were synthesized by MWG Biotech (Ebersberg) as 
HPSF (Highly purified salt free) grade. 
Primer Sequence (5' to 3') 
   T7 promoter    CGA AAT TAA TAC GAC TCA CTA TAG GG 
   T7 terminator1    GCT AGT TAT TGC TCA GCG G 
   S•Tag™ Primer1    CGA ACG CCA GCA CAT GGA CA 
   hNox1SM1 Primer    GGG GGT TCT TGG CTA AAT CCC 
   hNox1SM2 Primer    GGC TTC AGC ATG GAA GTG GGG 
   rEK-TEVseqF    C CAT CAT CAT CAT CAT TCT TCT GG 
   pGEX 3' 2    CCG GGA GCT GCA TGT GTC AGA GG 
   pGEX 5' 2    GGG CTG GCA AGC CAC GTT TGG TG 
1Novagen/ Merck Biosciences, Darmstadt 
2Amersham Biosciences/GE Healthcare, Freiburg 
 
4.1.4 Chromatographic matrices 
2’5’ADP Sepharose 4B Amersham Biosciences/GE Healthcare, Freiburg
DEAE-Sepharose FF Amersham Biosciences/GE Healthcare, Freiburg
Glutathione Sepharose 4B Amersham Biosciences/GE Healthcare, Freiburg
HiTrap Benzamidine FF (high sub) Amersham Biosciences/GE Healthcare, Freiburg
HiTrap Desalting columns Amersham Biosciences/GE Healthcare, Freiburg
HiTrap Ni-Chelating Sepharose Amersham Biosciences/GE Healthcare, Freiburg
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HiTrap Ni-Sepharose High Performance Amersham Biosciences/GE Healthcare, Freiburg
NAP-5 column Amersham Biosciences/GE Healthcare, Freiburg
Ni-NTA resin Qiagen, Hilden 
ODS Prontosil Hypersorb,  
     reversed phase C18 Bischoff Chromatography, Leonberg
Resource Q Amersham Biosciences/GE Healthcare, Freiburg
Superdex 200 Amersham Biosciences/GE Healthcare, Freiburg
Superdex 75 Amersham Biosciences/GE Healthcare, Freiburg
POROS® HQ resin Applied Biosystems, Foster City, CA, USA
 
4.1.5 Miscellaneous materials 
Amicon Ultra centrifugal concentrator Millipore, Schwalbach
Greiner low profile 96-well microplate Greiner Bio-One GmbH, Frickenhausen
Nunc nuclon 96-well microtiter plate Nunc, Wiesbaden
Qiagen Gel Extraction Kit Qiagen, Hilden
Qiagen Miniprep Kit Qiagen, Hilden
Vivapore static concentrator Sartorius, Göttingen
Wizard plus SV Miniprep-Kit Promega, Mannheim
 
4.1.6 Equipment 
ÄKTA Prime Amersham Biosciences/GE Healthcare, Freiburg
Beckman AvantiTM J-20 XP Centrifuge Beckman Coulter, Krefeld
Beckman DU®640 spectrophotometer Beckman Instruments, Munich
Beckman L8-70M Ultracentrifuge Beckman Coulter, Krefeld
Beckman Optima L-70K Ultracentrifuge Beckman Coulter, Krefeld
Criterion Blotter Bio-Rad, Munich
Finnigan LCQ Advantage Max Thermo Electron Corp, Langenselbold
Fluoromax-3 Horiba Jobin Yvon, Munich
GeneQuant /pro/ spectrophotometer Amersham Biosciences/GE Healthcare, Freiburg
INFORS Multitron Shakers INFORS HT, Bottmingen, Switzerland
Labsystem iEMS Reader MF Thermo Electron, Langenselbold
Latek HPLC Latek, Eppelheim
Microfluidizer Microfluidics, Lampertheim
MJ Research PTC-200 thermocycler Biozym Diagnostik, Hess. Oldendorf
Mosquito Crystallization Robot TTP Labtech, Royston, UK 
SX20 Stopped Flow apparatus Applied Photophysics, Leatherhead, UK
Waters HPLC Waters, Eschborn
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4.2 HUMAN NOX1 METHODS 
4.2.1 Coexpression of full-length human Nox1 and subunit b of E. coli F1Fo 
ATP synthase 
Chemically competent C41(DE3) cells were transformed via heat shock with 2 µl of either 
1) full-length human Nox1 cloned into pET41a via NcoI and XhoI (Prof. Dr. H.H.W. 
Schmidt, Monash University, Melbourne, Australia), 2) a plasmid containing subunit b 
(Prof. John E. Walker, MRC Cambridge), or 3) both plasmids, and plated on LB agar plates 
containing the appropriate antibiotic (subunit b: 100 µg/ml ampicillin; full-length human 
Nox1: 50 µg/ml kanamycin; both plasmids: 100 µg/ml ampicillin and 50 µg/ml kanamycin). 
Seven colonies were obtained from cells transformed with both plasmids, and each was used 
to inoculate seven individual flasks containing 100 ml of 2YT media supplemented with 
100 µg/ml ampicillin and 50 µg/ml kanamycin. A control for each individual plasmid was 
made likewise, inoculating 100 ml of 2YT containing the appropriate antibiotic with a 
single colony. All cultures were grown at 37°C until the cell density reached specific values:  
0.6 for subunit b alone, human Nox1 alone and two cultures containing both plasmids; 0.4-
0.5 for two cultures containing both plasmids; and 0.3 for three cultures containing both 
plasmids. Protein expression was induced with the addition of IPTG at a final concentration 
of 0.7 mM. The control with subunit b only and three cultures of cells transformed with both 
plasmids at cell densities of 0.3, 0.4 and 0.6 were incubated at 37°C for 3 hours, and the 
control with human Nox1 only and four cultures of cells transformed with both plasmids at 
cell densities of 0.3, 0.3, 0.4 and 0.6 were incubated at 25°C for 18 hours. Non-induced 
samples were included for each temperature set. 50 µl of each culture was centrifuged for 
analysis on 15% SDS-PAGE.  
The above protocol was repeated with some adjustments to determine the effect of the heme 
precursor, δ-aminolevulinic acid, on expression of human Nox1. Due to the unusually slow 
growth observed previously with cultures containing kanamycin, this antibiotic was used in 
a reduced final concentration of 35 µg/ml.  Starter cultures of 4 ml 2YT and the appropriate 
antibiotic were inoculated with a single colony containing subunit b alone, human Nox1 
alone, or both plasmids together. These cultures were first grown at 37°C for 9 hours, then 
supplemented with fresh antibiotic and allowed to continue growth at 25°C overnight. The 
overnight cultures were used to inoculate 100 ml of 2YT with the appropriate antibiotic and 
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grown at 25°C until a cell density at 600 nm of about 1. δ-aminolevulinic acid was added to 
each culture at a final concentration of 25 µg/ml. Each culture was divided in half to 
generate 50 ml of a non-induced sample and 50 ml of an induced sample. IPTG was added 
to each induced sample to a final concentration of 0.7 mM and all cultures were incubated at 
20°C for 2 days.  
 
4.2.2 Cloning of H6-Nox1cyt and TrxT-Nox1cyt 
H6-Nox1cyt 
Residues 290-564 of human Nox1 were amplified by PCR from the TrxE-Nox1cyt plasmid 
(Prof. Dr. H.H.W. Schmidt, Monash University, Melbourne, Australia) using Hot Star Taq 
polymerase (Qiagen) and the following primers, which simultaneously exchanged the NcoI 
restriction site for NdeI (bold and underlined). The XhoI restriction site is bold and italic. 
∆hNox1NdeF 5’   GCA GTG TAC CAT ATG CGC TCC CAG CAG AAG G   3’ 
hNox1XhoR  5’   CCA GCT  CGA G TC AAA AAT TTT CTT TGT TGA AG   3’ 
This PCR reaction utilized the following program: 
Temperature Time No. of Cycles 
   
95°C 15 min --- 
   
94°C 1 min  
52°C 1 min 10 
72°C 1 min 45 sec  
   
94°C 1 min  
62°C 1 min 20 
72°C 1 min 45 sec  
   
 
The vector, coding for an N-terminal His-tag followed by a TEV protease site (Dr. Kirill 
Alexandrov, MPI of Molecular Physiology, Dortmund), was sequentially digested with NdeI 
followed by XhoI, each for 4 hours at 37°C. The digested vector was treated with calf 
intestinal alkaline phosphatase (to remove the 5' phosphate and prevent vector re-ligation), 
and purified by gel extraction (Qiagen). The PCR-amplified human Nox1cyt insert was 
purified by gel extraction (Qiagen) and digested with NdeI and XhoI for 4 hours at 37°C. 
20 ng of digested vector was ligated with the human Nox1cyt insert at a vector:insert ratio of 
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1:5 using T4 DNA Ligase and overnight incubation at 16°C. Ligated plasmids containing 
the human Nox1cyt insert were transformed into XL1-Blue competent cells and plasmids 
were isolated (Miniprep Kit, Qiagen) from 4 ml cultures. Plasmids containing the desired 
human Nox1cyt insert were identified by restriction enzyme digest with NdeI and XhoI, as 
well as analytical PCR using the above primers. Sequences were verified with DNA 
sequencing. 
 
TrxT-Nox1cyt 
The TrxT-Nox1cyt construct was made with two sequential mutagenesis reactions utilizing 
the QuikChange® Site-Directed Mutagenesis Kit (Stratagene) and the plasmid for TrxE-
Nox1cyt as a template. The enterokinase protease site was removed with the following 
primers: 
-rEKforward  5’    CCA GAT CTG GGT ACC GCC ATG GGT CGC TCC     3’ 
-rEKreverse  5’    GGA GCG ACC CAT GGC GGT ACC CAG ATC TGG     3’ 
DNA sequencing identified plasmids with the desired deletion, which became the template 
for the second mutagenesis reaction, using the following primers to insert the TEV protease 
site: 
TEVforward 5’   CCA GAT CTG GGT ACC GAG AAT CTT TAT TTT CAG GGC GCC 
ATG GGT CGC TC      3’ 
TEVreverse 5’   GA GCG ACC CAT GGC GCC CTG AAA ATA AAG ATT CTC GGT 
ACC CAG ATC TGG     3’ 
Plasmids containing the desired TEV protease site were verified with DNA sequencing. 
 
4.2.3 Expression of recombinant human Nox1 constructs 
Chemically competent C41(DE3) cells were transformed via heat shock with 2 µl of either 
TrxE-Nox1cyt, H6-Nox1cyt, or TrxT-Nox1cyt miniprepped plasmid, and plated onto LB agar 
plates containing a final concentration of 100 µg/ml of ampicillin. Starter cultures of 50-100 
ml of LB supplemented with ampicillin at a final concentration of 100 µg/ml (used at this 
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concentration in all subsequent cultures) were inoculated with a single colony and grown at 
37°C overnight. Typically 5-10L of TB or ST1 media were used for large-scale protein 
expression and inoculated with the starter culture using a volume 1:200 of the final volume 
per flask. Cultures were grown at 37°C until the cell density at 600 nm reached 0.3-0.5, and 
then chilled on ice at 4°C prior to induction. Protein expression was induced at 20°C 
overnight with the addition of IPTG to a final concentration of 0.1 mM. Subsequent 
expressions indicated that 0.05 mM final IPTG was also sufficient for protein expression. 
Cells were harvested at 4°C by centrifugation for 15 minutes at 3500 rpm, flash frozen in 
liquid nitrogen and stored at -80°C. In some cases the cells were resuspended in the 
respective Buffer Ni-A with 1 Complete EDTA-free protease inhibitor cocktail tablet 
(Roche)/50 ml buffer at a volume 2x the mass of the cells, and flash frozen as a suspension 
in liquid nitrogen for storage at –80°C. 
Small scale expression of H6-Nox1220-564 was made from a single colony of BL21(DE3) 
cells containing the H6-Nox1220-564 plasmid (prepared by Monika Berthel). 1L of TB 
supplemented with kanamycin at a final concentration of 50 µg/ml was inoculated with 
50 ml of an overnight culture and grown at 37°C until the cell density at 600 nm reached 
approximately 1. Protein expression was induced at 37°C for 4 hours with the addition of 
IPTG to a final concentration 1 mM. Cells were harvested at 4°C by centrifugation for 15 
minutes at 5000 rpm, flash frozen in liquid nitrogen and stored at -80°C. 
 
4.2.4 Purification of recombinant human Nox1 constructs 
Due to the temperature instability of the Nox1 proteins, all chromatographic steps were 
carried out at 4°C. All stated pH values represent the pH of the respective buffer at 4°C, 
unless otherwise noted. All buffers were sterile filtered and degassed prior to use.   
 
TrxE-Nox1cyt 
Frozen cell pellets were thawed at room temperature and resuspended in ice-cold Buffer Ni-
A containing 1 Complete EDTA-free protease inhibitor cocktail tablet (Roche)/50 ml buffer 
at a volume 2x the mass of the cells. Resuspended cells were lysed 2-3 times with a 
microfluidizer (Microfluidics). Genomic DNA was digested with DNase (35µg/ml lysate) in 
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the presence of 10 mM MgCl2 with stirring for 10 minutes at 4°C. The lysate was then 
clarified via ultracentrifugation at 40,000 rpm for 1 hr at 4°C.  
Ni-NTA Chromatography 
Early purifications of TrxE-Nox1cyt were made using two 5 ml HiTrap Ni-Chelating 
Sepharose columns (Amersham Biosciences/GE Healthcare) connected in series for the 
initial capture. Separation was found to improve with the addition of a third 5 ml HiTrap Ni-
Sepharose column (Amersham Biosciences/GE Healthcare). Lysate containing TrxE-Nox1cyt 
was loaded onto these three columns connected in series at 1 ml/min with a peristaltic pump 
(Amersham Biosciences/GE Healthcare). The columns were washed with Buffer Ni-A until 
the absorbance reading at 280 nm returned to baseline and remained constant, and were then 
connected to an ÄKTA Prime (Amersham Biosciences/GE Healthcare). Initial separation 
was achieved with a linear gradient of 0-80% Buffer Ni-B in 150 ml at 2 ml/min, with 3 ml 
fractions. Fractions containing TrxE-Nox1cyt were identified with 15% SDS-PAGE.  
Buffer Ni-A:  20 mM Tris-HCl, pH 8, 300 mM NaCl, 5 mM Imidazole, 10% glycerol, 
2 mM β-mercaptoethanol 
Buffer Ni-B:  20 mM Tris-HCl, pH 8, 300 mM NaCl, 1 M Imidazole, 10% glycerol, 2 
mM β-mercaptoethanol 
Desalting Chromatography 
Fractions containing TrxE-Nox1cyt were desalted over 5 x 5 ml HiTrap Desalting columns 
(Amersham Biosciences/GE Healthcare) pre-equilibrated with Buffer Res Q-A. 6 ml of 
sample was loaded with a syringe, attached to an ÄKTA Prime, and desalted at 2 ml/min, 
with 1.5 ml fractions.  
Resource Q Anion Exchange Chromatography 
Desalted fractions containing TrxE-Nox1cyt were loaded with a syringe onto a 6 ml Resource 
Q anion exchange column (Amersham Biosciences/GE Healthcare) pre-equilibrated with 
Buffer Res Q-A. The column was then attached to an ÄKTA Prime, and washed with 3 
column volumes of Buffer Res Q-A, at a flow rate of 8 ml/min, collecting 3 ml fractions. 
Protein was eluted with a linear gradient of 0-100% Buffer Res Q-B over 300 ml. At 17% 
Buffer Res Q-B, the gradient was manually held until the absorbance reading at 280 nm 
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returned to baseline and remained constant. The linear gradient was then allowed to 
continue to completion. Fractions containing TrxE-Nox1cyt were identified with 15% SDS-
PAGE. 
Buffer Res Q-A:  20 mM Tris-HCl, pH 8, 25 mM NaCl, 10% glycerol, 2 mM β-
mercaptoethanol 
Buffer Res Q-B:  20 mM Tris-HCl, pH 8, 1M NaCl, 10 % glycerol, and 2 mM β-
mercaptoethanol 
2'5' ADP Sepharose Chromatography 
Fractions from Resource Q chromatography containing TrxE-Nox1cyt were loaded directly 
onto 4 ml of 2'5' ADP Sepharose resin pre-equilibrated with Buffer ADP-A. The column 
was washed by gravity with two column volumes of Buffer ADP-A, and a series of step 
elutions were made with 4 ml of Buffer ADP-A containing 200 mM, 300 mM, 400 mM, 500 
mM, 700 mM and 1M NaCl, respectively. Competitive elution was made with 4 ml of 8 
mM NADP+. Fractions were analyzed on 15% SDS-PAGE. 
Buffer ADP-A:  10 mM NaH2PO4, pH 7.3, 150 mM NaCl, 10 % glycerol, and 2 mM 
DTT 
Optimized Purification 
Due to the effectiveness achieved with 2'5' ADP Sepharose chromatography, the above 
protocol was streamlined to two chromatographic steps:  initial capture with Ni-NTA 
chromatography, followed by purification with 2'5' ADP Sepharose chromatography. For 
this reason, the linear gradient used in Ni-NTA chromatography was changed to 0-80% 
Buffer Ni-B in 70 ml, with 5 ml fractions to concentrate the protein in a minimal volume. 
Desalting chromatography was replaced with a simple 6-fold dilution of the pooled fractions 
containing TrxE-Nox1cyt with a pre-ADP Dilution Buffer containing no salt.  
pre-ADP Dilution Buffer:  10 mM NaH2PO4, pH 7.3, 10 % glycerol, and 2 mM DTT 
This diluted sample was loaded via an ÄKTA Prime onto a 10 ml 2'5' ADP Sepharose 
column, and washed with 50 ml of Buffer ADP-A, or until the absorbance reading at 280 
nm returned to baseline and remained constant. Step elution of TrxE-Nox1cyt was made with 
70 ml of 100% Buffer ADP-B.  
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Buffer ADP-A:  10 mM NaH2PO4, pH 7.3, 150 mM NaCl, 10 % glycerol, and 2 mM 
DTT 
Buffer ADP-B:  10 mM NaH2PO4, pH 7.3, 1M NaCl, 10 % glycerol, and 2 mM DTT 
Fractions containing TrxE-Nox1cyt were pooled, diluted with a post-ADP Dilution Buffer to 
a final concentration of 500 mM NaCl, and concentrated in 30 kDa MWCO (molecular 
weight cut-off) centrifugal concentrators (Millipore) at 4°C with 10 minute spins. The 
protein was buffer-exchanged  into a Final Storage Buffer via concentration. Protein 
concentration was determined by Bradford assay (Bradford, 1976) using BSA as a standard, 
aliquoted, flash frozen in liquid nitrogen, and stored at –80°C. 
post-ADP Dilution Buffer:  10 mM NaH2PO4, pH 8, 10 % glycerol, and 2 mM DTT 
Final Storage Buffer:  10 mM NaH2PO4, pH 8, 500 mM NaCl, 10 % glycerol, and 2 
mM DTT 
Purification under denaturing conditions 
The insoluble fraction of ~1L of lysed cells expressing TrxE-Nox1cyt was homogenized in 
Denaturing Buffer to a final volume of 30 ml and allowed to incubate with mild agitation 
for 20-30 min at room temperature. Buffers containing guanidinium hydrochloride were at 
room temperature when pHed. The solubilized fraction was clarified with 
ultracentrifugation at 40,000 xg, 4°C for 1 hour. Chromatography was carried out at 4°C. 
The supernatant was loaded via a peristaltic pump onto 10 ml of Ni-NTA resin (Qiagen) and 
washed with 100 ml of Wash Buffer. Refolding buffer was introduced with a manual 
gradient maker at 1.75 ml/min over 100 ml. Renatured protein was step eluted with Elution 
Buffer, and fractions were concentrated in a 30 kDa MWCO centrifugal concentrator. 
Denaturing buffer:  50 mM HEPES, pH 7.4, 150 mM NaCl, 20 mM Imidazole, 6 M 
guanidinium hydrochloride 
Wash Buffer:  50 mM HEPES, pH 7.4, 150 mM NaCl, 40 mM Imidazole, 6 M 
guanidinium hydrochloride 
Refolding buffer:  50 mM NaH2PO4, pH 7.4, 150 mM NaCl, 30 µM FAD, 0.3% Triton 
X-100 
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Elution Buffer:  50 mM NaH2PO4, pH 7.5, 150 mM NaCl, 250 mM Imidazole, 30 µM 
FAD, 0.3% Triton X-100 
 
H6-Nox1220-564 
Frozen cells from 1L of culture expressing H6-Nox1220-564 were thawed at room temperature 
and resuspended in ice-cold Lysis Buffer containing 1 Complete EDTA-free protease 
inhibitor cocktail tablet/50 ml buffer at a volume 2x the mass of the cells. Resuspended cells 
were lysed in re-circulation mode for 20-30 pulses with a microfluidizer. Genomic DNA 
was digested with DNase (35µg/ml lysate) in the presence of 10 mM MgCl2 with stirring for 
10 minutes at 4°C. The lysate was then clarified via ultracentrifugation at 12,100 rpm for 40 
min at 4°C.  
Ni-NTA Chromatography 
200 µl of a slurry of Ni-NTA resin pre-equilibrated with Lysis buffer was added to the 
clarified lysate and collected in a gravity column. The resin was washed with 1 ml of Lysis 
Buffer followed by 1ml of a series of step washes with Lysis Buffer containing 20, 40 and 
60 mM Imidazole, respectively, with a reduced detergent concentration of 0.3% Triton X-
100. H6-Nox1220-564 was eluted in 1.5 ml of Elution Buffer and collected in 300 µl fractions. 
Lysis Buffer:  20 mM NaH2PO4, pH 7.3, 5 mM Imidazole, 300 mM NaCl, 10% 
glycerol, 2% Triton X-100  
Elution Buffer:  20 mM NaH2PO4, pH 7.3, 250 mM Imidazole, 300 mM NaCl, 10% 
glycerol, 0.3% Triton X-100 
 
H6-Nox1cyt  
Frozen cell pellets were thawed at room temperature and resuspended in ice-cold Buffer Ni-
A containing one Complete EDTA-free protease inhibitor cocktail tablet/50 ml buffer at a 
volume 2x the mass of the cells. Resuspended cells were lysed 2-3 times with a 
microfluidizer. Genomic DNA was digested with DNase (35µg/ml lysate) in the presence of 
10 mM MgCl2 with stirring for 10 minutes at 4°C. The lysate was then clarified via 
ultracentrifugation at 40,000 rpm for 1 hr at 4°C.  
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Ni-NTA Chromatography 
Lysate containing H6-Nox1cyt was loaded at 1 ml/min with a peristaltic pump onto a 5 ml 
HiTrap Ni-Sepharose column connected to two 5 ml HiTrap Ni-Chelating Sepharose 
columns in series. The columns were washed with Buffer Ni-A until the absorbance reading 
at 280 nm returned to a stable baseline and were then connected to an ÄKTA Prime. 
Purification was achieved with a linear gradient of 0-80% Buffer Ni-B in 250 ml at 
2 ml/min, with 5 ml fractions. Fractions containing  H6-Nox1cyt were identified with 15% 
SDS-PAGE, diluted with Dilution Buffer to ~300 mM Imidazole and concentrated in 
Vivapore solvent absorption concentrators (Sartorius, Göttingen). 
Buffer Ni-A:  20 mM NaH2PO4, pH 7.3, 300 mM NaCl, 5 mM Imidazole, 10% 
glycerol 
Buffer Ni-B:  20 mM NaH2PO4, pH 7.3, 300 mM NaCl, 1M Imidazole, 10% glycerol 
Dilution Buffer:  20 mM NaH2PO4, pH 7.4, 500 mM NaCl, 10% glycerol 
Protein Concentration Determination 
Protein concentration was determined by SDS-PAGE analysis of various amounts of H6-
Nox1cyt run alongside known amounts (1, 2, 4, 5, and 7 µg) of a low molecular weight 
marker (Amersham Biosciences/GE Healthcare). The absorbance at 280 nm of the 
concentrated H6-Nox1cyt sample was measured and amounts corresponding to 1, 2, and 5 µg 
were calculated using the approximation of 1 OD = 1 mg/ml. The actual amounts of H6-
Nox1cyt loaded were then determined from direct comparison with the known quantities of 
the chymotrypsin marker at 30 kDa. 
2'5' ADP Sepharose Chromatography 
Fractions containing H6-Nox1cyt previously purified with Ni-NTA and size exclusion 
chromatography (Superdex 75, Amersham Biosciences/GE Healthcare) were dialyzed in 
10 mM NaH2PO4, pH 7.3, 150 mM NaCl, 10 % glycerol, and 2 mM DTE. This sample was 
then loaded via an ÄKTA Prime onto a 10 ml 2'5' ADP Sepharose column pre-equilibrated 
with Buffer ADP-A, and washed with 50 ml of Buffer ADP-A. Step elution of H6-Nox1cyt 
was made with 70 ml of 100% Buffer ADP-B, and fractions were analyzed on 15% SDS-
PAGE. 
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Buffer ADP-A:  10 mM NaH2PO4, pH 7.3, 150 mM NaCl, 10 % glycerol, and 2 mM 
DTT 
Buffer ADP-B:  10 mM NaH2PO4, pH 7.3, 1M NaCl, 10 % glycerol, and 2 mM DTT 
 
TrxT-Nox1cyt 
Cells expressing TrxT-Nox1cyt were flash frozen in liquid nitrogen as a resuspension in ice-
cold Buffer Ni-A containing 1 Complete EDTA-free protease inhibitor cocktail tablet/50 ml 
buffer at a volume 2x the mass of the cells. This resuspension was thawed and lysed by 4 
passes through a microfluidizer. The soluble fraction was separated via ultracentrifugation 
at 30,000 rpm for 30 minutes at 4°C. The clarified lysate was loaded onto 12 ml Ni-NTA 
resin (Qiagen) by gravity and washed with 350 ml of Buffer Ni-A. Step elutions were made 
with approximately 30 ml of Buffer Ni-A containing 50 mM, 100 mM and 250 mM 
Imidazole, respectively. Fractions (~10 ml) were manually collected and analyzed on 15% 
SDS-PAGE. Fractions containing TrxT-Nox1cyt were concentrated in a centrifugal 
concentrator (30 kDa MWCO) at 4000 rpm, 4°C, and loaded at 2 ml/min via a Waters 
HPLC onto a Superdex 75 column (Amersham Biosciences/GE Healthcare) pre-equilibrated 
with Buffer S75. Fractions were analyzed on 15% SDS-PAGE. 
Buffer Ni-A:  50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 20 mM Imidazole, 10% 
glycerol 
Buffer S75:  20 mM HEPES, pH 7, 300 mM NaCl, 10% glycerol 
 
4.2.5 Isoelectric Focusing 
 The pI of refolded TrxE-Nox1cyt was experimentally determined with isoelectric focusing. 
A sample was made consisting of 4 µl of 9.4 mg/ml refolded TrxE-Nox1cyt mixed with 4 µl 
100% glycerol and run alongside standards on a Ready Gel IEF gel (Bio-Rad) using a 
cathode buffer of 20 mM arginine and 20 mM lysine, and an anode buffer of 7 mM 
phosphoric acid. The following run conditions were used on a PowerPac 3000 power supply 
(Bio-Rad) at 4°C:   
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Voltage Current Time 
100 V (constant) limit 25 mA max 1 hour 
205 V (constant) limit 25 mA max 1 hour 
500 V (constant) limit 25 mA max 30 min 
 
The gel was stained for 45 min in IEF staining solution (Bio-Rad), and destained with 10% 
acetic acid and 40% methanol overnight.  
 
4.2.6 Western Blot 
Proteins were electrophoresed on SDS-PAGE, and the gel was rinsed three times with 
doubly distilled water to remove all traces of running buffer. The gel was then soaked in 
transfer buffer (10 mM CAPS, pH 11) for 15-20 minutes. Proteins were transferred to 
PVDF membrane (pre-wet with methanol) using tank transfer in a Criterion Blotter (Bio-
Rad) with 100 volts for 40 minutes at 4°C. After transfer, the PVDF membrane was blocked 
with shaking for 1 hour at room temperature in 10% milk in TBST, and then washed 4 times 
with 30 ml TBST (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween) for 10 min, with 
shaking. To detect His-tagged proteins, the membrane was incubated with either mouse 
monoclonal Anti-His antibody (Roche) at a concentration of 1:333 or rabbit polyclonal 
Anti-His antibody (Santa Cruz Biotechnology) at a concentration of 1:1000 in 3% milk in 
TBST for 1 hour at room temperature. To identify Nox1 proteins, the membrane was 
incubated with rabbit polyclonal Anti-Nox1 antibody (Prof. Dr. H.H.W. Schmidt, Monash 
University, Melbourne, Australia) at a concentration of 1:6700 in 3% milk in TBST for 
1 hour at room temperature. The membrane was again washed 4 times with 30 ml TBST for 
10 min, with shaking. The membrane was then incubated with anti-mouse IgG or anti-rabbit 
IgG secondary antibodies conjugated with alkaline phosphatase (Pierce) at a concentration 
of 1:30,000 in 3% milk in TBST for 1 hour at room temperature. The membrane was again 
washed 4 times with 30 ml TBST for 10 min, with shaking. Bands were visualized with 
NBT/BCIP one-step stain (Pierce). For TrxT-Nox1cyt, the blot was visualized with a 
chemiluminescence kit (Roche). 
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4.2.7 MALDI-TOF 
MALDI-TOF analysis (Dr. Robert Shoeman) was performed using sinapinic acid (3,5-
dimethoxy-4-hydroxy cinnamic acid) as the matrix. Samples were made via a "matrix 
sandwich": a layer of sinapinic acid was first added to the plate and allowed to dry, followed 
by the protein sample, and then another layer of sinapinic acid, allowing each layer to dry 
before application of the next layer. Due to the high salt and complex buffer composition 
present in the protein samples, the samples were washed twice with 1-2 µl of 0.1% TFA. 
Calibration was made with lysozyme and BSA standards.  
 
4.2.8 Screen for detergent stability 
This protocol is based on one used in a course on membrane proteins (NCCR course, 2004). 
Detergents at ~10x the CMC are incubated with an equal volume of target protein for one 
week at 4°C. Stability is determined by SDS-PAGE analysis of the soluble fraction. 
Detergent solutions were made with the following concentrations in 10 mM Tris-HCl, pH 
7.5 and 100 mM NaCl:  0.2% n-Dodecyl-β-D-maltopyranoside (DDM), 2% n-Decyl-β-D-
maltopyranoside (DM), 5% CHAPS, 1.2% CYMAL-5, 0.5% Fos-Choline-12, 0.15% Triton 
X-100, and 0.083% Genapol X-80. Due to solubility issues, n-Octyl-β-D-glucopyranoside 
(OG) was used as a 10% aqueous solution without buffer or NaCl. TrxE-Nox1cyt and H6-
Nox1cyt were each subjected to this screen. For TrxE-Nox1cyt, 7.2 µg in 5 µl was incubated 
individually with 5 µl of each respective detergent solution. An equivalent amount of TrxE-
Nox1cyt was incubated with 5 µl of the storage buffer for the protein, which does not contain 
detergent (10 mM NaH2PO4, 500 mM NaCl, 10% glycerol, 2 mM DTE, pH 8.0). To control 
the total protein amount for each sample, a gel sample of an equivalent amount was made 
from a freshly thawed sample of TrxE-Nox1cyt prior to running the SDS-PAGE. H6-Nox1cyt 
(7 µg) was processed in a similar way with the exception that the buffer used for the 
detergent solutions (10 mM Tris-HCl, pH 7.5 and 100 mM NaCl) was used for the no-
detergent control. Gel samples of the supernatant were made after centrifugation of each 
sample at 14,000 rpm for 30 min at 4°C. All gel samples (excluding markers) were made 
without boiling at 100°C. 
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4.2.9 NADPH-dependent diaphorase activity 
Spectrophotometric format 
H6-Nox1cyt was assayed for NADPH-dependent diaphorase activity at 37°C after an 
established procedure (Nisimoto et al., 2004). Intrinsic activity and activity in the presence 
of p67N-Rac(Q61L)•GTP or p67N-Rac•GppNHp was assayed in a final volume of 1 ml. 
For measurement of intrinsic activity, 100 µl of protein pre-incubation buffer containing 
4.5 µM H6-Nox1cyt was allowed to incubate for 15 minutes on ice. For the measurement of 
activity in the presence of p67N-Rac(Q61L)•GTP or p67N-Rac•GppNHp, 100 µl of protein 
pre-incubation buffer containing 4.5 µM H6-Nox1cyt and either 14.8 µM p67N-
Rac(Q61L)•GTP or 12.3 µM pre-loaded p67N-Rac•GppNHp was pre-incubated for 15 
minutes on ice. 100 µl of each sample was added to assay buffer and pre-incubated in a 39-
40°C water bath for 5 minutes. NADPH was added to a final concentration of 200 µM and 
the samples were assayed at 595 nm in a Beckman DU®640 spectrophotometer for 20-60 
minutes at 37°C. The spectrophotometer was blanked at 595 nm with 100 µl of protein pre-
incubation buffer in assay buffer after NADPH had been added to a final concentration of 
200 µM. Storage buffers for the respective proteins were assayed using volumes identical to 
the volumes of protein used in protein-containing assay samples. The change in absorbance 
at 595 nm over time produced by each storage buffer were subtracted from that of the 
respective protein-containing samples to buffer correct the measured values. For p67N-Rac, 
this particular protein sample did not contain DTT in the buffer. In the future, the assay 
buffer should contain 4 mM MgCl2, to ensure optimal nucleotide binding to Rac. To prevent 
light catalyzed reduction of NBT, all sample preparation was made in low light conditions. 
Assay Buffer:  50 mM NaH2PO4, pH 7.3, 50 mM NaCl, 20 µM FAD, 0.1 mM NBT 
final concentrations in 1ml 
Protein Pre-incubation Buffer: 25 mM NaH2PO4, pH 7.3, 20 µM FAD, and either 10 
µM GTP (for p67N-RacQ61L) or 10 µM GppNHp (for p67N-Rac)  
 
Microtiter format 
The NADPH-dependent diaphorase activity assay was modified for microtiter format with a 
few changes. Since H6-Nox1cyt is not active at 20°C, the assay samples were made at 20°C, 
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and were likewise prepared under low light conditions. Assay buffer was made as a 2-fold 
concentrated stock and 50 µl was added to wells in a Nunc Nunclon microtiter plate. H6-
Nox1cyt, detergent, p67N-Rac(Q61L)•GTP, and buffer controls were added as detailed 
below, and each sample was made to a final volume of 98 µl with water. Three 
concentrations of H6-Nox1cyt (0.46 µM, 2.3 µM, and 4.6 µM final concentration in 100 µl) 
were assayed and a concentration of 2.3 µM was used in all subsequent assays. Fos-choline-
12 was assayed with and without H6-Nox1cyt, at the following concentrations:  0.5x CMC 
(0.75 mM), 1x CMC (1.5 mM), 2x CMC (3 mM), 5x CMC (7.5 mM), and 10x CMC (15 
mM) from a freshly prepared 10% aqueous stock solution. H6-Nox1cyt was assayed with and 
without p67N-Rac(Q61L)•GTP, in the absence and presence of 2x CMC of Fos-choline-12. 
11 µM H6-Nox1cyt and 39 µM p67N-Rac(Q61L)•GTP were pre-incubated in pre-incubation 
buffer in a final volume of 21 µl for 15 minutes on ice prior to the assay. Buffer controls 
were made in exactly the same way as protein-containing samples, except the proteins were 
substituted by the respective protein storage buffer. For example, the buffer control for a 
sample containing 10 µl of H6-Nox1cyt in assay buffer with a final volume of 100 µl, 
consisted of 10 µl of the storage buffer for H6-Nox1cyt in assay buffer with a final volume of 
100 µl. For a sample containing 10 µl of H6-Nox1cyt and 0.5 µl of p67N-Rac(Q61L)•GTP 
pre-incubated with 10.5 µl of 2x protein pre-incubation buffer, all in assay buffer at a final 
volume of 100µl, the buffer control contained 10 µl of the storage buffer for H6-Nox1cyt, 
0.5 µl of the storage buffer for p67N-Rac(Q61L)•GTP, and 10.5 µl of 2x protein pre-
incubation buffer, all in assay buffer at a final volume of 100µl. A 20 mM solution of 
NADPH in 10 mM HEPES, pH 7.5 was made and the concentration checked 
spectrophotometrically using an extinction coefficient of 6.22 mM-1cm-1. 2µl of this 
NADPH solution was added to each sample. The plate was then sealed with Crystal Clear 
Tape and inserted into a Labsystem iEMS Reader MF (Thermo Electron, Langenselbold) 
preheated at 37°C. The plate was shaken for 10 seconds and read at 595 nm and 340 nm for 
1 hour, with samples reaching 37°C in the first 5 minutes.  
2x Assay Buffer:  100 mM NaH2PO4, pH 7.3, 100 mM NaCl, 8 mM MgCl2,0.2 mM 
NBT, 40 µM FAD 
2x Protein Pre-incubation Buffer: 50 mM NaH2PO4, pH 7.3, 40 µM FAD, 20 µM 
GTP, 8 mM MgCl2 
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Calculation of activity and turnover number 
Activity (mol of reduced NBT/min/mol of Nox1) can be calculated from the measured 
change in absorbance at 595 nm over time using the Beer-Lambert law: 
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A
c ∆⋅⋅
∆=∆
595
595
ε                                              Eq. 1 
where ε595 is the molar extinction coefficient of NBT at 595 nm (12.6 mM-1cm-1), and b is 
the pathlength, which is 1 cm in the spectrophotometric assay. Data were buffer corrected 
by subtracting the data of the corresponding buffer control, and the linear portion fit with 
linear regression in Origin version 6.0 (Microcal Software, Northampton, MA). The slopes 
obtained were used in Equation 1 to calculate the change in concentration of reduced NBT 
per minute. Moles of reduced NBT were calculated by multiplying Equation 1 with the 
volume of the assay sample and activity was calculated by dividing this value with the 
moles of Nox1 used in the assay. Rates of electron flow were calculated in 
electrons/min/molecule of protein assuming NBT is a 4 electron acceptor and using: 
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where Ne is the number of electrons, NA is Avogadro's number of 6.022 x 1023 
molecules/mole, nredNBT is the number of moles of reduced NBT, mole is mole of electrons, 
molredNBT is mole of reduced NBT and nNox1 is the number of moles of Nox1. 
 
4.2.10    Analytical size exclusion chromatography 
Two batches of H6-Nox1cyt were analyzed with analytical size exclusion chromatography. 
100 µg of H6-Nox1cyt was incubated with a 50-fold molar excess of FAD at 4°C for at least 
1 hour. 125 µl of this solution was injected with an autosampler using a Waters HPLC at 
0.5 ml/min onto an analytical Superdex 75 column pre-equilibrated with 20 mM NaH2PO4, 
pH 7.3, 300 mM NaCl, 250 mM Imidazole, and 10% glycerol. For the second batch of H6-
Nox1cyt, 280 µg was incubated with a 25-fold molar excess of FAD for 2.5 hours at 4°C. 
190 µl of this solution was loaded at 0.5 ml/min onto an analytical Superdex 75 column pre-
equilibrated with 50 mM NaH2PO4, pH 7.3, 300 mM NaCl, 250 mM Imidazole, and 10% 
glycerol. For each H6-Nox1cyt chromatographic run, Bio-Rad gel filtration standards were 
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run using identical volumes as the loaded protein samples with identical buffers and flow 
rates. 
 
4.2.11    Expression, purification, and characterization of p67N-Rac and p67N-
Rac(Q61L) 
Expression 
Chemically competent BL21(DE3) cells (Dr. Konstanze von König), were transformed via 
heat shock with the plasmid pGEX-2T containing either p67N-Rac or p67N-Rac(Q61L) 
(Dr. Minoru Tamura, Ehime University, Japan), and plated on LB agar plates containing a 
final concentration of 100 µg/ml of ampicillin (used at this concentration in all subsequent 
cultures). Typically, 3-4L of LB/ampicillin were inoculated with an overnight culture using 
a volume 1:500 of the final volume, and grown at 37°C until a cell density at 600 nm of 0.7-
0.8. Cultures were chilled at 4°C for 30-60 min, and protein expression was induced with 
IPTG at a final concentration of 0.05 mM, with overnight incubation at 20°C. Cells were 
harvested at 4000 rpm for 20 min at 4°C, flash frozen in liquid nitrogen and stored at –80°C. 
Glutathione Sepharose Chromatography 
In contrast to the Nox1 constructs, both Rac fusion proteins overexpress well, and cells from 
0.5 or 1L will provide more than enough protein in the end. Purification was performed at 
4°C and pH values of all buffers represent values at 4°C. Generally, cells from 1L of culture 
were thawed at room temperature and resuspended in Lysis Buffer with one Complete 
EDTA-free protease inhibitor cocktail tablet/50 ml buffer at a volume 2x the mass of the 
cells. Cells were lysed with 2 passes through a microfluidizer and genomic DNA was 
digested with DNase I (35µg/ml lysate) in the presence of 10 mM MgCl2 with stirring for 10 
minutes at 4°C. The lysate was then clarified via ultracentrifugation at 40,000 rpm for 1 hr 
at 4°C. The supernatant was incubated with ~7ml of Glutathione Sepharose 4B resin at 4°C 
for 1.5-2 hours with gentle shaking. This was then transferred to a gravity column and the 
resin was washed with 70 ml of Lysis Buffer, followed by 30 ml of Wash 1 Buffer and 30 
ml of Wash 2 buffer. Bound proteins were batch eluted with 20 ml of Elution Buffer and 
allowed to incubate at 4°C for 1.5 hours on a wheel. Eluted fusion proteins were dialyzed 
into Thrombin Digest buffer and digested with thrombin (2U/mg protein), with complete 
digestion requiring about one week at 4°C. To remove thrombin, NaCl was added to the 
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digest to a final concentration of 0.5 M and the sample was loaded on a HiTrap 
Benzamidine FF (high sub) column pre-equilibrated with Benzamidine Binding Buffer. The 
flow through was collected and concentrated in centrifugal concentrators (30 MWCO) to 3 
ml, then diluted 10-fold with Dilution Buffer. The GST tag and any uncut GST-fusion 
protein were removed with a second application over Glutathione Sepharose 4B resin. The 
desired fusion proteins were collected in the flow through fractions and concentrated in 
centrifugal concentrators (30 MWCO) to 1.5 ml.  
Lysis buffer: 50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 4 mM DTT, 2 mM EDTA, 
5 mM MgCl2 
Wash 1 buffer:  50 mM Tris-HCl, pH 7.5, 1M NaCl, 4 mM DTT, 2 mM EDTA, 5 mM 
MgCl2 
Wash 2 buffer:  50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2 mM DTT, 1 mM EDTA, 
5 mM MgCl2 
Elution Buffer:  100 mM Tris-HCl, pH 7.5, 50 mM reduced glutathione 
Thrombin Digest Buffer:  50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM DTT, 5 mM 
MgCl2, 2.5 mM CaCl2 
Benzamidine Binding Buffer:  50 mM Tris-HCl, pH 7.4, 0.5 M NaCl 
Dilution Buffer:  50 mM Tris-HCl, pH 7.5, 2 mM DTT, 1 mM EDTA, 5 mM MgCl2 
Size Exclusion Chromatography 
The concentrated elution from the second Glutathione Sepharose 4B column was loaded 
with an ÄKTA Prime onto a Superdex 200 gel filtration column at 1 ml/min, and 3 ml 
fractions were collected. Fractions containing the Rac fusion proteins were identified by 
SDS-PAGE and concentrated in centrifugal concentrators (30 MWCO). 
Superdex 200 Buffer:  50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2 mM DTT, 5 mM 
MgCl2 
Nucleotide Identification and Quantification 
Bound nucleotide for each Rac fusion protein was identified and quantified with HPLC. 
100 µl of 10 µM Rac fusion protein in water was heated for 3 min at 95°C, then centrifuged 
for 20 min at 14,000 rpm, 4°C. 20 µl of the supernatant was analyzed on a Latek HPLC 
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(Latek, Eppelheim) over a ODS Prontosil Hypersorb, reversed phase C18 column (Bischoff 
Chromatography, Leonberg) using isocratic elution with 0.1M potassium phosphate, pH 6.8, 
10 mM Tetra-n-butyl ammonium bromide, and 7.5% Acetonitrile. The amount of bound 
nucleotide was calculated from the average of three trials using the areas obtained from 
20 µl of a 30.8 µM GXP standard containing 10.27µM of GMP, GDP and GTP, 
respectively. This value was compared with the protein concentration as determined by the 
Ehresmann method (Ehresmann et al., 1973) to give the percent nucleotide bound, and the 
adjusted concentration of active protein. 
Intrinsic GTPase Activity of p67N-Rac(Q61L) 
720 µg of p67N-Rac(Q61L) was loaded with a 5-fold molar excess of GTP in 20 mM Tris-
HCl, pH 7.45, 3 mM NaCl, and 50 mM KCl at 20°C for 15 minutes. Excess nucleotide was 
removed with NAP 5 chromatography and simultaneously buffer exchanged into 50 mM 
Tris-HCl, pH 7.45, 50 mM NaCl, 2 mM DTT, and 5 MgCl2. A 200 µl solution of p67N-
Rac(Q61L) at a concentration of 54.5 µM was incubated at 37°C and aliquots were removed 
to make 100µl of a 10µM protein sample for each time point, which were then flash frozen 
in liquid nitrogen. Samples for each time point were analyzed in triplicate with HPLC and 
the amount of GTP bound was calculated from a GXP standard of known concentration in 
the same manner described for nucleotide identification and quantification. 
 
4.2.12 Fluorescence measurements 
Fluorescence measurements were made with a FluoroMax-3 at 20°C, after Nisimoto et al, 
1997. A 800 µl solution of mantGppNHp at a final concentration of 0.12 µM in 20 mM 
Tris-HCl, pH 7.45, 3 mM NaCl, 50 mM KCl, and 0.1 µM MgCl2, was excited with a 
wavelength of 355 nm and the emission at 445 nm was monitored over 5 minutes. p67N-
Rac•GDP (in 50 mM Tris-HCl, pH 7.5, 50 mM NaCl, 2 mM DTT, 5 mM MgCl2) was 
added to this solution at a final concentration of 0.25 µM and the emission was monitored 
further over 30 minutes. TrxE-Nox1cyt (in 10 mM NaH2PO4, pH 7.3, 500 mM NaCl, 10 % 
glycerol, and 2 mM DTT) was then added at a final concentration of 0.35 µM and the 
emission monitored further over 20 minutes. Data were corrected for volume changes, 
which did not exceed 1%.  
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4.3 CYCLIZED RAB7 METHODS 
4.3.1 Protein expression 
Cells transformed with a plasmid containing the intein and Rab7, residues 7-185 (a kind gift 
from Prof. Nick Dixon, University of Wollongong, New South Wales, Australia) were 
grown in LB at 30°C until an OD600 of 0.6-0.7 was reached. Protein expression was 
thermally induced by initially exposing the cultures to 45°C for 30 minutes, followed by 
2.5-3.5 hours at 42°C. Cyclization was promoted by cooling the flasks at 4°C for 2 hours. 
Cells were harvested via centrifugation and flash frozen at -80°C. 
 
4.3.2 Purification 
Cells expressing cyclized Rab7 were thawed and homogenized in lysis buffer and lysed in a 
microfluidizer. The lysate was clarified via ultracentrifugation and subjected to ammonium 
sulfate precipitation (40g/100 ml of lysate). The suspension was clarified via 
ultracentrifugation and the pellet was resuspended in Buffer DEAE-A, and subsequently 
dialyzed against the same buffer to remove the ammonium sulfate prior to application on a 
DEAE Sepharose Fast Flow column (Amersham Biosciences/GE Healthcare). After 
washing the column with Buffer DEAE-A until the absorbance reached baseline and 
remained stable, cyclized Rab7 was eluted with a linear gradient of 0-250mM NaCl in 
Buffer DEAE-A over 5 column volumes, and fractions were analyzed with SDS-PAGE. 
Cyclized Rab7 typically eluted at 100 mM NaCl, and fractions were pooled and 
concentrated with ammonium sulfate precipitation (0.5 g/ml). Higher molecular weight 
contaminants were removed with gel filtration chromatography on a Superdex 75 column 
(Amersham Biosciences/GE Healthcare) in Superdex 75 Buffer. Fractions were analyzed 
with SDS-PAGE, and fractions containing cyclized  Rab7 were pooled, diluted 10 times 
with Buffer HQ-A, and applied to a POROS® HQ anion exchange column (Applied 
Biosystems). Cyclized Rab7 was eluted with a step gradient of 80 mM NaCl, and purity was 
checked with SDS-PAGE. The final protein preparation was buffer exchanged into Final 
Buffer via centrifugal concentration (10 MWCO, Millipore). Cyclization of Rab7 was 
confirmed with ESI-MS, showing a mass of 21,353 Da (21,355 expected), which indicates 
the loss of a molecule of water upon cyclization (cf. linear mass 21,373 Da).  
150 
Materials and Methods 
 
Lysis Buffer:  50 mM Tris-HCl, pH 7.6, 100 mM NaCl, 10%w/v sucrose, 1 mM 
EDTA, 2 mM DTT 
Buffer DEAE-A:  50 mM Tris-HCl, pH 7.6, 15% glycerol, 1 mM EDTA, 2 mM DTT 
Buffer DEAE-B:  50 mM Tris-HCl, pH 7.6, 500 mM NaCl, 15% glycerol, 1 mM 
EDTA, 2 mM DTT 
Superdex 75 Buffer:  50 mM Tris-HCl, pH 7.6, 100 mM NaCl, 15% glycerol, 1 mM 
EDTA, 2 mM DTT. 
Buffer HQ-A:  50 mM Tris-HCl, pH 8.5, 1 mM EDTA, 1 mM DTT 
Buffer HQ-B:  50 mM Tris-HCl, pH 8.5, 1M NaCl, 1 mM EDTA, 1 mM DTT 
Final Buffer:  20 mM Tris-HCl, pH 7.6, 80 mM NaCl, 2 mM DTT 
 
4.3.3 ESI-MS 
Electrospray ionization mass spectrometry (ESI-MS) measurements were made with a LCQ 
Advantage Max mass spectrometer (Finnigan, San Jose, CA, USA). 2 µl of each protein 
sample were diluted with 28 µl of water to reduce the concentration of salt and buffer, and 
25 µl of this solution was analyzed. Deconvolution was made using Xcalibur software. 
  
4.3.4 Fluorescence measurements 
Fluorescence measurements were made on a Fluoromax-3 monitoring the intrinsic 
tryptophan fluorescence at an excitation wavelength of 290 nm. Protein samples were made 
at a concentration of 5 µM in 40 mM HEPES, pH 7.5, 1 mM MgCl2, 2 mM DTT. Spectra 
were recorded from 20°C to 85°C, with 10 minute equilibration at each temperature. 
Thermal recovery of the respective proteins was checked after the last temperature by 
cooling the sample to 20°C and re-measuring its fluorescence emission. 
 
4.3.5 Circular Dichroism (CD) spectroscopy  
Protein secondary structure was determined by CD measurements using a Jasco J-720 
spectropolarimeter. CD spectra were collected over the wavelength range from 190 to 
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260 nm at 0.2 nm intervals with a spectral bandwidth of 0.8 nm, 1 s integration time and a 
scanning speed of 200 nm/min, using a 0.1 cm quartz cuvette. Protein samples were 
prepared in a buffer consisting of 25 mM sodium phosphate, pH 7.5, 1 mM MgCl2, and 
1 mM DTT at a final concentration of 0.5 mg/ml (0.05 %w/v) and spectra were taken 
immediately after preparation. Thermal denaturation was monitored from 25°C to 85°C, 
with 10 minute equilibration at each respective temperature. Thermal recovery was checked 
after the last temperature by cooling the sample to 20°C and re-measuring its circular 
dichroism.  
All CD spectra are shown after buffer subtraction and smoothing with Origin 7 (Dr. 
Dahabada Lopes). The data are expressed as molar ellipticity [θ] in units of deg cm2 dmol-1, 
according to (Myers et al., 1997): 
Cnl
signal)(100][ =θ     Eq. 3 
where C is the protein concentration in mM, n is the number of residues and l is the 
pathlength in cm. The percentage of secondary structural elements was determined using the 
CONTIN program (Provencher, 1982) (Dr. Dahabada Lopes). 
 
4.3.6 Nucleotide exchange 
Endogenously bound GDP was exchanged for mantGDP or GTP by removing excess Mg2+ 
with incubation in 5 mM EDTA and a 20-fold molar excess of the desired nucleotide at 
25°C for 2 hours. The exchange was stopped with the addition of 10 mM MgCl2, and excess 
nucleotide was removed with Nap-5 columns. The incubation time was doubled to 4 hours 
for cyclized Rab7. GppNHp bound cyclized Rab7 used for crystallization was prepared by 
incubation with 10 mM EDTA for one hour at 4°C, followed by removal of excess EDTA 
with a Nap-5 column. A 10-fold molar excess of GppNHp was added, and residually bound 
GDP was hydrolyzed by incubation for 3-4 hours at 25°C with alkaline phosphatase (5U/mg 
protein) in the presence of 200 mM ammonium sulfate and 500 µM ZnCl2. The extent of 
nucleotide exchange/GDP hydrolysis was monitored by HPLC and was stopped after 
completion by the addition of 10 mM MgCl2. Excess nucleotides were removed with a Nap-
5 column and the protein was concentrated in centrifugal ultrafiltration concentrators (10 
MWCO). 
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4.3.7 GTPase activity 
GTPase activity was measured by incubating 150 µM of either Rab7 ∆C22•GTP or 
cyclized Rab7•GTP in 40 mM HEPES, pH 7.5 at 37°C in the presence of 10 mM MgCl2. 
Aliquots were removed at given time points, flash frozen in liquid nitrogen and analyzed on 
HPLC to quantify the amounts of GTP and GDP. The amount of GTP for each time point 
was normalized with the initial amount of GTP. Data were plotted with Origin version 6.0 
(Microcal Software, Northampton, MA, U.S.A.) and fit with the following single 
exponential equation: 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
+= 11 t
x
o eAyy     Eq. 4 
Rates were calculated from t1-1. 
 
4.3.8 Effector binding and dissociation 
Cyclized Rab7•mantGDP or Rab7∆C22•mantGDP at a final concentration of 0.5 µM in 
50 mM HEPES, pH 7.5, 50 mM NaCl, 2 mM MgCl2, 2 mM DTT, was mixed with various 
excess concentrations of Mrs6 in a SX 18MV-R stopped flow apparatus (Applied 
Photophysics, Surrey, UK) using a sample volume of 100 µl, at 20°C. FRET from 
tryptophan to the mant moiety was measured using an excitation wavelength of 295 nm and 
a 400 nm cutoff filter, with slit width of 1 mm. Association curves were fit using the 
corresponding manufacturer's program to the following double exponential equation: 
( ) ( ) endpteAeAy xratexrate ++= ⋅⋅ 2211     Eq. 5 
 
KD was determined independently using amplitude analysis, by calculating signal change as 
a percentage of the total signal and plotting this against Mrs6 concentration. The data were 
then fit to the following equation to obtain KD: 
         
[ ]61 Mrs
K
A
A
d
o
+
∆=∆     Eq. 6 
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where ∆A is the signal change observed for a given Mrs6 concentration and ∆Ao is the 
maximal change (i.e. that at infinite [Mrs6]). Displacement kinetics were measured by 
incubating a final concentration of 0.5 µM cyclized Rab7•mantGDP or 
Rab7∆C22•mantGDP with Mrs6 in a 1:1 molar ratio for 5 minutes at 20°C. Bound Rab7 
was displaced by the addition of a 10-fold molar excess of full-length Rab7SSSS, 
containing mutations in the two C-terminal cysteines for solubility. FRET was monitored 
using an excitation wavelength of 290 nm and a 400 nm cutoff filter. Displacement curves 
were fit to the following double exponential equation: 
( ) ( ) endpteAeAy tktk ++= ⋅−⋅− 21 21    Eq. 7 
 
4.3.9 Crystallization 
Cyclized Rab7 bound with GppNHp was crystallized using hanging drop vapor diffusion. 
1 µl of reservoir solution consisting of 1.3 M ammonium sulfate, 100 mM HEPES, pH 7.4, 
and 500 mM KCl was added to 0.5 µl of a 13 mg/ml protein solution, and suspended over 
500 ml of reservoir solution. Microseeding was employed to improve crystal quality. 
Briefly, larger bundles of crystals not suitable for x-ray diffraction studies were gathered in 
a stabilizing solution of 70% saturated ammonium sulfate and 100 mM HEPES, pH 7.4, and 
crushed with a needle. The stock microseed solution was serially diluted and scanned by 
adding 0.2 µl of each seed solution to crystallization drops to find the concentration of seed 
that would give 1-5 crystals per drop. 
 
4.3.10  X-ray data collection and processing 
Cyclized Rab7•GppNHp crystals were placed briefly in a cryoprotectant containing 70% 
saturated ammonium sulfate, 100 mM HEPES, pH 7.4, and 10% glycerol and cryocooled in 
liquid nitrogen. X-ray diffraction data (120° with an oscillation of 0.25°) were collected at 
the Swiss Light Source (SLS) synchrotron (Villingen, Switzerland) (Dr. Thomas Barends, 
Dr. Anton Meinhart), at 100K, with a detector distance of 180 mm. Data were processed 
with XDS, and the structure was solved with molecular replacement (CCP4) using 
Rab7•GDP (PDB code 1VG1) as a search model. The structure was initially refined with 
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REFMAC5 (CCP4) until twinning was discovered and confirmed with TRUNCATE (CCP4). 
A new reflection test set was generated to exclude twin-related reflections from belonging to 
both working and test sets with CNS, and the previous model bias was erased with simulated 
annealing (CNS). The resulting model was then refined against the twinned data set in 
SHELXL using the twin law -h, -k, l and an initial twinning fraction of 0.441. All structure 
figures were made using PyMOL (DeLano Scientific LLC, Palo Alto, U.S.A.)  
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Epilogue 
 
 
 
 
 
Here the heart may give an useful lesson to the head, 
 And learning wiser grow without his books. 
Knowledge and wisdom, far from b ing one, 
 Have ofttimes no connection.   
Knowledge dwells in heads replete with thoughts of other men; 
 Wisdom in minds attentive to their own. 
Knowledge, a rude unprofitable mass, 
 The mere materials with which wisdom builds, 
Till smoothed and squared and fitted to its place, 
 Does but encumber whom it seems to enrich. 
Knowledge is proud that he has learned so much, 
 Wisdom is humble that he knows no more. 
 
 
William Cowper,  The Task ,   Book 6 ,   1785 
 
 
 
